Arginine methyltransferase inhibitors and uses thereof

ABSTRACT

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described.

RELATED APPLICATIONS

The present application claims priority under 35 U.S.C. §119(e) to U.S.Provisional Patent Application, U.S. Ser. No. 61/781,046, filed Mar. 14,2013, the entire contents of which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

Epigenetic regulation of gene expression is an important biologicaldeterminant of protein production and cellular differentiation and playsa significant pathogenic role in a number of human diseases.

Epigenetic regulation involves heritable modification of geneticmaterial without changing its nucleotide sequence. Typically, epigeneticregulation is mediated by selective and reversible modification (e.g.,methylation) of DNA and proteins (e.g., histones) that control theconformational transition between transcriptionally active and inactivestates of chromatin. These covalent modifications can be controlled byenzymes such as methyltransferases (e.g., arginine methyltransferases),many of which are associated with specific genetic alterations that cancause human disease.

Disease-associated chromatin-modifying enzymes (e.g., argininemethyltransferases) play a role in diseases such as proliferativedisorders, autoimmune disorders, muscular disorders, vascular disorders,metabolic disorders, and neurological disorders. Thus, there is a needfor the development of small molecules that are capable of inhibitingthe activity of arginine methyltransferases.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS

Arginine methyltransferases are attractive targets for modulation giventheir role in the regulation of diverse biological processes. It has nowbeen found that compounds described herein, and pharmaceuticallyacceptable salts and compositions thereof, are effective as inhibitorsof arginine methyltransferases. Such compounds have the general Formula(I):

or a pharmaceutically acceptable salt thereof, wherein X, Y, Z, Q, R³,and R^(x) are as defined herein.

In some embodiments, pharmaceutical compositions are provided whichcomprise a compound described herein (e.g., a compound of Formula (I)),or a pharmaceutically acceptable salt thereof, and optionally apharmaceutically acceptable excipient.

In certain embodiments, compounds described herein inhibit activity ofan arginine methyltransferase (RMT) (e.g., PRMT1, PRMT3, CARM1, PRMT6,and/or PRMT8). In certain embodiments, methods of inhibiting an argininemethyltransferase are provided which comprise contacting the argininemethyltransferase with an effective amount of a compound of Formula (I),or a pharmaceutically acceptable salt thereof. The RMT may be purifiedor crude, and may be present in a cell, tissue, or a subject. Thus, suchmethods encompass inhibition of RMT activity both in vitro and in vivo.In certain embodiments, the RMT is wild-type. In certain embodiments,the RMT is overexpressed. In certain embodiments, the RMT is a mutant.In certain embodiments, the RMT is in a cell. In some embodiments, theRMT is expressed at normal levels in a subject, but the subject wouldbenefit from RMT inhibition (e.g., because the subject has one or moremutations in an RMT substrate that causes an increase in methylation ofthe substrate with normal levels of RMT). In some embodiments, the RMTis in a subject known or identified as having abnormal RMT activity(e.g., overexpression).

In certain embodiments, methods of modulating gene expression in a cellare provided which comprise contacting a cell with an effective amountof a compound of Formula (I), or a pharmaceutically acceptable saltthereof, or a pharmaceutical composition thereof. In certainembodiments, the cell in culture in vitro. In certain embodiments, cellis in an animal, e.g., a human.

In certain embodiments, methods of modulating transcription in a cellare provided which comprise contacting a cell with an effective amountof a compound of Formula (I), or a pharmaceutically acceptable saltthereof, or a pharmaceutical composition thereof. In certainembodiments, the cell in culture in vitro. In certain embodiments, thecell is in an animal, e.g., a human.

In some embodiments, methods of treating an RMT-mediated disorder (e.g.,a PRMT1-, PRMT3-, CARM1-, PRMT6-, or PRMT8-mediated disorder) areprovided which comprise administering to a subject suffering from anRMT-mediated disorder an effective amount of a compound described herein(e.g., a compound of Formula (I)), or a pharmaceutically acceptable saltthereof, or a pharmaceutical composition thereof. In certainembodiments, the RMT-mediated disorder is a proliferative disorder. Incertain embodiments, compounds described herein are useful for treatingcancer. In certain embodiments, compounds described herein are usefulfor treating breast cancer, prostate cancer, lung cancer, colon cancer,bladder cancer, or leukemia. In certain embodiments, the RMT-mediateddisorder is a muscular disorder. In certain embodiments, theRMT-mediated disorder is an autoimmune disorder. In certain embodiments,the RMT-mediated disorder is a neurological disorder. In certainembodiments, the RMT-mediated disorder is a vascular disorder. Incertain embodiments, the RMT-mediated disorder is a metabolic disorder.

Compounds described herein are also useful for the study of argininemethyltransferases in biological and pathological phenomena, the studyof intracellular signal transduction pathways mediated by argininemethyltransferases, and the comparative evaluation of new RMTinhibitors.

This application refers to various issued patent, published patentapplications, journal articles, and other publications, all of which areincorporated herein by reference.

Definitions of specific functional groups and chemical terms aredescribed in more detail below. The chemical elements are identified inaccordance with the Periodic Table of the Elements, CAS version,Handbook of Chemistry and Physics, 75^(th) Ed., a inside cover, andspecific functional groups are generally defined as described therein.Additionally, general principles of organic chemistry, as well asspecific functional moieties and reactivity, are described in ThomasSorrell, Organic Chemistry, University Science Books, Sausalito, 1999;Smith and March, March's Advanced Organic Chemistry, 5^(th) Edition,John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive OrganicTransformations, VCH Publishers, Inc., New York, 1989; and Carruthers,Some Modern Methods of Organic Synthesis, 3^(rd) Edition, CambridgeUniversity Press, Cambridge, 1987.

Compounds described herein can comprise one or more asymmetric centers,and thus can exist in various isomeric forms, e.g., enantiomers and/ordiastereomers. For example, the compounds described herein can be in theform of an individual enantiomer, diastereomer or geometric isomer, orcan be in the form of a mixture of stereoisomers, including racemicmixtures and mixtures enriched in one or more stereoisomer. Isomers canbe isolated from mixtures by methods known to those skilled in the art,including chiral high pressure liquid chromatography (HPLC) and theformation and crystallization of chiral salts; or preferred isomers canbe prepared by asymmetric syntheses. See, for example, Jacques et al.,Enantiomers, Racemates and Resolutions (Wiley Interscience, New York,1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistryof Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables ofResolving Agents and Optical Resolutions p. 268 (E. L. Eliel, Ed., Univ.of Notre Dame Press, Notre Dame, Ind. 1972). The present disclosureadditionally encompasses compounds described herein as individualisomers substantially free of other isomers, and alternatively, asmixtures of various isomers.

It is to be understood that the compounds of the present invention maybe depicted as different tautomers. It should also be understood thatwhen compounds have tautomeric forms, all tautomeric forms are intendedto be included in the scope of the present invention, and the naming ofany compound described herein does not exclude any tautomer form.

Unless otherwise stated, structures depicted herein are also meant toinclude compounds that differ only in the presence of one or moreisotopically enriched atoms. For example, compounds having the presentstructures except for the replacement of hydrogen by deuterium ortritium, replacement of ¹⁹F with ¹⁸F, or the replacement of a carbon bya ¹³C- or ¹⁴C-enriched carbon are within the scope of the disclosure.Such compounds are useful, for example, as analytical tools or probes inbiological assays.

When a range of values is listed, it is intended to encompass each valueand sub-range within the range. For example “C₁₋₆ alkyl” is intended toencompass, C₁, C₂, C₃, C₄, C₅, C₆, C₁₋₆, C₁₋₅, C₁₋₄, C₁₋₃, C₁₋₂, C₂₋₆,C₂₋₅, C₂₋₄, C₂₋₃, C₃₋₆, C₃₋₅, C₃₋₄, C₄₋₆, C₄₋₅, and C₅₋₆ alkyl.

“Alkyl” refers to a radical of a straight-chain or branched saturatedhydrocarbon group having from 1 to 20 carbon atoms (“C₁₋₂₀ alkyl”). Insome embodiments, an alkyl group has 1 to 10 carbon atoms (“C₁₋₁₀alkyl”). In some embodiments, an alkyl group has 1 to 9 carbon atoms(“C₁₋₉ alkyl”). In some embodiments, an alkyl group has 1 to 8 carbonatoms (“C₁₋₈ alkyl”). In some embodiments, an alkyl group has 1 to 7carbon atoms (“C₁₋₇ alkyl”). In some embodiments, an alkyl group has 1to 6 carbon atoms (“C₁₋₆ alkyl”). In some embodiments, an alkyl grouphas 1 to 5 carbon atoms (“C₁₋₅ alkyl”). In some embodiments, an alkylgroup has 1 to 4 carbon atoms (“C₁₋₄ alkyl”). In some embodiments, analkyl group has 1 to 3 carbon atoms (“C₁₋₃ alkyl”). In some embodiments,an alkyl group has 1 to 2 carbon atoms (“C₁₋₂ alkyl”). In someembodiments, an alkyl group has 1 carbon atom (“C₁ alkyl”). In someembodiments, an alkyl group has 2 to 6 carbon atoms (“C₂₋₆ alkyl”).Examples of C₁ ₆ alkyl groups include methyl (C₁), ethyl (C₂), n-propyl(C₃), isopropyl (C₃), n-butyl (C₄), tert-butyl (C₄), sec-butyl (C₄),iso-butyl (C₄), n-pentyl (C₅), 3-pentanyl (C₅), amyl (C₅), neopentyl(C₅), 3-methyl-2-butanyl (C₅), tertiary amyl (C₅), and n-hexyl (C₆).Additional examples of alkyl groups include n-heptyl (C₇), n-octyl (C₈)and the like. In certain embodiments, each instance of an alkyl group isindependently optionally substituted, e.g., unsubstituted (an“unsubstituted alkyl”) or substituted (a “substituted alkyl”) with oneor more substituents. In certain embodiments, the alkyl group isunsubstituted C₁₋₁₀ alkyl (e.g., —CH₃). In certain embodiments, thealkyl group is substituted C₁₋₁₀ alkyl.

In some embodiments, an alkyl group is substituted with one or morehalogens. “Perhaloalkyl” is a substituted alkyl group as defined hereinwherein all of the hydrogen atoms are independently replaced by ahalogen, e.g., fluoro, bromo, chloro, or iodo. In some embodiments, thealkyl moiety has 1 to 8 carbon atoms (“C₁₋₈ perhaloalkyl”). In someembodiments, the alkyl moiety has 1 to 6 carbon atoms (“C₁₋₆perhaloalkyl”). In some embodiments, the alkyl moiety has 1 to 4 carbonatoms (“C₁₋₄ perhaloalkyl”). In some embodiments, the alkyl moiety has 1to 3 carbon atoms (“C₁₋₃ perhaloalkyl”). In some embodiments, the alkylmoiety has 1 to 2 carbon atoms (“C₁₋₂ perhaloalkyl”). In someembodiments, all of the hydrogen atoms are replaced with fluoro. In someembodiments, all of the hydrogen atoms are replaced with chloro.Examples of perhaloalkyl groups include —CF₃, —CF₂CF₃, —CF₂CF₂CF₃,—CCl₃, —CFCl₂, —CF₂Cl, and the like.

As used herein, “alkenyl” refers to a radical of a straightchain orbranched hydrocarbon group having from 2 to 20 carbon atoms and one ormore carbon-carbon double bonds (e.g., 1, 2, 3, or 4 double bonds), andoptionally one or more triple bonds (e.g., 1, 2, 3, or 4 triple bonds)(“C₂₋₂₀ alkenyl”). In certain embodiments, alkenyl does not comprisetriple bonds. In some embodiments, an alkenyl group has 2 to 10 carbonatoms (“C₂₋₁₀ alkenyl”). In some embodiments, an alkenyl group has 2 to9 carbon atoms (“C₂₋₉ alkenyl”). In some embodiments, an alkenyl grouphas 2 to 8 carbon atoms (“C₂₋₈ alkenyl”). In some embodiments, analkenyl group has 2 to 7 carbon atoms (“C₂₋₇ alkenyl”). In someembodiments, an alkenyl group has 2 to 6 carbon atoms (“C₂₋₆ alkenyl”).In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C₂₋₅alkenyl”). In some embodiments, an alkenyl group has 2 to 4 carbon atoms(“C₂₋₄ alkenyl”). In some embodiments, an alkenyl group has 2 to 3carbon atoms (“C₂₋₃ alkenyl”). In some embodiments, an alkenyl group has2 carbon atoms (“C₂ alkenyl”). The one or more carboncarbon double bondscan be internal (such as in 2butenyl) or terminal (such as in1-butenyl). Examples of C₂₋₄ alkenyl groups include ethenyl (C₂),1-propenyl (C₃), 2-propenyl (C₃), 1-butenyl (C₄), 2-butenyl (C₄),butadienyl (C₄), and the like. Examples of C₂₋₆ alkenyl groups includethe aforementioned C₂₋₄ alkenyl groups as well as pentenyl (C₅),pentadienyl (C₅), hexenyl (C₆), and the like. Additional examples ofalkenyl include heptenyl (C₇), octenyl (C₈), octatrienyl (C₈), and thelike. In certain embodiments, each instance of an alkenyl group isindependently optionally substituted, e.g., unsubstituted (an“unsubstituted alkenyl”) or substituted (a “substituted alkenyl”) withone or more substituents. In certain embodiments, the alkenyl group isunsubstituted C₂₋₁₀ alkenyl. In certain embodiments, the alkenyl groupis substituted C₂₋₁₀ alkenyl.

As used herein, “alkynyl” refers to a radical of a straightchain orbranched hydrocarbon group having from 2 to 20 carbon atoms and one ormore carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds), andoptionally one or more double bonds (e.g., 1, 2, 3, or 4 double bonds)(“C₂₋₂₀ alkynyl”). In certain embodiments, alkynyl does not comprisedouble bonds. In some embodiments, an alkynyl group has 2 to 10 carbonatoms (“C₂₋₁₀ alkynyl”). In some embodiments, an alkynyl group has 2 to9 carbon atoms (“C₂₋₉ alkynyl”). In some embodiments, an alkynyl grouphas 2 to 8 carbon atoms (“C₂₋₈ alkynyl”). In some embodiments, analkynyl group has 2 to 7 carbon atoms (“C₂₋₇ alkynyl”). In someembodiments, an alkynyl group has 2 to 6 carbon atoms (“C₂₋₆ alkynyl”).In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C₂₋₅alkynyl”). In some embodiments, an alkynyl group has 2 to 4 carbon atoms(“C₂₋₄ alkynyl”). In some embodiments, an alkynyl group has 2 to 3carbon atoms (“C₂₋₃ alkynyl”). In some embodiments, an alkynyl group has2 carbon atoms (“C₂ alkynyl”). The one or more carboncarbon triple bondscan be internal (such as in 2-butynyl) or terminal (such as in1-butynyl). Examples of C₂₋₄ alkynyl groups include, without limitation,ethynyl (C₂), 1-propynyl (C₃), 2-propynyl (C₃), 1-butynyl (C₄),2-butynyl (C₄), and the like. Examples of C₂₋₆ alkenyl groups includethe aforementioned C₂₋₄ alkynyl groups as well as pentynyl (C₅), hexynyl(C₆), and the like. Additional examples of alkynyl include heptynyl(C₇), octynyl (C₈), and the like. In certain embodiments, each instanceof an alkynyl group is independently optionally substituted, e.g.,unsubstituted (an “unsubstituted alkynyl”) or substituted (a“substituted alkynyl”) with one or more substituents. In certainembodiments, the alkynyl group is unsubstituted C₂₋₁₀ alkynyl. Incertain embodiments, the alkynyl group is substituted C₂₋₁₀ alkynyl.

“Carbocyclyl” or “carbocyclic” refers to a radical of a nonaromaticcyclic hydrocarbon group having from 3 to 10 ring carbon atoms (“C₃₋₁₀carbocyclyl”) and zero heteroatoms in the nonaromatic ring system. Insome embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms(“C₃₋₈ carbocyclyl”). In some embodiments, a carbocyclyl group has 3 to6 ring carbon atoms (“C₃₋₆ carbocyclyl”). In some embodiments, acarbocyclyl group has 3 to 6 ring carbon atoms (“C₃₋₆ carbocyclyl”). Insome embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms(“C₅₋₁₀ carbocyclyl”). Exemplary C₃₋₆ carbocyclyl groups include,without limitation, cyclopropyl (C₃), cyclopropenyl (C₃), cyclobutyl(C₄), cyclobutenyl (C₄), cyclopentyl (C₅), cyclopentenyl (C₅),cyclohexyl (C₆), cyclohexenyl (C₆), cyclohexadienyl (C₆), and the like.Exemplary C₃₋₈ carbocyclyl groups include, without limitation, theaforementioned C₃₋₆ carbocyclyl groups as well as cycloheptyl (C₇),cycloheptenyl (C₇), cycloheptadienyl (C₇), cycloheptatrienyl (C₇),cyclooctyl (C₈), cyclooctenyl (C₈), bicyclo[2.2.1]heptanyl (C₇),bicyclo[2.2.2]octanyl (C₈), and the like. Exemplary C₃₋₁₀ carbocyclylgroups include, without limitation, the aforementioned C₃₋₈ carbocyclylgroups as well as cyclononyl (C₉), cyclononenyl (C₉), cyclodecyl (C₁₀),cyclodecenyl (C₁₀), octahydro-1H-indenyl (C₉), decahydronaphthalenyl(C₁₀), spiro[4.5]decanyl (C₁₀), and the like. As the foregoing examplesillustrate, in certain embodiments, the carbocyclyl group is eithermonocyclic (“monocyclic carbocyclyl”) or contain a fused, bridged orspiro ring system such as a bicyclic system (“bicyclic carbocyclyl”) andcan be saturated or can be partially unsaturated. “Carbocyclyl” alsoincludes ring systems wherein the carbocyclyl ring, as defined above, isfused with one or more aryl or heteroaryl groups wherein the point ofattachment is on the carbocyclyl ring, and in such instances, the numberof carbons continue to designate the number of carbons in thecarbocyclic ring system. In certain embodiments, each instance of acarbocyclyl group is independently optionally substituted, e.g.,unsubstituted (an “unsubstituted carbocyclyl”) or substituted (a“substituted carbocyclyl”) with one or more substituents. In certainembodiments, the carbocyclyl group is unsubstituted C₃₋₁₀ carbocyclyl.In certain embodiments, the carbocyclyl group is a substituted C₃₋₁₀carbocyclyl.

In some embodiments, “carbocyclyl” is a monocyclic, saturatedcarbocyclyl group having from 3 to 10 ring carbon atoms (“C₃₋₁₀cycloalkyl”). In some embodiments, a cycloalkyl group has 3 to 8 ringcarbon atoms (“C₃ ₈ cycloalkyl”). In some embodiments, a cycloalkylgroup has 3 to 6 ring carbon atoms (“C₃₋₆ cycloalkyl”). In someembodiments, a cycloalkyl group has 5 to 6 ring carbon atoms (“C₅₋₆cycloalkyl”). In some embodiments, a cycloalkyl group has 5 to 10 ringcarbon atoms (“C₅₋₁₀ cycloalkyl”). Examples of C₅₋₆ cycloalkyl groupsinclude cyclopentyl (C₅) and cyclohexyl (C₅). Examples of C₃₋₆cycloalkyl groups include the aforementioned C₅₋₆ cycloalkyl groups aswell as cyclopropyl (C₃) and cyclobutyl (C₄). Examples of C₃₋₈cycloalkyl groups include the aforementioned C₃₋₆ cycloalkyl groups aswell as cycloheptyl (C₇) and cyclooctyl (C₈). In certain embodiments,each instance of a cycloalkyl group is independently unsubstituted (an“unsubstituted cycloalkyl”) or substituted (a “substituted cycloalkyl”)with one or more substituents. In certain embodiments, the cycloalkylgroup is unsubstituted C₃₋₁₀ cycloalkyl. In certain embodiments, thecycloalkyl group is substituted C₃₋₁₀ cycloalkyl.

“Heterocyclyl” or “heterocyclic” refers to a radical of a 3- to10-membered non-aromatic ring system having ring carbon atoms and 1 to 4ring heteroatoms, wherein each heteroatom is independently selected fromnitrogen, oxygen, and sulfur (“3-10 membered heterocyclyl”). Inheterocyclyl groups that contain one or more nitrogen atoms, the pointof attachment can be a carbon or nitrogen atom, as valency permits. Aheterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”)or a fused, bridged or spiro ring system such as a bicyclic system(“bicyclic heterocyclyl”), and can be saturated or can be partiallyunsaturated. Heterocyclyl bicyclic ring systems can include one or moreheteroatoms in one or both rings. “Heterocyclyl” also includes ringsystems wherein the heterocyclyl ring, as defined above, is fused withone or more carbocyclyl groups wherein the point of attachment is eitheron the carbocyclyl or heterocyclyl ring, or ring systems wherein theheterocyclyl ring, as defined above, is fused with one or more aryl orheteroaryl groups, wherein the point of attachment is on theheterocyclyl ring, and in such instances, the number of ring memberscontinue to designate the number of ring members in the heterocyclylring system. In certain embodiments, each instance of heterocyclyl isindependently optionally substituted, e.g., unsubstituted (an“unsubstituted heterocyclyl”) or substituted (a “substitutedheterocyclyl”) with one or more substituents. In certain embodiments,the heterocyclyl group is unsubstituted 3-10 membered heterocyclyl. Incertain embodiments, the heterocyclyl group is substituted 3-10 memberedheterocyclyl.

In some embodiments, a heterocyclyl group is a 5-10 membered nonaromaticring system having ring carbon atoms and 1-4 ring heteroatoms, whereineach heteroatom is independently selected from nitrogen, oxygen, andsulfur (“5-10 membered heterocyclyl”). In some embodiments, aheterocyclyl group is a 5-8 membered nonaromatic ring system having ringcarbon atoms and 1-4 ring heteroatoms, wherein each heteroatom isindependently selected from nitrogen, oxygen, and sulfur (“5-8 memberedheterocyclyl”). In some embodiments, a heterocyclyl group is a 5-6membered nonaromatic ring system having ring carbon atoms and 1-4 ringheteroatoms, wherein each heteroatom is independently selected fromnitrogen, oxygen, and sulfur (“5-6 membered heterocyclyl”). In someembodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatomsselected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen,oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclylhas one ring heteroatom selected from nitrogen, oxygen, and sulfur.

Exemplary 3-membered heterocyclyl groups containing one heteroatominclude, without limitation, azirdinyl, oxiranyl, and thiorenyl.Exemplary 4-membered heterocyclyl groups containing one heteroatominclude, without limitation, azetidinyl, oxetanyl, and thietanyl.Exemplary 5-membered heterocyclyl groups containing one heteroatominclude, without limitation, tetrahydrofuranyl, dihydrofuranyl,tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl,and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groupscontaining two heteroatoms include, without limitation, dioxolanyl,oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-memberedheterocyclyl groups containing three heteroatoms include, withoutlimitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary6-membered heterocyclyl groups containing one heteroatom include,without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl,and thianyl. Exemplary 6-membered heterocyclyl groups containing twoheteroatoms include, without limitation, piperazinyl, morpholinyl,dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groupscontaining two heteroatoms include, without limitation, triazinanyl.Exemplary 7-membered heterocyclyl groups containing one heteroatominclude, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary8-membered heterocyclyl groups containing one heteroatom include,without limitation, azocanyl, oxecanyl, and thiocanyl. Exemplary5-membered heterocyclyl groups fused to a C₆ aryl ring (also referred toherein as a 5,6-bicyclic heterocyclic ring) include, without limitation,indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl,benzoxazolinonyl, and the like. Exemplary 6-membered heterocyclyl groupsfused to an aryl ring (also referred to herein as a 6,6-bicyclicheterocyclic ring) include, without limitation, tetrahydroquinolinyl,tetrahydroisoquinolinyl, and the like.

“Aryl” refers to a radical of a monocyclic or polycyclic (e.g., bicyclicor tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 πelectrons shared in a cyclic array) having 6-14 ring carbon atoms andzero heteroatoms provided in the aromatic ring system (“C₆₋₁₄ aryl”). Insome embodiments, an aryl group has six ring carbon atoms (“C₆ aryl”;e.g., phenyl). In some embodiments, an aryl group has ten ring carbonatoms (“C₁₀ aryl”; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). Insome embodiments, an aryl group has fourteen ring carbon atoms (“C₁₋₄aryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein thearyl ring, as defined above, is fused with one or more carbocyclyl orheterocyclyl groups wherein the radical or point of attachment is on thearyl ring, and in such instances, the number of carbon atoms continue todesignate the number of carbon atoms in the aryl ring system. In certainembodiments, each instance of an aryl group is independently optionallysubstituted, e.g., unsubstituted (an “unsubstituted aryl”) orsubstituted (a “substituted aryl”) with one or more substituents. Incertain embodiments, the aryl group is unsubstituted C₆₋₁₄ aryl. Incertain embodiments, the aryl group is substituted C₆₋₁₄ aryl.

“Heteroaryl” refers to a radical of a 5-10 membered monocyclic orbicyclic 4n+2 aromatic ring system (e.g., having 6 or 10π electronsshared in a cyclic array) having ring carbon atoms and 1-4 ringheteroatoms provided in the aromatic ring system, wherein eachheteroatom is independently selected from nitrogen, oxygen and sulfur(“5-10 membered heteroaryl”). In heteroaryl groups that contain one ormore nitrogen atoms, the point of attachment can be a carbon or nitrogenatom, as valency permits. Heteroaryl bicyclic ring systems can includeone or more heteroatoms in one or both rings. “Heteroaryl” includes ringsystems wherein the heteroaryl ring, as defined above, is fused with oneor more carbocyclyl or heterocyclyl groups wherein the point ofattachment is on the heteroaryl ring, and in such instances, the numberof ring members continue to designate the number of ring members in theheteroaryl ring system. “Heteroaryl” also includes ring systems whereinthe heteroaryl ring, as defined above, is fused with one or more arylgroups wherein the point of attachment is either on the aryl orheteroaryl ring, and in such instances, the number of ring membersdesignates the number of ring members in the fused (aryl/heteroaryl)ring system. Bicyclic heteroaryl groups wherein one ring does notcontain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and thelike) the point of attachment can be on either ring, e.g., either thering bearing a heteroatom (e.g., 2-indolyl) or the ring that does notcontain a heteroatom (e.g., 5-indolyl).

In some embodiments, a heteroaryl group is a 5-10 membered aromatic ringsystem having ring carbon atoms and 1-4 ring heteroatoms provided in thearomatic ring system, wherein each heteroatom is independently selectedfrom nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”). In someembodiments, a heteroaryl group is a 5-8 membered aromatic ring systemhaving ring carbon atoms and 1-4 ring heteroatoms provided in thearomatic ring system, wherein each heteroatom is independently selectedfrom nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”). In someembodiments, a heteroaryl group is a 5-6 membered aromatic ring systemhaving ring carbon atoms and 1-4 ring heteroatoms provided in thearomatic ring system, wherein each heteroatom is independently selectedfrom nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”). In someembodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatomsselected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen,oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has1 ring heteroatom selected from nitrogen, oxygen, and sulfur. In certainembodiments, each instance of a heteroaryl group is independentlyoptionally substituted, e.g., unsubstituted (“unsubstituted heteroaryl”)or substituted (“substituted heteroaryl”) with one or more substituents.In certain embodiments, the heteroaryl group is unsubstituted 5-14membered heteroaryl. In certain embodiments, the heteroaryl group issubstituted 5-14 membered heteroaryl.

Exemplary 5-membered heteroaryl groups containing one heteroatominclude, without limitation, pyrrolyl, furanyl and thiophenyl. Exemplary5-membered heteroaryl groups containing two heteroatoms include, withoutlimitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, andisothiazolyl. Exemplary 5-membered heteroaryl groups containing threeheteroatoms include, without limitation, triazolyl, oxadiazolyl, andthiadiazolyl. Exemplary 5-membered heteroaryl groups containing fourheteroatoms include, without limitation, tetrazolyl. Exemplary6-membered heteroaryl groups containing one heteroatom include, withoutlimitation, pyridinyl. Exemplary 6-membered heteroaryl groups containingtwo heteroatoms include, without limitation, pyridazinyl, pyrimidinyl,and pyrazinyl. Exemplary 6-membered heteroaryl groups containing threeor four heteroatoms include, without limitation, triazinyl andtetrazinyl, respectively. Exemplary 7-membered heteroaryl groupscontaining one heteroatom include, without limitation, azepinyl,oxepinyl, and thiepinyl. Exemplary 6,6-bicyclic heteroaryl groupsinclude, without limitation, naphthyridinyl, pteridinyl, quinolinyl,isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl.Exemplary 5,6-bicyclic heteroaryl groups include, without limitation,any one of the following formulae:

In any of the monocyclic or bicyclic heteroaryl groups, the point ofattachment can be any carbon or nitrogen atom, as valency permits.

“Partially unsaturated” refers to a group that includes at least onedouble or triple bond. The term “partially unsaturated” is intended toencompass rings having multiple sites of unsaturation, but is notintended to include aromatic groups (e.g., aryl or heteroaryl groups) asherein defined. Likewise, “saturated” refers to a group that does notcontain a double or triple bond, i.e., contains all single bonds.

In some embodiments, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl,aryl, and heteroaryl groups, as defined herein, are optionallysubstituted (e.g., “substituted” or “unsubstituted” alkyl, “substituted”or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl,“substituted” or “unsubstituted” carbocyclyl, “substituted” or“unsubstituted” heterocyclyl, “substituted” or “unsubstituted” aryl or“substituted” or “unsubstituted” heteroaryl group). In general, the term“substituted”, whether preceded by the term “optionally” or not, meansthat at least one hydrogen present on a group (e.g., a carbon ornitrogen atom) is replaced with a permissible substituent, e.g., asubstituent which upon substitution results in a stable compound, e.g.,a compound which does not spontaneously undergo transformation such asby rearrangement, cyclization, elimination, or other reaction. Unlessotherwise indicated, a “substituted” group has a substituent at one ormore substitutable positions of the group, and when more than oneposition in any given structure is substituted, the substituent iseither the same or different at each position. The term “substituted” iscontemplated to include substitution with all permissible substituentsof organic compounds, including any of the substituents described hereinthat results in the formation of a stable compound. The presentdisclosure contemplates any and all such combinations in order to arriveat a stable compound. For purposes of this disclosure, heteroatoms suchas nitrogen may have hydrogen substituents and/or any suitablesubstituent as described herein which satisfy the valencies of theheteroatoms and results in the formation of a stable moiety.

Exemplary carbon atom substituents include, but are not limited to,halogen, —CN, —NO₂, —N₃, —SO₂H, —SO₃H, —OH, —OR^(aa), —ON(R^(bb))₂,—N(R^(bb))₂, —N(R^(bb))₃ ⁺X⁻, —N(OR^(cc))R^(bb), —SH, —SR^(aa),—SSR^(cc), —C(═O)R^(aa), —CO₂H, —CHO, —C(OR^(cc))₂, —CO₂R^(aa),—OC(═O)R^(aa), —OCO₂R^(aa), —C(═O)N(R^(bb))₂, —OC(═O)N(R^(bb))₂,—NR^(bb)C(═O)Raa, —NR^(bb)CO₂R^(aa), —NR^(bb)C(═O)N(R^(bb))₂,—C(═NR^(bb))R^(aa), —C(═NR^(bb))OR^(aa), —OC(═NR^(bb))R^(aa),—OC(═NR^(bb))OR^(aa), —C(═NR^(bb))N(R^(bb))₂, —OC(═NR^(bb))N(R^(bb))₂,—NR^(bb)C(═NR^(bb))N(R^(bb))₂, —C(═O)NR^(bb)SO₂R^(aa),—NR^(bb)SO₂R^(aa), —SO₂N(R^(bb))₂, —SO₂R^(aa), —SO₂OR^(aa), —OSO₂R^(aa),—S(═O)R^(aa), —OS(═O)R^(aa), —Si(R^(aa))₃,—OSi(R^(aa))₃—C(═S)N(R^(bb))₂, —C(═O)SR^(aa), —C(═S)SR^(aa),—SC(═S)SR^(aa), —SC(═O)SR^(aa), —OC(═O)SR^(aa), —SC(═O)OR^(aa),—SC(═O)R^(aa), —P(═O)₂R^(aa), —OP(═O)₂R^(aa), —P(═O)(R^(aa))₂,—OP(═O)(R^(aa))₂, —OP(═O)(OR^(cc))₂, —P(═O)₂N(R^(bb))₂,—OP(═O)₂N(R^(bb))₂, —P(═O)(NR^(bb))₂, —OP(═O)(NR^(bb))₂,—NR^(bb)P(═O)(OR^(cc))₂, —NR^(bb)P(═O)(NR^(bb))₂, —P(R^(cc))₂,—P(R^(cc))₃, —OP(R^(cc))₂, —OP(R^(cc))₃, —B(R^(aa))₂, —B(OR^(cc))₂,-BR^(aa)(OR^(cc)), C₁₋₁₀ alkyl, C₁₋₁₀ perhaloalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀ carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl,carbocyclyl, heterocyclyl, aryl, and heteroaryl is independentlysubstituted with 0, 1, 2, 3, 4, or 5 R^(dd) groups;

or two geminal hydrogens on a carbon atom are replaced with the group═O, ═S, ═NN(R^(bb))₂, ═NNR^(bb)C(═O)R^(aa), ═NNR^(bb)C(═O)OR^(aa),═NNR^(bb)S(═O)₂R^(aa), ═NRbb, or ═NOR^(cc); each instance of R^(aa) is,independently, selected from C₁₋₁₀ alkyl, C₁₋₁₀ perhaloalkyl, C₂₋₁₀alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀ carbocyclyl, 3-14 membered heterocyclyl,C₆₋₁₄ aryl, and 5-14 membered heteroaryl, or two R^(aa) groups arejoined to form a 3-14 membered heterocyclyl or 5-14 membered heteroarylring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl,aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or5 R^(dd) groups;

each instance of Rbb is, independently, selected from hydrogen, —OH,—OR^(aa), —N(R^(cc))₂, —CN, —C(═O)R^(aa), —C(═O)N(R^(cc))₂, —CO₂R^(aa),—SO₂R^(aa), —C(═NR^(cc))OR^(aa), —C(═NR^(cc))N(R^(cc))₂, —SO₂N(R^(cc))₂,—SO₂R^(cc), —SO₂OR^(cc), —SOR^(aa), —C(═S)N(R^(cc))₂, —C(═O)SR^(cc),—C(═S)SR^(cc), —P(═O)₂R^(aa), —P(═O)(R^(aa))₂, —P(═O)₂N(R^(cc))₂,—P(═O)(NR^(cc))₂, C₁₋₁₀ alkyl, C₁₋₁₀ perhaloalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀ carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and5-14 membered heteroaryl, or two R^(bb) groups are joined to form a 3-14membered heterocyclyl or 5-14 membered heteroaryl ring, wherein eachalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroarylis independently substituted with 0, 1, 2, 3, 4, or 5 R^(dd) groups;each instance of R^(cc) is, independently, selected from hydrogen, C₁₋₁₀alkyl, C₁₋₁₀ perhaloalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 memberedheteroaryl, or two R^(cc) groups are joined to form a 3-14 memberedheterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl,alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl isindependently substituted with 0, 1, 2, 3, 4, or 5 R^(dd) groups;

each instance of R^(dd) is, independently, selected from halogen, —CN,—NO₂, —N₃, —SO₂H, —SO₃H, —OH, —OR^(ee), —ON (R^(ff))₂, —N(R^(ff))₂,—N(R^(ff))₃ ⁺X⁻, —N(OR^(ee))R^(ff), -SH, —SR^(ee), -SSR^(ee),—C(═O)R^(ee), —CO₂H, —CO₂R^(ee), —OC(═O)R^(ee), —OCO₂R^(ee),—C(═O)N(R^(ff))₂, —OC(═O)N(R^(ff))₂, —NR^(ff)C(═O)R^(ee),—NR^(ff)CO₂R^(ee), —NR^(ff)C(═O)N(R^(ff))₂, —C(═NR^(ff))OR^(ee),—OC(═NR^(ff))R^(ee), —OC(═NR^(ff))OR^(ee), —C(═NR^(ff))N(R^(ff))₂,—OC(═NR^(ff))N(R^(ff))₂,—NR^(ff)C(═NR^(ff))N(R^(ff))₂,—NR^(ff)SO₂R^(ee), —SO₂N(R^(ff))₂,—SO₂R^(ee), —SO₂OR^(ee), —OSO₂R^(ee), —S (═O)R^(ee), -S i (R^(ee))₃,—OSi(R^(ee))₃, —C(═S)N(R^(ff))₂, —C(═O)SR^(ee), —C(═S)SR^(ee),—SC(═S)SR^(ee), —P(═O)₂R^(ee), —P(═O)(R^(ee))₂, —OP(═O)(R^(ee))₂,—OP(═O)(OR^(ee))₂, C₁₋₆ alkyl, C₁₋₆ perhaloalkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₃₋₁₀ carbocyclyl, 3-10 membered heterocyclyl, C₆₋₁₀ aryl, 5-10membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl,heterocyclyl, aryl, and heteroaryl is independently substituted with 0,1, 2, 3, 4, or 5 R^(gg) groups, or two geminal R^(dd) substituents canbe joined to form ═O or ═S; each instance of R^(ee) is, independently,selected from C₁₋₆ alkyl, C₁₋₆ perhaloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₁₀ carbocyclyl, C₆₋₁₀ aryl, 3-10 membered heterocyclyl, and 3-10membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, carbocyclyl,heterocyclyl, aryl, and heteroaryl is independently substituted with 0,1, 2, 3, 4, or 5 R^(gg) groups; each instance of R^(ff) is,independently, selected from hydrogen, C₁₋₆ alkyl, C₁₋₆ perhaloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ carbocyclyl, 3-10 memberedheterocyclyl, C₆₋₁₀ aryl and 5-10 membered heteroaryl, or two R^(ff)groups are joined to form a 3-14 membered heterocyclyl or 5-14 memberedheteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl,heterocyclyl, aryl, and heteroaryl is independently substituted with 0,1, 2, 3, 4, or 5 R^(gg) groups; and

each instance of R^(gg) is, independently, halogen, —CN, —NO₂, —N₃,—SO₂H, -S 0₃H, —OH, —OC₁₋₆ alkyl, —ON(C₁₋₆ alkyl)₂, —N(C₁₋₆ alkyl)₂,—N(C₁₋₆ alkyl)₃ ⁺X⁻, —NH(C₁₋₆ alkyl)₂ ⁺X⁻, —NH₂(C₁₋₆ alkyl) ⁺X⁻, —NH₃⁺X⁻, —N(OC₁₋₆ alkyl)(C₁₋₆ alkyl), —N(OH)(C₁₋₆ alkyl), —NH(OH), —SH,—SC₁₋₆ alkyl, -SS(C₁₋₆ alkyl), —C(═O)(C₁₋₆ alkyl), —CO₂H, —OO₂(C₁₅alkyl), —OC(═O)(C₁₋₆ alkyl), —OCO₂(C₁₋₆ alkyl), —C(═O)NH₂, —C(═O)N(C₁₋₆alkyl)₂, —OC(═O)NH(C₁₋₆ alkyl), —NHC(═O)(C₁₋₆ alkyl), —N(C₁₋₆alkyl)C(═O)(C₁₋₆ alkyl), —NHCO₂(C₁₋₆ alkyl), —NHC(═O)N(C₁₋₆ alkyl)₂,—NHC(═O)NH(C₁₋₆ alkyl), —NHC(═O)NH₂, —C(═NH)O (C₁₆ alkyl), —OC(═NH)(C₁₋₆alkyl), —OC(═NH)OC₁₋₆ alkyl, —C(═NH)N(C₁₋₆ alkyl)₂, —C(═NH)NH(C₁₋₆alkyl), —C(═NH)NH₂, —OC(═NH)N(C₁ ₆ alkyl)₂, —OC(NH)NH(C₁₋₆ alkyl),—OC(NH)NH₂, —NHC(NH)N(C₁₋₆ alkyl)₂, —NHC(═NH)NH₂, —NHS O₂ (C₁₋₆ alkyl),—SO₂N(C₁₋₆ alkyl)₂, ⁻SO₂NH(C₁₋₆ alkyl), —SO₂NH₂, —SO₂C₁₋₆ alkyl,—SO₂OC₁₋₆ alkyl, —OSO₂C₁₋₆ alkyl, —SOC₁₋₆ alkyl, —Si(C₁₋₆ alkyl)₃,—OSi(C₁₋₆ alkyl)₃—C(═S)N(C₁₋₆ alkyl)₂, C(═S)NH(C₁₋₆ alkyl), C(═S)NH₂,—C(═O)S(C₁₋₆ alkyl), —C(═S)SC₁₋₆ alkyl, —SC(═S)SC₁₋₆ alkyl, -P(═O)₂(C₁₋₆alkyl), -P(═O)(C₁₋₆ alkyl)₂, —OP(═O)(C₁₋₆ alkyl)₂, —OP(═O)(OC₁₋₆alkyl)₂, C₁ alkyl, C₁₋₆ perhaloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀carbocyclyl, C₆₋₁₀ aryl, 3-10 membered heterocyclyl, 5-10 memberedheteroaryl; or two geminal R^(gg) substituents can be joined to form ═Oor ═S; wherein X⁻ is a counterion.

A “counterion” or “anionic counterion” is a negatively charged groupassociated with a cationic quaternary amino group in order to maintainelectronic neutrality. Exemplary counterions include halide ions (e.g.,F⁻, Cl⁻, Br⁻, I⁻), NO₃ ⁻, ClO₄ ⁻, OH⁻, H₂PO₄ ⁻, HSO₄ ⁻, sulfonate ions(e.g., methansulfonate, trifluoromethanesulfonate, p-toluenesulfonate,benzenesulfonate, 10-camphor sulfonate, naphthalene-2-sulfonate,naphthalene-1-sulfonic acid-5-sulfonate, ethan-1-sulfonicacid-2-sulfonate, and the like), and carboxylate ions (e.g., acetate,ethanoate, propanoate, benzoate, glycerate, lactate, tartrate,glycolate, and the like). “Halo” or “halogen” refers to fluorine(fluoro, —F), chlorine (chloro, —Cl), bromine (bromo, —Br), or iodine(iodo, —I).

Nitrogen atoms can be substituted or unsubstituted as valency permits,and include primary, secondary, tertiary, and quarternary nitrogenatoms. Exemplary nitrogen atom substitutents include, but are notlimited to, hydrogen, —OH, —OR^(aa), —N(R^(cc))₂, —CN, —C(═O)R^(aa),—C(═O)N(R^(cc))₂, —CO₂R^(aa), —SO₂R^(aa), —C(═NR^(bb))R^(aa),—C(═NR″)ORaa, —C(═NR^(cc))N(R^(cc))₂, —SO₂N(R^(cc))₂, —SO₂R^(cc),—SO₂OR^(cc), —SOR^(aa), —C(═S)N(R^(cc))₂, —C(═O)SR^(cc), —C(═S)SR^(cc),—P(═O)₂R^(aa), —P(═O)(R^(aa))₂, —P(═O)₂N(R^(cc))₂, —P(═O)(NR^(cc))₂,C₁₋₁₀ alkyl, C₁₋₁₀ perhaloalkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 memberedheteroaryl, or two R^(cc) groups attached to a nitrogen atom are joinedto form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring,wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl,and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5R^(dd) groups, and wherein R^(aa), R^(bb), R^(cc) and R^(dd) are asdefined above. In certain embodiments, the substituent present on anitrogen atom is a nitrogen protecting group (also referred to as anamino protecting group). Nitrogen protecting groups include, but are notlimited to, —OH, —OR^(aa), —N(R^(cc))₂, —C(═O)R^(aa), —C(═O)N(R^(cc))₂,—CO₂R^(aa), —SO₂R^(aa), —C(═NR^(cc))R^(aa), —C(═NR^(cc))OR^(aa),—C(═NR^(cc))N(R^(cc))₂, —SO₂N(R^(cc))₂, —SO₂R^(cc), —SO₂OR^(cc),—SOR^(aa), —C(═S)N(R^(cc))₂, —C(═O)SR^(cc), —C(═S)SR^(cc), C₁₋₁₀ alkyl(e.g., aralkyl, heteroaralkyl), C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₃₋₁₀carbocyclyl, 3-14 membered heterocyclyl, C₆₋₁₄ aryl, and 5-14 memberedheteroaryl groups, wherein each alkyl, alkenyl, alkynyl, carbocyclyl,heterocyclyl, aralkyl, aryl, and heteroaryl is independently substitutedwith 0, 1, 2, 3, 4, or 5 R^(dd) groups, and wherein R^(aa), R^(bb),R^(cc), and R^(dd) are as defined herein. Nitrogen protecting groups arewell known in the art and include those described in detail inProtecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts,3^(rd) edition, John Wiley & Sons, 1999, incorporated herein byreference.

Amide nitrogen protecting groups (e.g., —C(═O)R^(aa)) include, but arenot limited to, formamide, acetamide, chloroacetamide,trichloroacetamide, trifluoroacetamide, phenylacetamide,3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide,N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide,o-nitophenylacetamide, o-nitrophenoxyacetamide, acetoacetamide,(N′-dithiobenzyloxyacylamino)acetamide, 3-(p-hydroxyphenyl)propanamide,3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide,2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide,3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine,o-nitrobenzamide, and o-(benzoyloxymethyl)benzamide. Carbamate nitrogenprotecting groups (e.g., —C(═O)OR^(aa)) include, but are not limited to,methyl carbamate, ethyl carbamante, 9-fluorenylmethyl carbamate (Fmoc),9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluoroenylmethylcarbamate,2,7-di-t-butyl-[9-(10,10-dioxo-10,10,10,10-tetrahydrothioxanthyl)]methylcarbamate (DBD-Tmoc), 4-methoxyphenacyl carbamate (Phenoc),2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate(Teoc), 2-phenylethyl carbamate (hZ), 1-(1-adamantyl)-1-methylethylcarbamate (Adpoc), 1,1-dimethyl-2-haloethyl carbamate,1,1-dimethyl-2,2-dibromethyl carbamate (DBtBOC),1,1dimethyl-2,2,2trichloroethyl carbamate (TCBOC),1methyl-1(4biphenylyl)ethyl carbamate (Bpoc),1(3,5ditbutylphenyl)-1methylethyl carbamate (tBumeoc), 2(2′ and4′pyridyl)ethyl carbamate (Pyoc), 2(N,N-dicyclohexylcarboxamido)ethylcarbamate, t-butyl carbamate (BOC), 1adamantyl carbamate (Adoc), vinylcarbamate (Voc), allyl carbamate (Alloc), 1isopropylallyl carbamate(Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc),8quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithiocarbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz),p-nitobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzylcarbamate, 2,4dichlorobenzyl carbamate, 4methylsulfinylbenzyl carbamate(Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate,2methylthioethyl carbamate, 2-methylsulfonylethyl carbamate,2(ptoluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methyl carbamate(Dmoc), 4methylthiophenyl carbamate (Mtpc), 2,4-dimethylthiophenylcarbamate (Bmpc), 2phosphonioethyl carbamate (Peoc),2-triphenylphosphonioisopropyl carbamate (Ppoc), 1,1dimethyl-2cyanoethylcarbamate, m-chloropacyloxybenzyl carbamate, p(dihydroxyboryl)benzylcarbamate, 5-benzisoxazolylmethyl carbamate,2(trifluoromethyl)-6chromonylmethyl carbamate (Tcroc), mnitrophenylcarbamate, 3,5dimethoxybenzyl carbamate, onitrobenzyl carbamate,3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(onitrophenyl)methylcarbamate, tamyl carbamate, S-benzyl thiocarbamate, pcyanobenzylcarbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentylcarbamate, cyclopropylmethyl carbamate, pdecyloxybenzyl carbamate,2,2dimethoxyacylvinyl carbamate, o(N,Ndimethylcarboxamido)benzylcarbamate, 1,1dimethyl-3(N,Ndimethylcarboxamido)propyl carbamate,1,1-dimethylpropynyl carbamate, di(2pyridyl)methyl carbamate,2furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate,isobutyl carbamate, isonicotinyl carbamate,p-(p′-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate,1-methylcyclohexyl carbamate, 1-methyllcyclopropylmethyl carbamate,1-methyl-1-(3,5-dimethoxyphenyl)ethyl carbamate,1-methyl-1-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1-phenylethylcarbamate, 1-methyl-1-(4-pyridyl)ethyl carbamate, phenyl carbamate,p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate,4-(trimethylammonium)benzyl carbamate, and 2,4,6-trimethylbenzylcarbamate.

Sulfonamide nitrogen protecting groups (e.g., S(═O)₂R^(aa)) include, butare not limited to, ptoluenesulfonamide (Ts), benzenesulfonamide,2,3,6,-trimethyl-4-methoxybenzenesulfonamide (Mtr),2,4,6-trimethoxybenzenesulfonamide (Mtb),2,6-dimethyl-4-methoxybenzenesulfonamide (Pme),2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte),4methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide(Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds),2,2,5,7,8-p-entamethylchroman-6-sulfonamide (Pmc), methanesulfonamide(Ms), 13-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide,4(4′,8′-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS),benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.Other nitrogen protecting groups include, but are not limited to,phenothiazinyl-(10)-acyl derivative, N′-p-toluenesulfonylaminoacylderivative, N′-phenylaminothioacyl derivative, N-benzoylphenylalanylderivative, N-acetylmethionine derivative,4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts),N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole,N-1,1,4,4-tetramethyldisilylazacyclopentane adduct (STABASE),5-substituted 1,3-dimethyl-1,3,5-triazacyclohexan-2-one, 5-substituted1,3-dibenzyl-1,3,5-triazacyclohexan-2one, 1-substituted3,5-dinitro-4-pyridone, Nmethylamine, N-allylamine,N-[2-(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine,N-(1-isopropyl-4-nitro-2oxo-3pyroolin-3yl)amine, quaternary ammoniumsalts, N-benzylamine, N-di(4-methoxyphenyl)methylamine,N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr),N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr),N-9-phenylfluorenylamine (PhF),N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fcm),N-2-picolylamino N′-oxide, N-1,1-dimethylthiomethyleneamine,N-benzylideneamine, N-p-methoxybenzylideneamine,N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine,N-(N′,N′-dimethylaminomethylene)amine, N,N′-isopropylidenediamine,N-p-nitrobenzylideneamine, N-salicylideneamine,N-5-chlorosalicylideneamine,N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine,N-cyclohexylideneamine, N-(5,5dimethyl-3-oxo-1-cyclohexenyl)amine,N-borane derivative, N-diphenylborinic acid derivative,N-[phenyl(pentaacylchromium- or tungsten)acyl]amine, N-copper chelate,N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide,diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt),diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzylphosphoramidate, diphenyl phosphoramidate, benzenesulfenamide,onitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide,pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide,triphenylmethylsulfenamide, and 3-nitropyridinesulfenamide (Npys).

In certain embodiments, the substituent present on an oxygen atom is anoxygen protecting group (also referred to as a hydroxyl protectinggroup). Oxygen protecting groups include, but are not limited to,—R^(aa), —N(R^(bb))₂, —C(═O)SR^(aa), —C(═O)R^(aa), —CO₂R^(aa),—C(═O)N(R^(bb))₂, —C(═NR^(bb))R^(aa), —C(═NR^(bb))OR^(aa),—C(═NR^(bb))N(R^(bb))₂, —S(═O)R^(aa), —SO₂R^(aa), —Si(R^(aa))₃,—P(R^(cc))₂, —P(R^(cc))₃, —P(═O)₂R^(aa), —P(═O)(R^(aa))₂,—P(═O)(OR^(cc))₂, —P(═O)₂N(R^(bb))₂, and —P(═O)(NR^(bb))₂, whereinR^(aa), R^(bb), and R^(cc) are as defined herein. Oxygen protectinggroups are well known in the art and include those described in detailin Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M.Wuts, 3^(rd) edition, John Wiley & Sons, 1999, incorporated herein byreference.

Exemplary oxygen protecting groups include, but are not limited to,methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl,(phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM),p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM),guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM),siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl,bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR),tetrahydropyranyl (THP), 3-bromotetrahydropyranyl,tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl(MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranylS,S-dioxide, 1[(2chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP),1,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl,2,3,3a,4,5,6,7,7aoctahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl,1-ethoxyethyl, 1-(2-chloroethoxy)ethyl, 1-methyllmethoxyethyl,1-methyl-1-benzyloxyethyl, 1-methyl-1-benzyloxy-2-fluoroethyl,2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl,t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl,benzyl (Bn), p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl,p-nitrobenzyl, phalobenzyl, 2,6-dichlorobenzyl, pcyanobenzyl,pphenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxido,diphenylmethyl, p,p′-dinitrobenzhydryl, 5-dibenzosuberyl,triphenylmethyl, anaphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl,di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl,4(4′-bromophenacyloxyphenyl)diphenylmethyl,4,4′,4″-tris(4,5-dichlorophthalimidophenyl)methyl,4,4′,4″-tris(levulinoyloxyphenyl)methyl,4,4′,4″-tris(benzoyloxyphenyl)methyl,3-(imidazol-1-yl)bis(4′,4″-dimethoxyphenyl)methyl,1,1-bis(4-methoxyphenyl)-1′-pyrenylmethyl, 9-anthryl,9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl,1,3-benzodithiolan-2-yl, benzisothiazolyl S,S-dioxido, trimethylsilyl(TMS), triethylsilyl (TES), triisopropylsilyl (TIPS),dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS),dimethylthexylsilyl, t butyldimethylsilyl (TBDMS), t-butyldiphenylsilyl(TBDPS), tribenzylsilyl, tri-p-xylylsil-yl, triphenylsilyl,diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate,benzoylformate, acetate, chloroacetate, dichloroacetate,trichloroacetate, trifluoroacetate, methoxyacetate,triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate,3-phenylpropionate, 4-oxopentanoate (levulinate),4,4-(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate,adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate,2,4,6-trimethylbenzoate (mesitoate), methyl carbonate, 9-fluorenylmethylcarbonate (Fmoc), ethyl carbonate, 2,2,2-trichloroethyl carbonate(Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC),2-(phenylsulfonyl)ethyl carbonate (P-sec), 2-(triphenylphosphonio)ethylcarbonate (P-eoc), isobutyl carbonate, vinyl carbonate, allyl carbonate,t-butyl carbonate (BOC), p-nitrophenyl carbonate, benzyl carbonate,p-methoxybenzyl carbonate, 3,4-dimethoxybenzyl carbonate, onitrobenzylcarbonate, p-nitrobenzyl carbonate, S-benzyl thiocarbonate,4ethoxy-1napththyl carbonate, methyl dithiocarbonate, 2-iodobenzoate,4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate,2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl,4-(methylthiomethoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate,2,6-dichloro-4-methylphenoxyacetate,2,6-dichloro-4-(1,1,3,3-tetramethylbutyl)phenoxyacetate,2,4-bis(1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate,isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate,o-(methoxyacyl)benzoate, α-naphthoate, nitrate, alkylN,N,N′,N′-tetramethylphosphorodiamidate, alkyl N-phenylcarbamate,borate, dimethylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate,sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate(Ts). In certain embodiments, the substituent present on a sulfur atomis a sulfur protecting group (also referred to as a thiol protectinggroup). Sulfur protecting groups include, but are not limited to,—R^(aa), —N(R^(bb))₂, —C(═O)SR^(aa), —C═O)R^(aa), —CO₂R^(aa),—C(═O)N(R^(bb))₂, —C(═NR^(bb))R^(aa), —C(═NR^(bb))OR^(aa),C(═NR^(bb))N(R^(bb))₂, —S(═O)R^(aa), —SO₂R^(aa), —Si(R^(aa))₃,—P(R^(cc))₂, —P(R^(cc))₃, —P(═O)₂R^(aa), —P(═O)(R^(aa))₂,—P(═O)(OR^(cc))₂, —P(═O)₂N(R^(bb))₂, and —P(═O)(NR^(bb))₂, whereinR^(aa), R^(bb), and R^(cc) are as defined herein. Sulfur protectinggroups are well known in the art and include those described in detailin Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M.Wuts, 3^(rd) edition, John Wiley & Sons, 1999, incorporated herein byreference.

These and other exemplary substituents are described in more detail inthe Detailed Description, Examples, and claims. The present disclosureis not intended to be limited in any manner by the above exemplarylisting of substituents.

“Pharmaceutically acceptable salt” refers to those salts which are,within the scope of sound medical judgment, suitable for use in contactwith the tissues of humans and other animals without undue toxicity,irritation, allergic response, and the like, and are commensurate with areasonable benefit/risk ratio. Pharmaceutically acceptable salts arewell known in the art. For example, Berge et al. describepharmaceutically acceptable salts in detail in J. PharmaceuticalSciences (1977) 66:1-19. Pharmaceutically acceptable salts of thecompounds describe herein include those derived from suitable inorganicand organic acids and bases. Examples of pharmaceutically acceptable,nontoxic acid addition salts are salts of an amino group formed withinorganic acids such as hydrochloric acid, hydrobromic acid, phosphoricacid, sulfuric acid and perchloric acid or with organic acids such asacetic acid, oxalic acid, maleic acid, tartaric acid, citric acid,succinic acid, or malonic acid or by using other methods used in the artsuch as ion exchange. Other pharmaceutically acceptable salts includeadipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate,bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate,cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,formate, fumarate, glucoheptonate, glycerophosphate, gluconate,hemisulfate, heptanoate, hexanoate, hydroiodide,2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, laurylsulfate, malate, maleate, malonate, methanesulfonate,2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate,pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate,pivalate, propionate, stearate, succinate, sulfate, tartrate,thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and thelike. Salts derived from appropriate bases include alkali metal,alkaline earth metal, ammonium and N⁺(C₁₋₄alkyl)₄ salts. Representativealkali or alkaline earth metal salts include sodium, lithium, potassium,calcium, magnesium, and the like. Further pharmaceutically acceptablesalts include, when appropriate, quaternary salts.

A “subject” to which administration is contemplated includes, but is notlimited to, humans (e.g., a male or female of any age group, e.g., apediatric subject (e.g, infant, child, adolescent) or adult subject(e.g., young adult, middle-aged adult or senior adult)) and/or othernonhuman animals, for example, non-human mammals (e.g., primates (e.g.,cynomolgus monkeys, rhesus monkeys); commercially relevant mammals suchas cattle, pigs, horses, sheep, goats, cats, and/or dogs), birds (e.g.,commercially relevant birds such as chickens, ducks, geese, and/orturkeys), rodents (e.g., rats and/or mice), reptiles, amphibians, andfish. In certain embodiments, the nonhuman animal is a mammal. Thenonhuman animal may be a male or female at any stage of development. Anonhuman animal may be a transgenic animal.

“Condition,” “disease,” and “disorder” are used interchangeably herein.

“Treat,” “treating” and “treatment” encompasses an action that occurswhile a subject is suffering from a condition which reduces the severityof the condition or retards or slows the progression of the condition(“therapeutic treatment”). “Treat,” “treating” and “treatment” alsoencompasses an action that occurs before a subject begins to suffer fromthe condition and which inhibits or reduces the severity of thecondition (“prophylactic treatment”).

An “effective amount” of a compound refers to an amount sufficient toelicit the desired biological response, e.g., treat the condition. Aswill be appreciated by those of ordinary skill in this art, theeffective amount of a compound described herein may vary depending onsuch factors as the desired biological endpoint, the pharmacokinetics ofthe compound, the condition being treated, the mode of administration,and the age and health of the subject. An effective amount encompassestherapeutic and prophylactic treatment.

A “therapeutically effective amount” of a compound is an amountsufficient to provide a therapeutic benefit in the treatment of acondition or to delay or minimize one or more symptoms associated withthe condition. A therapeutically effective amount of a compound means anamount of therapeutic agent, alone or in combination with othertherapies, which provides a therapeutic benefit in the treatment of thecondition. The term “therapeutically effective amount” can encompass anamount that improves overall therapy, reduces or avoids symptoms orcauses of the condition, or enhances the therapeutic efficacy of anothertherapeutic agent.

A “prophylactically effective amount” of a compound is an amountsufficient to prevent a condition, or one or more symptoms associatedwith the condition or prevent its recurrence. A prophylacticallyeffective amount of a compound means an amount of a therapeutic agent,alone or in combination with other agents, which provides a prophylacticbenefit in the prevention of the condition. The term “prophylacticallyeffective amount” can encompass an amount that improves overallprophylaxis or enhances the prophylactic efficacy of anotherprophylactic agent.

As used herein, the term “methyltransferase” represents transferaseclass enzymes that are able to transfer a methyl group from a donormolecule to an acceptor molecule, e.g., an amino acid residue of aprotein or a nucleic base of a DNA molecule. Methytransferases typicallyuse a reactive methyl group bound to sulfur in S-adenosyl methionine(SAM) as the methyl donor. In some embodiments, a methyltransferasedescribed herein is a protein methyltransferase. In some embodiments, amethyltransferase described herein is a histone methyltransferase.Histone methyltransferases (HMT) are histone-modifying enzymes,(including histone-lysine N-methyltransferase and histone-arginineN-methyltransferase), that catalyze the transfer of one or more methylgroups to lysine and arginine residues of histone proteins. In certainembodiments, a methyltransferase described herein is a histone-arginineN-methyltransferase.

As generally described above, provided herein are compounds useful asarginine methyltransferase (RMT) inhibitors. In some embodiments, thepresent disclosure provides a compound of Formula (I):

or a pharmaceutically acceptable salt thereof,wherein

X is N, Z is NR⁴, and Y is CR⁵; or

X is NR⁴, Z is N, and Y is CR⁵; or

X is CR⁵, Z is NR⁴, and Y is N; or

X is CR⁵, Z is N, and Y is NR⁴;

Q is an optionally substituted, monocyclic or bicyclic heteroaryl having1-4 heteroatoms independently selected from nitrogen, oxygen, andsulfur, wherein Q is not pyridine;

R³ is hydrogen, C₁₋₄ alkyl, or C₃₋₄ cycloalkyl;

R⁴ is hydrogen, optionally substituted C₁₋₆ alkyl, optionallysubstituted C₂₋₆ alkenyl, optionally substituted C₂₋₆ alkynyl,optionally substituted C₃₋₇ cycloalkyl, optionally substituted 4- to7-membered heterocyclyl; or optionally substituted C₁₋₄ alkyl-Cy;

Cy is optionally substituted C₃₋₇ cycloalkyl, optionally substituted 4-to 7-membered heterocyclyl, optionally substituted aryl, or optionallysubstituted heteroaryl; and

R⁵ is hydrogen, halo, —CN, optionally substituted C₁₋₄ alkyl, oroptionally substituted C₃₋₄ cycloalkyl.

In certain embodiments, a provided compound is of Formula (II):

or a pharmaceutically acceptable salt thereof, wherein Q, R³, R⁴, R⁵,and R^(x) are as described herein.

In certain embodiments, a provided compound is of Formula (III):

or a pharmaceutically acceptable salt thereof, wherein Q, R³, R⁴, R⁵,and R^(x) are as described herein.

In certain embodiments, a provided compound is of Formula (IV):

or a pharmaceutically acceptable salt thereof, wherein Q, R³, R⁴, R⁵,and R^(x) are as described herein.

In certain embodiments, a provided compound is of Formula (V):

or a pharmaceutically acceptable salt thereof, wherein Q, R³, R⁴, R⁵,and R^(x) are as described herein.

As defined generally above, Q is optionally substituted heteroaryl. Insome embodiments, Q is an optionally substituted 5- to 10-memberedheteroaryl having 1-4 heteroatoms independently selected from nitrogen,oxygen, and sulfur. In some embodiments, Q is an optionally substituted5- to 8-membered heteroaryl having 1-4 heteroatoms independentlyselected from nitrogen, oxygen, and sulfur. In some embodiments, Q is anoptionally substituted 5- to 6-membered heteroaryl having 1-4heteroatoms independently selected from nitrogen, oxygen, and sulfur. Insome embodiments, Q is an optionally substituted 5- to 6-memberedheteroaryl having 1-3 heteroatoms independently selected from nitrogen,oxygen, and sulfur. In some embodiments, Q is an optionally substituted5- to 6-membered heteroaryl having 1-2 heteroatoms independentlyselected from nitrogen, oxygen, and sulfur. In some embodiments, Q is anoptionally substituted 5- to 6-membered heteroaryl having 1 heteroatomselected from nitrogen, oxygen, and sulfur.

In some embodiments, Q is an optionally substituted 8- to 10-memberedbicyclic heteroaryl having 1-4 heteroatoms independently selected fromnitrogen, oxygen, and sulfur. In some embodiments, Q is an optionallysubstituted 9- to 10-membered bicyclic heteroaryl having 1-4 heteroatomsindependently selected from nitrogen, oxygen, and sulfur. In someembodiments, Q is an optionally substituted 9-membered bicyclicheteroaryl having 1-4 heteroatoms independently selected from nitrogen,oxygen, and sulfur. In some embodiments, Q is an optionally substituted9-membered bicyclic heteroaryl having 1-3 heteroatoms independentlyselected from nitrogen, oxygen, and sulfur. In some embodiments, Q is anoptionally substituted 9-membered bicyclic heteroaryl having 1-2heteroatoms independently selected from nitrogen, oxygen, and sulfur. Insome embodiments, Q is an optionally substituted 9-membered bicyclicheteroaryl having 1 heteroatom selected from nitrogen, oxygen, andsulfur. In some embodiments, Q is an optionally substituted 10-memberedbicyclic heteroaryl having 1-4 heteroatoms independently selected fromnitrogen, oxygen, and sulfur. In some embodiments, Q is an optionallysubstituted 10-membered bicyclic heteroaryl having 1-3 heteroatomsindependently selected from nitrogen, oxygen, and sulfur. In someembodiments, Q is an optionally substituted 10-membered bicyclicheteroaryl having 1-2 heteroatoms independently selected from nitrogen,oxygen, and sulfur. In some embodiments, Q is an optionally substituted10-membered bicyclic heteroaryl having 1 heteroatom selected fromnitrogen, oxygen, and sulfur.

In certain embodiments, Q is substituted. In certain embodiments, Q isunsubstituted.

In certain embodiments, Q is substituted pyrrolyl. In certainembodiments, Q is unsubstituted pyrrolyl. In certain embodiments, Q issubstituted furanyl. In certain embodiments, Q is unsubstituted furanyl.In certain embodiments, Q is substituted thienyl. In certainembodiments, Q is unsubstituted thienyl. In certain embodiments, Q issubstituted imidazolyl. In certain embodiments, Q is unsubstitutedimidazolyl. In certain embodiments, Q is substituted pyrazolyl. Incertain embodiments, Q is unsubstituted pyrazolyl. In certainembodiments, Q is substituted oxazolyl. In certain embodiments, Q isunsubstituted oxazolyl. In certain embodiments, Q is substitutedthiazolyl. In certain embodiments, Q is unsubstituted thiazolyl. Incertain embodiments, Q is substituted isothiazolyl. In certainembodiments, Q is unsubstituted isothiazolyl. In certain embodiments, Qis substituted triazolyl. In certain embodiments, Q is unsubstitutedtriazolyl. In certain embodiments, Q is substituted oxadiazolyl. Incertain embodiments, Q is unsubstituted thiadiazolyl. In certainembodiments, Q is substituted oxadiazolyl. In certain embodiments, Q isunsubstituted thiadiazolyl. In certain embodiments, Q is substitutedtetrazolyl. In certain embodiments, Q is unsubstituted tetrazolyl.

In certain embodiments, Q is substituted pyridyl. In certainembodiments, Q is unsubstituted pyridyl. In certain embodiments, Q issubstituted pyrimidyl. In certain embodiments, Q is unsubstitutedpyrimidyl. In certain embodiments, Q is substituted pyrazinyl. Incertain embodiments, Q is unsubstituted pyrazinyl. In certainembodiments, Q is substituted pyridazinyl. In certain embodiments, Q isunsubstituted pyridazinyl. In certain embodiments, Q is substitutedtriazinyl. In certain embodiments, Q is unsubstituted triazinyl.

In certain embodiments, Q is substituted indolyl. In certainembodiments, Q is unsubstituted indolyl. In certain embodiments, Q issubstituted isoindolyl. In certain embodiments, Q is unsubstitutedisoindolyl. In certain embodiments, Q is substituted indazolyl. Incertain embodiments, Q is unsubstituted indazolyl. In certainembodiments, Q is substituted benzotriazolyl. In certain embodiments, Qis unsubstituted benzotriazolyl. In certain embodiments, Q issubstituted benzothiophenyl. In certain embodiments, Q is unsubstitutedbenzothiophenyl. In certain embodiments, Q is substitutedisobenzothiophenyl. In certain embodiments, Q is unsubstitutedisobenzothiophenyl. In certain embodiments, Q is substitutedbenzofuranyl. In certain embodiments, Q is unsubstituted benzofuranyl.In certain embodiments, Q is substituted benzoisofuranyl. In certainembodiments, Q is unsubstituted benzoisofuranyl. In certain embodiments,Q is substituted benzimidazolyl. In certain embodiments, Q isunsubstituted benzimidazolyl. In certain embodiments, Q is substitutedbenzoxazolyl. In certain embodiments, Q is unsubstituted benzoxazolyl.In certain embodiments, Q is substituted benzoxadiazolyl. In certainembodiments, Q is unsubstituted benzoxadiazolyl. In certain embodiments,Q is substituted benzisoxazolyl. In certain embodiments, Q isunsubstituted benzisoxazolyl. In certain embodiments, Q is substitutedbenzthiazolyl. In certain embodiments, Q is unsubstituted benzthiazolyl.In certain embodiments, Q is substituted benzisothiazolyl. In certainembodiments, Q is unsubstituted benzisothiazolyl. In certainembodiments, Q is substituted benzthiadiazolyl. In certain embodiments,Q is unsubstituted benzthiadiazolyl. In certain embodiments, Q issubstituted indolizinyl. In certain embodiments, Q is unsubstitutedindolizinyl. In certain embodiments, Q is substituted purinyl. Incertain embodiments, Q is unsubstituted purinyl. In certain embodiments,Q is substituted pyrrolopyridinyl. In certain embodiments, Q isunsubstituted pyrrolopyridinyl. In certain embodiments, Q is substitutedtriazolopyridinyl. In certain embodiments, Q is unsubstitutedtriazolopyridinyl.

In certain embodiments, Q is substituted naphthyridinyl. In certainembodiments, Q is unsubstituted naphthyridinyl. In certain embodiments,Q is substituted pteridinyl. In certain embodiments, Q is unsubstitutedpteridinyl. In certain embodiments, Q is substituted quinolinyl. Incertain embodiments, Q is unsubstituted quinolinyl. In certainembodiments, Q is substituted isoquinolinyl. In certain embodiments, Qis unsubstituted isoquinolinyl. In certain embodiments, Q is substitutedcinnolinyl. In certain embodiments, Q is unsubstituted cinnolinyl. Incertain embodiments, Q is substituted quinoxalinyl. In certainembodiments, Q is unsubstituted quinoxalinyl. In certain embodiments, Qis substituted quinazolinyl. In certain embodiments, Q is unsubstitutedquinazolinyl. In certain embodiments, Q is substituted phthalazinyl. Incertain embodiments, Q is unsubstituted phthalazinyl.

In some embodiments, Q is substituted with one or more R^(q) groups,wherein each R^(q) is independently selected from the group consistingof halo, —CN, —NO₂, optionally substituted alkyl, optionally substitutedalkenyl, optionally substituted alkynyl, optionally substitutedcarbocyclyl, optionally substituted aryl, optionally substitutedheterocyclyl, optionally substituted heteroaryl, —OR^(A), —N(R^(B))₂,—SR^(A), —C(═O)R^(A), —C(O)OR^(A), —C(O)SR^(A), —C(O)N(R^(B))₂,—C(O)N(R^(B))N(R^(B))₂, —OC(O)R^(A), —OC(O)N(R^(B))₂, —NR^(B)C(O)R^(A),—NR^(B)C(O)N(R^(B))₂, —NR^(B)C(O)N(R^(B))N(R^(B))₂, —NR^(B)C(O)OR^(A),—SC(O)R^(A), —C(═NR^(B))R^(A), —C(═NNR^(B))R^(A), —C(═NOR^(A))R^(A),—C(═NR^(B))N(R^(B))₂, —NR^(B)C(═NR^(B))R^(B), —C(═S)R^(A),—C(═S)N(R^(B))₂, —NR^(B)C(═S)R^(A), —S(O)R^(A), —OS(O)₂R^(A), —SO₂R^(A),—NR^(B)SO₂R^(A), or —SO₂N(R^(B))₂; wherein each R^(A) is independentlyselected from the group consisting of hydrogen, optionally substitutedalkyl, optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted carbocyclyl, optionally substituted heterocyclyl,optionally substituted aryl, optionally substituted heteroaryl, anoxygen protecting group when attached to an oxygen atom, and a sulfurprotecting group when attached to a sulfur atom; and each R^(B) isindependently selected from the group consisting of hydrogen, optionallysubstituted alkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted carbocyclyl, optionallysubstituted heterocyclyl, optionally substituted aryl, optionallysubstituted heteroaryl, and a nitrogen protecting group, or two R^(B)groups are taken together with their intervening atoms to form anoptionally substituted heterocyclic ring. In some embodiments, R^(q) ishalo. In certain embodiments, R^(q) is fluoro. In certain embodiments,R^(q) is chloro. In some embodiments, R^(q) is optionally substitutedalkyl, optionally substituted alkenyl, optionally substituted alkynyl,or optionally substituted carbocyclyl. In certain embodiments, R^(q) isoptionally substituted C₁₋₆ alkyl, optionally substituted C₂₋₆ alkenyl,optionally substituted C₂₋₆ alkynyl, or optionally substituted C₃₋₆carbocyclyl. In certain embodiments, R^(q) is optionally substitutedC₁₋₆ alkyl. In certain embodiments, R^(q) is substituted C₁₋₆ alkyl. Incertain embodiments, R^(q) is CF₃. In certain embodiments, R^(q) is—CHF₂. In certain embodiments, R^(q) is —C₁₋₆alkyl-carbocyclyl. Incertain embodiments, R^(q) is CH₂-cyclopropyl or CH₂-cyclobutyl. Incertain embodiments, R^(q) is unsubstituted C₁₋₆ alkyl. In certainembodiments, R^(q) is methyl, ethyl, propyl, butyl, or pentyl. Incertain embodiments, R^(q) is isopropyl, isobutyl, or isoamyl. Incertain embodiments, R^(q) is isobutyl. In some embodiments, R^(q) isCN. In some embodiments, R^(q) is optionally substituted carbocyclyl,optionally substituted aryl, optionally substituted heterocyclyl, oroptionally substituted heteroaryl. In some embodiments, R^(q) iscyclopropyl or cyclobutyl. In some embodiments, R^(q) is _^(ORA,)N(R^(B))₂, —SR^(A), —C(═O)R^(A), —C(O)OR^(A), —C(O)SR^(A),—C(O)N(R^(B))₂, —C(O)N(R^(B))N(R^(B))₂, —OC(O)R^(A), —OC(O)N(R^(B))₂,—NR^(B)C(O)N(R^(B))₂, —NRBC(O)N(RB)N(RB. ₂,)NR^(B)C(O)OR^(A),—SC(O)R^(A), —C(═NR^(B))R^(A), —C(═NNR^(B))R^(A), C(—NOR^(A))R^(A),C(═NR^(B))N(R^(B))₂, —NR^(B)C(═NR^(B))R^(B), —C(═S)R^(A),—C(═S)N(R^(B))₂, —NR^(B)C(═S)R^(A), —S(O)R^(A), —OS(O)₂R^(A), —SO₂R^(A),or —SO₂N(R^(B))₂. In certain embodiments, R^(q) is —N(R^(B))₂. Incertain embodiments, R^(q) is —NHR^(B). In certain embodiments, R^(q) is—NHR^(B), wherein R^(B) is optionally substituted C₁₋₆ alkyl. In certainembodiments, R^(q) is —NHR^(B), wherein R^(B) is unsubstituted C₁₋₆alkyl. In certain embodiment, R^(q) is —NHR^(B), wherein R^(B) issubstituted C₁₋₆ alkyl. In certain embodiments, R^(q) is —NH-benzyl. Incertain embodiments, R^(q) is —N(R^(B))₂, wherein each R^(B) isindependently optionally substituted C₁₋₆ alkyl. In certain embodiments,R^(q) is —N(R^(B))₂, wherein each R^(B) is independently unsubstitutedC₁₋₆ alkyl. In certain embodiments, R^(q) is —N(CH₃)R^(B), wherein eachR^(B) is independently optionally substituted C₁₋₆ alkyl. In certainembodiments, R^(q) is —N(CH₃)R^(B), wherein each R^(B) is independentlyunsubstituted C₁₋₆ alkyl. In certain embodiments, R^(q) is—N(CH₂CH₃)R^(B), wherein each R^(B) is independently optionallysubstituted C₁₋₆ alkyl. In certain embodiments, R^(q) is—N(CH₂CH₃)R^(B), wherein each R^(B) is independently unsubstituted C₁₋₆alkyl. In certain embodiments, R^(q) is —N(R^(B))₂, wherein each R^(B)is independently selected from the group consisting of methyl, ethyl,isopropyl, isobutyl, isoamyl, and benzyl. In some embodiments, R^(q) is—N(R^(B))₂, wherein each R^(B) is the same. In some embodiments, R^(q)is N(R^(B))₂, wherein each R^(B) is different. In certain embodiments,R^(q) is —NH₂. In certain embodiments, R^(q) is —OR^(A). In certainembodiments, R^(q) is —OH. In certain embodiments, R^(q) is —OR^(A),wherein R^(A) is optionally substituted alkyl, optionally substitutedalkenyl, optionally substituted alkynyl, or optionally substitutedcarbocyclyl. In certain embodiments, R^(q) is O-isobutylenyl. In certainembodiments, R^(q) is —OR^(A), wherein R^(A) is optionally substitutedC₁₋₆ alkyl. In certain embodiments, R^(q) is —OR^(A), wherein R^(A) isunsubstituted C₁₋₆ alkyl. In certain embodiments, R^(q) is —O-propyl,0-isopropyl, —O-isobutyl, or —O-isoamyl. In certain embodiments, R^(q)is —OR^(A), wherein R^(A) is substituted C₁₋₆ alkyl. In certainembodiments, R^(q) is —O—C₁₋₆alkyl-O—C₁₋₆alkyl. In certain embodiments,R¹ is —OCH₂CH₂OCH₃ or —OCH₂CH₂CH₂OCH₃. In certain embodiments, R^(q) is—O—C₁₋₆alkyl-carbocyclyl. In certain embodiments, R^(q) is—O—CH₂-cyclobutyl or —O—CH₂-cyclopropyl. In certain embodiments, R^(q)is —O—C₁₋₆alkyl-heterocyclyl. In certain embodiments, R^(q) isO‘CH₂-tetrahydropyranyl or —O—CH₂-oxetanyl. In certain embodiments,R^(q) is —OR^(A), wherein R^(A) is optionally substituted heterocyclyl.In certain embodiments, R^(q) is —O-tetrahydropyranyl or —O-oxetanyl. Incertain embodiments, R^(q) is —OR^(A), wherein R^(A) is optionallysubstituted aryl. In certain embodiments, R^(q) is O-phenyl. In certainembodiments, R^(q) is OR^(A), wherein R^(A) is optionally substitutedheteroaryl.

In some embodiments, Q is unsubstituted. In some embodiments, Q issubstituted with one R^(q) group. In some embodiments, Q is substitutedwith two R^(q) groups. In some embodiments, Q is substituted with threeR^(q) groups. In some embodiments, Q is substituted with four R^(q)groups.

In certain embodiments, Q is of Formula (q-1):

In certain embodiments, Q is of Formula (q-2):

In certain embodiments, Q is of Formula (q-3):

In certain embodiments, Q is of Formula (q-4):

As used herein, each instance of V¹, V², V³, V⁴, V⁵, V⁶, V⁷, V⁸, and V⁹may independently be O, S, N, NR^(N), C, or CR^(C), as valency permits,wherein at least one of V¹, V², V³, V⁴, V⁵, V⁶, V⁷, V⁸, and V⁹ is O, S,N, NR^(N), and wherein:

each instance of R^(c) is independently selected from the groupconsisting of halo, —CN, —NO₂, optionally substituted alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted carbocyclyl, optionally substituted aryl, optionallysubstituted heterocyclyl, optionally substituted heteroaryl, —OR^(A),—N(R^(B))₂, —SR^(A), —C(═O)R^(A), —C(O)OR^(A), —C(O)SR^(A),—C(O)N(R^(B))₂, —C(O)N(R^(B))N(R^(B))₂, —OC(O)R^(A), —OC(O)N(R^(B))₂,—NR^(B)C(O)R^(A), —NR^(B)C(O)N(R^(B))₂, —NR^(B)C(O)N(R^(B))N(R^(B))₂,—NR^(B)C(O)OR^(A), —SC(O)R^(A), —C(═NR^(B))R^(A), —C(═NNR^(B))R^(A),—C(═NOR^(A))R^(A), —C(═NR^(B))N(R^(B))₂, —NR^(B)C(═NR^(B))R^(B),—C(═S)R^(A), —C(═S)N(R^(B))₂, —NR^(B)C(═S)R^(A), —S(O)R^(A),—OS(O)₂R^(A), —SO₂R^(A), —NR^(B)SO₂R^(A), or —SO₂N(R^(B))₂; and

each instance of R^(N) is independently selected from the groupconsisting of hydrogen, optionally substituted alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted carbocyclyl, optionally substituted heterocyclyl, optionallysubstituted aryl, optionally substituted heteroaryl, —C(═O)R^(A),—C(═O)OR^(A), —C(═O)SR^(A), —C(═O)N(R^(B))₂, —C(═NR^(B))R^(A),—C(═NNR^(B))R^(A), —C(═NOR^(A))R^(A), —C(═NR^(B))N(R^(B))₂, —C(═S)R^(A),—C(═S)N(R^(B))₂, —S(═O)R^(A), —SO₂R^(A), —SO₂N(R^(B))₂, and a nitrogenprotecting group.

In certain embodiments, V¹ is O, S, N or NR^(N). In certain embodiments,V¹ is N or NR^(N). In certain embodiments, V¹ is 0. In certainembodiments, V¹ is S. In certain embodiments, only one of V¹, V², V³,V⁴, V⁵, V⁶, V⁷, V⁸, and V⁹ is selected from the group consisting of O,S, N, and NR^(N). In certain embodiments, only one of V¹, V², V³, V⁴,V⁵, V⁶, V⁷, V⁸, _(and V) ⁹ is selected from the group consisting of Nand NR^(N). In certain embodiments, only one of V¹, V², V³, V⁴, V⁵, V⁶,V⁷, V⁸, and V⁹ is 0. In certain embodiments, only one of V¹, V⁷, V⁸, andV⁹ is S. In certain embodiments, only two of V¹, V², V³, V⁴, V⁵, V⁶, V⁷,V⁸, and V⁹ are each independently selected from the group consisting ofO, S, N, and NR^(N). In certain embodiments, only two of V¹, V², V³, V⁴,V⁵, V⁶, V⁷, V⁸, v and V⁹ are each independently selected from the groupconsisting of N and NR^(N). In certain embodiments, only two of V¹, V²,V³, V⁴, V⁵, V⁶, V⁷, V⁸, and V⁹ are each independently selected from thegroup consisting of O, N and NR^(N). In certain embodiments, only two ofV¹, V², V³, V⁴, V⁵, V⁶, V⁷, V⁸, and V⁹ are each independently selectedfrom the group consisting of S, N and NR^(N). In certain embodiments,only three of V¹, V², V³, V⁴, V⁵, V⁶, V⁷, V⁸, and V⁹ are eachindependently selected from the group consisting of O, S, N, and NR^(N).In certain embodiments, only three of V¹, V², V³, V⁴, V⁵, V⁶, V⁷, V⁸,and V⁹ are each independently selected from the group consisting of Nand NR^(N). In certain embodiments, only three of V¹, V², V³, V⁴, V⁵,V⁶, V⁷, V⁸, and V⁹ are each independently selected from the groupconsisting of O, N and NR^(N). In certain embodiments, only three of V¹,V², V³, V⁴, V⁵, V⁶, V⁷, V⁸, and V⁹ are each independently selected fromthe group consisting of S, N and NR^(N). In certain embodiments, onlyfour of V¹, V², V³, V⁴, V⁵, V⁶, V⁷, V⁸, and V⁹ are each independentlyselected from the group consisting of O, S, N, and NR^(N). In certainembodiments, only four of V¹, V², V³, V⁴, V⁵, V⁶, V⁷, V⁸, and V⁹ areeach independently selected from the group consisting of N and NR^(N).In certain embodiments, only four of V¹, V², V³, V⁴, V⁵, V⁶, V⁷, V⁸, andV⁹ are each independently selected from the group consisting of 0, N andNR^(N). In certain embodiments, only four of V¹, V², V³, V⁴, V⁵, V⁶, V⁷,V⁸, and V⁹ are each independently selected from the group consisting ofS, N and NR^(N). In certain embodiments, only five of V¹, V², V³, V⁴,V⁵, V⁶, V⁷, V⁸, and V⁹ are each independently selected from the groupconsisting of O, S, N, and NR^(N). In certain embodiments, only five ofV¹, V², V³, V⁴, V⁵, V⁶, V⁷, V⁸, and V⁹ are each independently selectedfrom the group consisting of N and NR^(N).

In certain embodiments, Q is an optionally substituted 5-memberedheteroaryl ring. In certain embodiments, Q is of Formula (q-5):

As used herein, each instance of V¹⁰, V¹¹, V¹², V¹³, and V¹⁴ mayindependently be O, S, N, NR^(N), C, or CR^(c), as valency permits,wherein R^(N) and R^(c) are as defined herein, and wherein at least oneof V¹⁰, V¹¹, V¹², V¹³, and V¹⁴ is O, S, N, or NR^(N). In certainembodiments, only one of V¹⁰, V¹¹, V¹², V¹³, and V¹⁴ is selected fromthe group consisting of O, S, N, and NR^(N). In certain embodiments,only two of V¹⁰, V¹¹, V¹², V¹³, and V¹⁴ are selected from the groupconsisting of O, S, N, and NR^(N). In certain embodiments, only three ofV¹⁰, V¹¹, V¹², V¹³, and V¹⁴ are selected from the group consisting of O,S, N, and NR^(N). In certain embodiments, only four of V¹⁰, V¹¹, V¹²,V¹³, and V¹⁴ are selected from the group consisting of O, S, N, andNR^(N). In certain embodiments, Q is an optionally substituted6-membered heteroaryl ring. In certain embodiments, Q is of Formula(q-6):

In compounds of Formula (q-6), V¹⁵, V¹⁶, V¹⁷, V¹⁸, V¹⁹, and V²⁰ are eachindependently selected from the group consisting of N or CR^(c), whereinat least one of V¹⁵, V¹⁶, V¹⁷, V¹⁸, V¹⁹, and V²⁰ is N. In certainembodiments, only one of _(V) ¹⁵, V¹⁶, V¹⁷, V¹⁸, V¹⁹, and V²⁰ is N. Incertain embodiments, only two of V¹⁵, V¹⁶, V¹⁷, V¹⁸, V¹⁹, and V²⁰ are N.In certain embodiments, only three of V¹⁵, V¹⁶, V¹⁷, V¹⁸, V¹⁹, and V²⁰are N.

In certain embodiments, Q has one of the following structures:

As defined generally above, R³ is hydrogen, C₁₋₄ alkyl, or C₃₋₄cycloalkyl. In certain embodiments, R³ is hydrogen. In certainembodiments, R³ is C₁₋₄ alkyl. In certain embodiments, R³ is methyl. Incertain embodiments, R³ is ethyl. In certain embodiments, R³ is propylor butyl. In certain embodiments, R³ is cyclopropyl. In certainembodiment, R³ is cyclobutyl.

As defined generally above, R⁴ is hydrogen, optionally substituted C₁₋₆alkyl, optionally substituted C₂₋₆ alkenyl, optionally substituted C₂₋₆alkynyl, optionally substituted C₃₋₇ cycloalkyl, optionally substituted4- to 7-membered heterocyclyl; or optionally substituted C₁₋₄ alkyl-Cy,wherein Cy is optionally substituted C₃₋₇ cycloalkyl, optionallysubstituted 4- to 7-membered heterocyclyl, optionally substituted aryl,or optionally substituted heteroaryl. In certain embodiments, R⁴ ishydrogen. In certain embodiments, R⁴ is optionally substituted C₁₋₆alkyl. In certain embodiments, R⁴ is unsubstituted C₁₋₆ alkyl. Incertain embodiments, R⁴ is methyl, ethyl, or isopropyl. In certainembodiments, R⁴ is substituted C₁₋₆ alkyl. In certain embodiments, R⁴ ismethoxyethyl. In certain embodiments, R⁴ is hydroxyethyl orpropane-1,2-diol. In certain embodiments, R⁴ is optionally substitutedC₃₋₇ cycloalkyl. In certain embodiments, R⁴ is unsubstituted C₃₋₇cycloalkyl. In certain embodiments, R⁴ is cyclopropyl, cyclobutyl,cyclopentyl, or cyclohexyl. In certain embodiments, R⁴ is optionallysubstituted 4- to 7-membered heterocyclyl. In certain embodiments, R⁴ isoptionally substituted 4- to 7-membered heterocyclyl having 1-2heteroatoms independently selected from nitrogen, oxygen, and sulfur. Incertain embodiments, R⁴ is oxetane, tetrahydrofuran, or tetrahydropyran.In certain embodiments, R⁴ is optionally substituted C₁₋₄ alkyl-Cy,wherein Cy is optionally substituted C₃₋₇ cycloalkyl, optionallysubstituted 4- to 7-membered heterocyclyl, optionally substituted aryl,or optionally substituted heteroaryl. In some embodiments, Cy isoptionally substituted C₃₋₇ cycloalkyl. In some embodiments, Cy isoptionally substituted 4- to 7-membered heterocyclyl having 1-2heteroatoms independently selected from nitrogen, oxygen, and sulfur. Insome embodiments, Cy is oxetane, tetrahydrofuran, or tetrahydropyran. Insome embodiments, Cy is optionally substituted aryl. In someembodiments, Cy is optionally substituted phenyl. In some embodiments,Cy is unsubstituted phenyl. In some embodiments, Cy is optionallysubstituted heteroaryl having 1-3 heteroatoms independently selectedfrom nitrogen, oxygen, and sulfur. In some embodiments, Cy is optionallysubstituted 5- to 6-membered heteroaryl having 1-3 heteroatomsindependently selected from nitrogen, oxygen, and sulfur. In someembodiments, Cy is pyridyl. In some embodiments, R⁴ is In

some embodiments, R⁴ is

In some embodiments, R⁴ is

As defined generally above, R⁵ is hydrogen, halo, —CN, optionallysubstituted C₁₋₄ alkyl, or optionally substituted C₃₋₄ cycloalkyl. Incertain embodiments, R⁵ is hydrogen. In certain embodiments, R⁵ is halo.In certain embodiments, R⁵ is chloro. In certain embodiments, R⁵ isfluoro. In certain embodiments, R⁵ is CN. In certain embodiments, R⁵ isoptionally substituted C₁₋₄ alkyl. In certain embodiments, R⁵ isunsubstituted C₁₋₄ alkyl. In certain embodiments, R⁵ is methyl. Incertain embodiments, R⁵ is ethyl. In certain embodiments, R⁵ is propylor butyl. In certain embodiments, R⁵ is C₁₋₄ alkyl substituted with oneor more fluoro groups. In certain embodiments, R⁵ is CF₃. In certainembodiments, R⁵ is CHF₂. In certain embodiments, R⁵ is optionallysubstituted C₃₋₄ cycloalkyl. In certain embodiments, R⁵ is cyclopropylor cyclobutyl.

As defined generally above, IV is optionally substituted C₁₋₄ alkyl oroptionally substituted C₃₋₄ cycloalkyl. In certain embodiments, IV isoptionally substituted C₁₋₄ alkyl. In certain embodiments, IV isunsubstituted C₁₋₄ alkyl. In certain embodiments, IV is methyl. Incertain embodiments, IV is ethyl. In certain embodiments, IV isisopropyl. In certain embodiments, IV is propyl or butyl. In certainembodiments, IV is substituted C₁₋₄ alkyl. In certain embodiments, IV isC₁₋₄ alkyl substituted with hydroxyl or alkoxy. In certain embodiments,IV is hydroxyethyl or methoxyethyl. In certain embodiments, IV isoptionally substituted C₃₋₄ cycloalkyl. In certain embodiments, IV isunsubstituted C₃₋₄ cycloalkyl. In certain embodiments, IV iscyclopropyl. In certain embodiments, IV is cyclobutyl.

As defined generally above, each R^(A) is independently selected fromthe group consisting of hydrogen, optionally substituted alkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted carbocyclyl, optionally substituted heterocyclyl,optionally substituted aryl, optionally substituted heteroaryl, anoxygen protecting group when attached to an oxygen atom, and a sulfurprotecting group when attached to a sulfur atom. In some embodiments,R^(A) is hydrogen. In some embodiments, R^(A) is optionally substitutedalkyl. In some embodiments, R^(A) is optionally substituted alkylsubstituted with a Cy group to form optionally substituted alkyl-Cy,wherein Cy is described herein. In some embodiments, R^(A) is optionallysubstituted alkenyl or optionally substituted alkynyl. In someembodiments, R^(A) is optionally substituted carbocyclyl, optionallysubstituted heterocyclyl, optionally substituted aryl, or optionallysubstituted heteroaryl. In some embodiments, R^(A) is an oxygenprotecting group when attached to an oxygen atom. In some embodiments,R^(A) is not an oxygen protecting group. In some embodiments, R^(A) issulfur protecting group when attached to an sulfur atom. In someembodiments, R^(A) is not a sulfur protecting group.

As defined generally above, each R^(B) is independently selected fromthe group consisting of hydrogen, optionally substituted alkyl,optionally substituted alkenyl, optionally substituted alkynyl,optionally substituted carbocyclyl, optionally substituted heterocyclyl,optionally substituted aryl, and optionally substituted heteroaryl, anda nitrogen protecting group, or two R^(B) groups are taken together withtheir intervening atoms to form an optionally substituted heterocyclicring. In some embodiments, R^(B) is hydrogen. In some embodiments, R^(B)is optionally substituted alkyl. In some embodiments, R^(B) isoptionally alkyl substituted with a Cy group to form optionallysubstituted alkyl-Cy, wherein Cy is described herein. In someembodiments, R^(B) is optionally substituted alkenyl or optionallysubstituted alkynyl. In some embodiments, R^(B) is optionallysubstituted carbocyclyl, optionally substituted heterocyclyl, optionallysubstituted aryl, or optionally substituted heteroaryl. In someembodiments, R^(B) is a nitrogen protecting group. In some embodiments,R^(B) is not a nitrogen protecting group. In some embodiments, two R^(B)groups are taken together with their intervening atoms to form anoptionally substituted heterocyclic ring.

In certain embodiments, a provided compound is a compound listed inTable 1, or a pharmaceutically acceptable salt thereof.

TABLE 1 Exemplary Compounds Cmpd LC-MS m/z No Structure (M + H)  1

301.2  2

247.2  3

237.1  4

 232.28  5

 236.34  6

221.2  7

221.2  8

235.1  9

288.1 10

250.0 11

263.2 12

221.2 13

271.2 14

221.3 15

235.4 16

249.4 17

297.1 18

265.1 19

285.4 20

272.2 21

271.1 22

262.3 23

277.1 24

311.1 25

249.3 26

263.4 27

271.3 28

273.1 29

220.2 30

271.3

In certain embodiments, a provided compound inhibits an RMT (e.g.,PRMT1, PRMT3, CARM1, PRMT6, and/or PRMT8). In certain embodiments, aprovided compound inhibits wild-type PRMT1, PRMT3, CARM1, PRMT6, and/orPRMT8. In certain embodiments, a provided compound inhibits a mutantRMT. In certain embodiments, a provided compound inhibits PRMT1, PRMT3,CARM1, PRMT6, and/or PRMT8, e.g., as measured in an assay describedherein. In certain embodiments, the RMT is from a human. In certainembodiments, a provided compound inhibits an RMT (e.g., PRMT1, PRMT3,CARM1, PRMT6, and/or PRMT8) at an IC₅₀ less than or equal to 10 μM. Incertain embodiments, a provided compound inhibits an RMT (e.g., PRMT1,PRMT3, CARM1, PRMT6, and/or PRMT8) at an IC₅₀ less than or equal to 1μM. In certain embodiments, a provided compound inhibits an RMT (e.g.,PRMT1, PRMT3, CARM1, PRMT6, and/or PRMT8) at an IC₅₀ less than or equalto 0.1 μM. In certain embodiments, a provided compound inhibits an RMT(e.g., PRMT1, PRMT3, CARM1, PRMT6, and/or PRMT8) at an IC₅₀ less than orequal to 0.01 μM. In certain embodiments, a provided compound inhibitsan RMT (e.g., PRMT1, PRMT3, CARM1, PRMT6, and/or PRMT8) in a cell at anEC₃₀ less than or equal to 10 μM. In certain embodiments, a providedcompound inhibits an RMT (e.g., PRMT1, PRMT3, CARM1, PRMT6, and/orPRMT8) in a cell at an EC₃₀ less than or equal to 12 μM. In certainembodiments, a provided compound inhibits an RMT (e.g., PRMT1, PRMT3,CARM1, PRMT6, and/or PRMT8) in a cell at an EC₃₀ less than or equal to 3μM. In certain embodiments, a provided compound inhibits PRMT1 in a cellat an EC₃₀ less than or equal to 12 μM. In certain embodiments, aprovided compound inhibits PRMT1 in a cell at an EC₃₀ less than or equalto 3 μM. In certain embodiments, a provided compound inhibits an RMT(e.g., PRMT1, PRMT3, CARM1, PRMT6, and/or PRMT8) in a cell at an EC₃₀less than or equal to 1 μM. In certain embodiments, a provided compoundinhibits an RMT (e.g., PRMT1, PRMT3, CARM1, PRMT6, and/or PRMT8) in acell at an EC₃₀ less than or equal to 0.1 μM. In certain embodiments, aprovided compound inhibits cell proliferation at an EC₅₀ less than orequal to 10 μM. In certain embodiments, a provided compound inhibitscell proliferation at an EC₅₀ less than or equal to l_(i).tM. In certainembodiments, a provided compound inhibits cell proliferation at an EC₅₀less than or equal to 0.1 μM.

It will be understood by one of ordinary skill in the art that the RMTcan be wild-type, or any mutant or variant.

The present disclosure provides pharmaceutical compositions comprising acompound described herein, e.g., a compound of Formula (I), or apharmaceutically acceptable salt thereof, as described herein, andoptionally a pharmaceutically acceptable excipient. It will beunderstood by one of ordinary skill in the art that the compoundsdescribed herein, or salts thereof, may be present in various forms,such as amorphous, hydrates, solvates, or polymorphs. In certainembodiments, a provided composition comprises two or more compoundsdescribed herein. In certain embodiments, a compound described herein,or a pharmaceutically acceptable salt thereof, is provided in aneffective amount in the pharmaceutical composition. In certainembodiments, the effective amount is a therapeutically effective amount.In certain embodiments, the effective amount is an amount effective forinhibiting an RMT (e.g., PRMT1, PRMT3, CARM1, PRMT6, and/or PRMT8). Incertain embodiments, the effective amount is an amount effective fortreating an RMT-mediated disorder (e.g., a PRMT1-, PRMT3-, CARM1-,PRMT6-, and/or PRMT8-mediated disorder). In certain embodiments, theeffective amount is a prophylactically effective amount. In certainembodiments, the effective amount is an amount effective to prevent anRMT-mediated disorder.

Pharmaceutically acceptable excipients include any and all solvents,diluents, or other liquid vehicles, dispersions, suspension aids,surface active agents, isotonic agents, thickening or emulsifyingagents, preservatives, solid binders, lubricants, and the like, assuited to the particular dosage form desired. General considerations informulation and/or manufacture of pharmaceutical compositions agents canbe found, for example, in Remington's Pharmaceutical Sciences, SixteenthEdition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), andRemington: The Science and Practice of Pharmacy, 21st Edition(Lippincott Williams & Wilkins, 2005).

Pharmaceutical compositions described herein can be prepared by anymethod known in the art of pharmacology. In general, such preparatorymethods include the steps of bringing a compound described herein (the“active ingredient”) into association with a carrier and/or one or moreother accessory ingredients, and then, if necessary and/or desirable,shaping and/or packaging the product into a desired single or multidoseunit.

Pharmaceutical compositions can be prepared, packaged, and/or sold inbulk, as a single unit dose, and/or as a plurality of single unit doses.As used herein, a “unit dose” is discrete amount of the pharmaceuticalcomposition comprising a predetermined amount of the active ingredient.The amount of the active ingredient is generally equal to the dosage ofthe active ingredient which would be administered to a subject and/or aconvenient fraction of such a dosage such as, for example, onehalf oronethird of such a dosage.

Relative amounts of the active ingredient, the pharmaceuticallyacceptable excipient, and/or any additional ingredients in apharmaceutical composition of the present disclosure will vary,depending upon the identity, size, and/or condition of the subjecttreated and further depending upon the route by which the composition isto be administered. By way of example, the composition may comprisebetween 0.1% and 100% (w/w) active ingredient.

In some embodiments, a pharmaceutical composition described herein issterilized.

Pharmaceutically acceptable excipients used in the manufacture ofprovided pharmaceutical compositions include inert diluents, dispersingand/or granulating agents, surface active agents and/or emulsifiers,disintegrating agents, binding agents, preservatives, buffering agents,lubricating agents, and/or oils. Excipients such as cocoa butter andsuppository waxes, coloring agents, coating agents, sweetening,flavoring, and perfuming agents may also be present in the composition.

Exemplary diluents include calcium carbonate, sodium carbonate, calciumphosphate, dicalcium phosphate, calcium sulfate, calcium hydrogenphosphate, sodium phosphate lactose, sucrose, cellulose,microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodiumchloride, dry starch, cornstarch, powdered sugar, and mixtures thereof.

Exemplary granulating and/or dispersing agents include potato starch,corn starch, tapioca starch, sodium starch glycolate, clays, alginicacid, guar gum, citrus pulp, agar, bentonite, cellulose and woodproducts, natural sponge, cationexchange resins, calcium carbonate,silicates, sodium carbonate, crosslinked poly(vinylpyrrolidone)(crospovidone), sodium carboxymethyl starch (sodium starch glycolate),carboxymethyl cellulose, crosslinked sodium carboxymethyl cellulose(croscarmellose), methylcellulose, pregelatinized starch (starch 1500),microcrystalline starch, water insoluble starch, calcium carboxymethylcellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate,quaternary ammonium compounds, and mixtures thereof.

Exemplary surface active agents and/or emulsifiers include naturalemulsifiers (e.g., acacia, agar, alginic acid, sodium alginate,tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk,casein, wool fat, cholesterol, wax, and lecithin), colloidal clays(e.g., bentonite (aluminum silicate) and Veegum (magnesium aluminumsilicate)), long chain amino acid derivatives, high molecular weightalcohols (e.g., stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetinmonostearate, ethylene glycol distearate, glyceryl monostearate, andpropylene glycol monostearate, polyvinyl alcohol), carbomers (e.g.,carboxy polymethylene, polyacrylic acid, acrylic acid polymer, andcarboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g.,carboxymethylcellulose sodium, powdered cellulose, hydroxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose,methylcellulose), sorbitan fatty acid esters (e.g., polyoxyethylenesorbitan monolaurate (Tween 20), polyoxyethylene sorbitan (Tween 60),polyoxyethylene sorbitan monooleate (Tween 80), sorbitan monopalmitate(Span 40), sorbitan monostearate (Span 60], sorbitan tristearate (Span65), glyceryl monooleate, sorbitan monooleate (Span 80)),polyoxyethylene esters (e.g., polyoxyethylene monostearate (Myrj 45),polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil,polyoxymethylene stearate, and Solutol), sucrose fatty acid esters,polyethylene glycol fatty acid esters (e.g., Cremophor™) polyoxyethyleneethers, (e.g., polyoxyethylene lauryl ether (Brij 30)),poly(vinylpyrrolidone), diethylene glycol monolaurate, triethanolamineoleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyllaurate, sodium lauryl sulfate, Pluronic F68, Poloxamer 188, cetrimoniumbromide, cetylpyridinium chloride, benzalkonium chloride, docusatesodium, and/or mixtures thereof.

Exemplary binding agents include starch (e.g., cornstarch and starchpaste), gelatin, sugars (e.g., sucrose, glucose, dextrose, dextrin,molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums(e.g., acacia, sodium alginate, extract of Irish moss, panwar gum,ghatti gum, mucilage of isapol husks, carboxymethylcellulose,methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, microcrystalline cellulose,cellulose acetate, poly(vinylpyrrolidone), magnesium aluminum silicate(Veegum), and larch arabogalactan), alginates, polyethylene oxide,polyethylene glycol, inorganic calcium salts, silicic acid,polymethacrylates, waxes, water, alcohol, and/or mixtures thereof.

Exemplary preservatives include antioxidants, chelating agents,antimicrobial preservatives, antifungal preservatives, alcoholpreservatives, acidic preservatives, and other preservatives.

Exemplary antioxidants include alpha tocopherol, ascorbic acid, acorbylpalmitate, butylated hydroxyanisole, butylated hydroxytoluene,monothioglycerol, potassium metabisulfite, propionic acid, propylgallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, andsodium sulfite.

Exemplary chelating agents include ethylenediaminetetraacetic acid(EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodiumedetate, trisodium edetate, calcium disodium edetate, dipotassiumedetate, and the like), citric acid and salts and hydrates thereof(e.g., citric acid monohydrate), fumaric acid and salts and hydratesthereof, malic acid and salts and hydrates thereof, phosphoric acid andsalts and hydrates thereof, and tartaric acid and salts and hydratesthereof. Exemplary antimicrobial preservatives include benzalkoniumchloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide,cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol,chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea,phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate,propylene glycol, and thimerosal.

Exemplary antifungal preservatives include butyl paraben, methylparaben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoicacid, potassium benzoate, potassium sorbate, sodium benzoate, sodiumpropionate, and sorbic acid.

Exemplary alcohol preservatives include ethanol, polyethylene glycol,phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate,and phenylethyl alcohol. Exemplary acidic preservatives include vitaminA, vitamin C, vitamin E, betacarotene, citric acid, acetic acid,dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.

Other preservatives include tocopherol, tocopherol acetate, deteroximemesylate, cetrimide, butylated hydroxyanisol (BHA), butylatedhydroxytoluened (BHT), ethylenediamine, sodium lauryl sulfate (SLS),sodium lauryl ether sulfate (SLES), sodium bisulfite, sodiummetabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus,Phenonip, methylparaben, Germall 115, Germaben II, Neolone, Kathon, andEuxyl. In certain embodiments, the preservative is an antioxidant. Inother embodiments, the preservative is a chelating agent.

Exemplary buffering agents include citrate buffer solutions, acetatebuffer solutions, phosphate buffer solutions, ammonium chloride, calciumcarbonate, calcium chloride, calcium citrate, calcium glubionate,calcium gluceptate, calcium gluconate, Dgluconic acid, calciumglycerophosphate, calcium lactate, propanoic acid, calcium levulinate,pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasiccalcium phosphate, calcium hydroxide phosphate, potassium acetate,potassium chloride, potassium gluconate, potassium mixtures, dibasicpotassium phosphate, monobasic potassium phosphate, potassium phosphatemixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodiumcitrate, sodium lactate, dibasic sodium phosphate, monobasic sodiumphosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide,aluminum hydroxide, alginic acid, pyrogenfree water, isotonic saline,Ringer's solution, ethyl alcohol, and mixtures thereof.

Exemplary lubricating agents include magnesium stearate, calciumstearate, stearic acid, silica, talc, malt, glyceryl behanate,hydrogenated vegetable oils, polyethylene glycol, sodium benzoate,sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate,sodium lauryl sulfate, and mixtures thereof.

Exemplary natural oils include almond, apricot kernel, avocado, babassu,bergamot, black current seed, borage, cade, camomile, canola, caraway,carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee,corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed,geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate,jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademianut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange,orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed,pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood,sasquana, savoury, sea buckthorn, sesame, shea butter, silicone,soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, andwheat germ oils. Exemplary synthetic oils include, but are not limitedto, butyl stearate, caprylic triglyceride, capric triglyceride,cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate,mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and mixturesthereof.

Liquid dosage forms for oral and parenteral administration includepharmaceutically acceptable emulsions, microemulsions, solutions,suspensions, syrups and elixirs. In addition to the active ingredients,the liquid dosage forms may comprise inert diluents commonly used in theart such as, for example, water or other solvents, solubilizing agentsand emulsifiers such as ethyl alcohol, isopropyl alcohol, ethylcarbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3butylene glycol, dimethylformamide, oils (e.g., cottonseed,groundnut, corn, germ, olive, castor, and sesame oils), glycerol,tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid estersof sorbitan, and mixtures thereof. Besides inert diluents, the oralcompositions can include adjuvants such as wetting agents, emulsifyingand suspending agents, sweetening, flavoring, and perfuming agents. Incertain embodiments for parenteral administration, the compoundsdescribed herein are mixed with solubilizing agents such as Cremophor™,alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins,polymers, and mixtures thereof.

Injectable preparations, for example, sterile injectable aqueous oroleaginous suspensions can be formulated according to the known artusing suitable dispersing or wetting agents and suspending agents. Thesterile injectable preparation can be a sterile injectable solution,suspension or emulsion in a nontoxic parenterally acceptable diluent orsolvent, for example, as a solution in 1,3butanediol. Among theacceptable vehicles and solvents that can be employed are water,Ringer's solution, U.S.P. and isotonic sodium chloride solution. Inaddition, sterile, fixed oils are conventionally employed as a solventor suspending medium. For this purpose any bland fixed oil can beemployed including synthetic mono or diglycerides. In addition, fattyacids such as oleic acid are used in the preparation of injectables.

The injectable formulations can be sterilized, for example, byfiltration through a bacterialretaining filter, or by incorporatingsterilizing agents in the form of sterile solid compositions which canbe dissolved or dispersed in sterile water or other sterile injectablemedium prior to use.

In order to prolong the effect of a drug, it is often desirable to slowthe absorption of the drug from subcutaneous or intramuscular injection.This can be accomplished by the use of a liquid suspension ofcrystalline or amorphous material with poor water solubility. The rateof absorption of the drug then depends upon its rate of dissolutionwhich, in turn, may depend upon crystal size and crystalline form.Alternatively, delayed absorption of a parenterally administered drugform is accomplished by dissolving or suspending the drug in an oilvehicle.

Compositions for rectal or vaginal administration are typicallysuppositories which can be prepared by mixing the compounds describedherein with suitable nonirritating excipients or carriers such as cocoabutter, polyethylene glycol or a suppository wax which are solid atambient temperature but liquid at body temperature and therefore melt inthe rectum or vaginal cavity and release the active ingredient.

Solid dosage forms for oral administration include capsules, tablets,pills, powders, and granules. In such solid dosage forms, the activeingredient is mixed with at least one inert, pharmaceutically acceptableexcipient or carrier such as sodium citrate or dicalcium phosphateand/or a) fillers or extenders such as starches, lactose, sucrose,glucose, mannitol, and silicic acid, b) binders such as, for example,carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone,sucrose, and acacia, c) humectants such as glycerol, d) disintegratingagents such as agar, calcium carbonate, potato or tapioca starch,alginic acid, certain silicates, and sodium carbonate, e) solutionretarding agents such as paraffin, f) absorption accelerators such asquaternary ammonium compounds, g) wetting agents such as, for example,cetyl alcohol and glycerol monostearate, h) absorbents such as kaolinand bentonite clay, and i) lubricants such as talc, calcium stearate,magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate,and mixtures thereof. In the case of capsules, tablets and pills, thedosage form may comprise buffering agents.

Solid compositions of a similar type can be employed as fillers in softand hardfilled gelatin capsules using such excipients as lactose or milksugar as well as high molecular weight polyethylene glycols and thelike. The solid dosage forms of tablets, dragees, capsules, pills, andgranules can be prepared with coatings and shells such as entericcoatings and other coatings well known in the pharmaceutical formulatingart. They may optionally comprise opacifying agents and can be of acomposition that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract, optionally,in a delayed manner. Examples of embedding compositions which can beused include polymeric substances and waxes. Solid compositions of asimilar type can be employed as fillers in soft and hardfilled gelatincapsules using such excipients as lactose or milk sugar as well as highmolecular weight polyethylene glycols and the like.

The active ingredient can be in microencapsulated form with one or moreexcipients as noted above. The solid dosage forms of tablets, dragees,capsules, pills, and granules can be prepared with coatings and shellssuch as enteric coatings, release controlling coatings and othercoatings well known in the pharmaceutical formulating art. In such soliddosage forms the active ingredient can be admixed with at least oneinert diluent such as sucrose, lactose, or starch. Such dosage forms maycomprise, as is normal practice, additional substances other than inertdiluents, e.g., tableting lubricants and other tableting aids such amagnesium stearate and microcrystalline cellulose. In the case ofcapsules, tablets, and pills, the dosage forms may comprise bufferingagents. They may optionally comprise opacifying agents and can be of acomposition that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract, optionally,in a delayed manner. Examples of embedding compositions which can beused include polymeric substances and waxes.

Dosage forms for topical and/or transdermal administration of a providedcompound may include ointments, pastes, creams, lotions, gels, powders,solutions, sprays, inhalants and/or patches. Generally, the activeingredient is admixed under sterile conditions with a pharmaceuticallyacceptable carrier and/or any desired preservatives and/or buffers ascan be required. Additionally, the present disclosure encompasses theuse of transdermal patches, which often have the added advantage ofproviding controlled delivery of an active ingredient to the body. Suchdosage forms can be prepared, for example, by dissolving and/ordispensing the active ingredient in the proper medium. Alternatively oradditionally, the rate can be controlled by either providing a ratecontrolling membrane and/or by dispersing the active ingredient in apolymer matrix and/or gel.

Formulations suitable for topical administration include, but are notlimited to, liquid and/or semi liquid preparations such as liniments,lotions, oil in water and/or water in oil emulsions such as creams,ointments and/or pastes, and/or solutions and/or suspensions.Topically—administrable formulations may, for example, comprise fromabout 1% to about 10% (w/w) active ingredient, although theconcentration of the active ingredient can be as high as the solubilitylimit of the active ingredient in the solvent. Formulations for topicaladministration may further comprise one or more of the additionalingredients described herein.

A provided pharmaceutical composition can be prepared, packaged, and/orsold in a formulation suitable for pulmonary administration via thebuccal cavity. Such a formulation may comprise dry particles whichcomprise the active ingredient and which have a diameter in the rangefrom about 0.5 to about 7 nanometers or from about 1 to about 6nanometers. Such compositions are conveniently in the form of drypowders for administration using a device comprising a dry powderreservoir to which a stream of propellant can be directed to dispersethe powder and/or using a self propelling solvent/powder dispensingcontainer such as a device comprising the active ingredient dissolvedand/or suspended in a lowboiling propellant in a sealed container. Suchpowders comprise particles wherein at least 98% of the particles byweight have a diameter greater than 0.5 nanometers and at least 95% ofthe particles by number have a diameter less than 7 nanometers.Alternatively, at least 95% of the particles by weight have a diametergreater than 1 nanometer and at least 90% of the particles by numberhave a diameter less than 6 nanometers. Dry powder compositions mayinclude a solid fine powder diluent such as sugar and are convenientlyprovided in a unit dose form.

Low boiling propellants generally include liquid propellants having aboiling point of below 65° F. at atmospheric pressure. Generally thepropellant may constitute 50 to 99.9% (w/w) of the composition, and theactive ingredient may constitute 0.1 to 20% (w/w) of the composition.The propellant may further comprise additional ingredients such as aliquid non ionic and/or solid anionic surfactant and/or a solid diluent(which may have a particle size of the same order as particlescomprising the active ingredient).

Pharmaceutical compositions formulated for pulmonary delivery mayprovide the active ingredient in the form of droplets of a solutionand/or suspension. Such formulations can be prepared, packaged, and/orsold as aqueous and/or dilute alcoholic solutions and/or suspensions,optionally sterile, comprising the active ingredient, and mayconveniently be administered using any nebulization and/or atomizationdevice. Such formulations may further comprise one or more additionalingredients including, but not limited to, a flavoring agent such assaccharin sodium, a volatile oil, a buffering agent, a surface activeagent, and/or a preservative such as methylhydroxybenzoate. The dropletsprovided by this route of administration may have an average diameter inthe range from about 0.1 to about 200 nanometers.

Formulations described herein as being useful for pulmonary delivery areuseful for intranasal delivery of a pharmaceutical composition. Anotherformulation suitable for intranasal administration is a coarse powdercomprising the active ingredient and having an average particle fromabout 0.2 to 500 micrometers. Such a formulation is administered byrapid inhalation through the nasal passage from a container of thepowder held close to the nares.

Formulations for nasal administration may, for example, comprise fromabout as little as 0.1% (w/w) and as much as 100% (w/w) of the activeingredient, and may comprise one or more of the additional ingredientsdescribed herein. A provided pharmaceutical composition can be prepared,packaged, and/or sold in a formulation for buccal administration. Suchformulations may, for example, be in the form of tablets and/or lozengesmade using conventional methods, and may contain, for example, 0.1 to20% (w/w) active ingredient, the balance comprising an orallydissolvable and/or degradable composition and, optionally, one or moreof the additional ingredients described herein. Alternately,formulations for buccal administration may comprise a powder and/or anaerosolized and/or atomized solution and/or suspension comprising theactive ingredient. Such powdered, aerosolized, and/or aerosolizedformulations, when dispersed, may have an average particle and/ordroplet size in the range from about 0.1 to about 200 nanometers, andmay further comprise one or more of the additional ingredients describedherein.

A provided pharmaceutical composition can be prepared, packaged, and/orsold in a formulation for ophthalmic administration. Such formulationsmay, for example, be in the form of eye drops including, for example, a0.1/1.0% (w/w) solution and/or suspension of the active ingredient in anaqueous or oily liquid carrier. Such drops may further comprisebuffering agents, salts, and/or one or more other of the additionalingredients described herein. Other opthalmicallyadministrableformulations which are useful include those which comprise the activeingredient in microcrystalline form and/or in a liposomal preparation.Ear drops and/or eye drops are contemplated as being within the scope ofthis disclosure.

Although the descriptions of pharmaceutical compositions provided hereinare principally directed to pharmaceutical compositions which aresuitable for administration to humans, it will be understood by theskilled artisan that such compositions are generally suitable foradministration to animals of all sorts. Modification of pharmaceuticalcompositions suitable for administration to humans in order to renderthe compositions suitable for administration to various animals is wellunderstood, and the ordinarily skilled veterinary pharmacologist candesign and/or perform such modification with ordinary experimentation.

Compounds provided herein are typically formulated in dosage unit formfor ease of administration and uniformity of dosage. It will beunderstood, however, that the total daily usage of provided compositionswill be decided by the attending physician within the scope of soundmedical judgment. The specific therapeutically effective dose level forany particular subject or organism will depend upon a variety of factorsincluding the disease, disorder, or condition being treated and theseverity of the disorder; the activity of the specific active ingredientemployed; the specific composition employed; the age, body weight,general health, sex and diet of the subject; the time of administration,route of administration, and rate of excretion of the specific activeingredient employed; the duration of the treatment; drugs used incombination or coincidental with the specific active ingredientemployed; and like factors well known in the medical arts.

The compounds and compositions provided herein can be administered byany route, including enteral (e.g., oral), parenteral, intravenous,intramuscular, intraarterial, intramedullary, intrathecal, subcutaneous,intraventricular, transdermal, interdermal, rectal, intravaginal,intraperitoneal, topical (as by powders, ointments, creams, and/ordrops), mucosal, nasal, bucal, sublingual; by intratrachealinstillation, bronchial instillation, and/or inhalation; and/or as anoral spray, nasal spray, and/or aerosol. Specifically contemplatedroutes are oral administration, intravenous administration (e.g.,systemic intravenous injection), regional administration via bloodand/or lymph supply, and/or direct administration to an affected site.In general the most appropriate route of administration will depend upona variety of factors including the nature of the agent (e.g., itsstability in the environment of the gastrointestinal tract), and/or thecondition of the subject (e.g., whether the subject is able to tolerateoral administration).

The exact amount of a compound required to achieve an effective amountwill vary from subject to subject, depending, for example, on species,age, and general condition of a subject, severity of the side effects ordisorder, identity of the particular compound(s), mode ofadministration, and the like. The desired dosage can be delivered threetimes a day, two times a day, once a day, every other day, every thirdday, every week, every two weeks, every three weeks, or every fourweeks. In certain embodiments, the desired dosage can be delivered usingmultiple administrations (e.g., two, three, four, five, six, seven,eight, nine, ten, eleven, twelve, thirteen, fourteen, or moreadministrations).

In certain embodiments, an effective amount of a compound foradministration one or more times a day to a 70 kg adult human maycomprise about 0.0001 mg to about 3000 mg, about 0.0001 mg to about 2000mg, about 0.0001 mg to about 1000 mg, about 0.001 mg to about 1000 mg,about 0.01 mg to about 1000 mg, about 0.1 mg to about 1000 mg, about 1mg to about 1000 mg, about 1 mg to about 100 mg, about 10 mg to about1000 mg, or about 100 mg to about 1000 mg, of a compound per unit dosageform.

In certain embodiments, a compound described herein may be administeredat dosage levels sufficient to deliver from about 0.001 mg/kg to about1000 mg/kg, from about 0.01 mg/kg to about mg/kg, from about 0.1 mg/kgto about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, orfrom about 1 mg/kg to about 25 mg/kg, of subject body weight per day,one or more times a day, to obtain the desired therapeutic effect.

In some embodiments, a compound described herein is administered one ormore times per day, for multiple days. In some embodiments, the dosingregimen is continued for days, weeks, months, or years.

It will be appreciated that dose ranges as described herein provideguidance for the administration of provided pharmaceutical compositionsto an adult. The amount to be administered to, for example, a child oran adolescent can be determined by a medical practitioner or personskilled in the art and can be lower or the same as that administered toan adult.

It will be also appreciated that a compound or composition, as describedherein, can be administered in combination with one or more additionaltherapeutically active agents. In certain embodiments, a compound orcomposition provided herein is administered in combination with one ormore additional therapeutically active agents that improve itsbioavailability, reduce and/or modify its metabolism, inhibit itsexcretion, and/or modify its distribution within the body. It will alsobe appreciated that the therapy employed may achieve a desired effectfor the same disorder, and/or it may achieve different effects.

The compound or composition can be administered concurrently with, priorto, or subsequent to, one or more additional therapeutically activeagents. In certain embodiments, the additional therapeutically activeagent is a compound of Formula (I). In certain embodiments, theadditional therapeutically active agent is not a compound of Formula(I). In general, each agent will be administered at a dose and/or on atime schedule determined for that agent. In will further be appreciatedthat the additional therapeutically active agent utilized in thiscombination can be administered together in a single composition oradministered separately in different compositions. The particularcombination to employ in a regimen will take into account compatibilityof a provided compound with the additional therapeutically active agentand/or the desired therapeutic effect to be achieved. In general, it isexpected that additional therapeutically active agents utilized incombination be utilized at levels that do not exceed the levels at whichthey are utilized individually. In some embodiments, the levels utilizedin combination will be lower than those utilized individually.

Exemplary additional therapeutically active agents include, but are notlimited to, small organic molecules such as drug compounds (e.g.,compounds approved by the U.S. Food and Drug Administration as providedin the Code of Federal Regulations (CFR)), peptides, proteins,carbohydrates, monosaccharides, oligosaccharides, polysaccharides,nucleoproteins, mucoproteins, lipoproteins, synthetic polypeptides orproteins, small molecules linked to proteins, glycoproteins, steroids,nucleic acids, DNAs, RNAs, nucleotides, nucleosides, oligonucleotides,antisense oligonucleotides, lipids, hormones, vitamins, and cells. Incertain embodiments, an additional therapeutically active agent isprednisolone, dexamethasone, doxorubicin, vincristine, mafosfamide,cisplatin, carboplatin, Ara-C, rituximab, azacitadine, panobinostat,vorinostat, everolimus, rapamycin, ATRA (all-trans retinoic acid),daunorubicin, decitabine, Vidaza, mitoxantrone, or IBET-151.

Also encompassed by the present discosure are kits (e.g., pharmaceuticalpacks). The kits provided may comprise a provided pharmaceuticalcomposition or compound and a container (e.g., a vial, ampule, bottle,syringe, and/or dispenser package, or other suitable container). In someembodiments, provided kits may optionally further include a secondcontainer comprising a pharmaceutical excipient for dilution orsuspension of a provided pharmaceutical composition or compound. In someembodiments, a provided pharmaceutical composition or compound providedin the container and the second container are combined to form one unitdosage form. In some embodiments, a provided kits further includesinstructions for use.

Compounds and compositions described herein are generally useful for theinhibition of RMT (e.g., PRMT1, PRMT3, CARM1, PRMT6, and/or PRMT8). Insome embodiments, methods of treating an RMT-mediated disorder in asubject are provided which comprise administering an effective amount ofa compound described herein (e.g., a compound of Formula (I)), or apharmaceutically acceptable salt thereof), to a subject in need oftreatment. In certain embodiments, the effective amount is atherapeutically effective amount. In certain embodiments, the effectiveamount is a prophylactically effective amount. In certain embodiments,the subject is suffering from a RMT-mediated disorder. In certainembodiments, the subject is susceptible to a RMT-mediated disorder.

As used herein, the term “RMT-mediated disorder” means any disease,disorder, or other pathological condition in which an RMT (e.g., PRMT1,PRMT3, CARM1, PRMT6, and/or PRMT8) is known to play a role. Accordingly,in some embodiments, the present disclosure relates to treating orlessening the severity of one or more diseases in which an RMT is knownto play a role.

In some embodiments, the present disclosure provides a method ofinhibiting an RMT comprising contacting the RMT with an effective amountof a compound described herein (e.g., a compound of Formula (I)), or apharmaceutically acceptable salt thereof. The RMT may be purified orcrude, and may be present in a cell, tissue, or subject. Thus, suchmethods encompass both inhibition of in vitro and in vivo RMT activity.In certain embodiments, the method is an in vitro method, e.g., such asan assay method. It will be understood by one of ordinary skill in theart that inhibition of an RMT does not necessarily require that all ofthe RMT be occupied by an inhibitor at once. Exemplary levels ofinhibition of an RMT (e.g., PRMT1, PRMT3, CARM1, PRMT6, and/or PRMT8)include at least 10% inhibition, about 10% to about 25% inhibition,about 25% to about 50% inhibition, about 50% to about 75% inhibition, atleast 50% inhibition, at least 75% inhibition, about 80% inhibition,about 90% inhibition, and greater than 90% inhibition.

In some embodiments, provided is a method of inhibiting RMT activity ina subject in need thereof (e.g., a subject diagnosed as having anRMT-mediated disorder) comprising administering to the subject aneffective amount of a compound described herein (e.g., a compound ofFormula (I)), or a pharmaceutically acceptable salt thereof, or apharmaceutical composition thereof.

In certain embodiments, provided is a method of modulating geneexpression in a cell which comprises contacting a cell with an effectiveamount of a compound of Formula (I), or a pharmaceutically acceptablesalt thereof. In certain embodiments, the cell is in culture in vitro.In certain embodiments, the cell is in an animal, e.g., a human. Incertain embodiments, the cell is in a subject in need of treatment.

In certain embodiments, provided is a method of modulating transcriptionin a cell which comprises contacting a cell with an effective amount ofa compound of Formula (I), or a pharmaceutically acceptable saltthereof. In certain embodiments, the cell is in culture in vitro. Incertain embodiments, the cell is in an animal, e.g., a human. In certainembodiments, the cell is in a subject in need of treatment.

In certain embodiments, a method is provided of selecting a therapy fora subject having a disease associated with an RMT-mediated disorder ormutation comprising the steps of determining the presence of anRMT-mediated disorder or gene mutation in an RMT gene (e.g., a PRMT1,PRMT3, CARM1, PRMT6, and/or PRMT8 gene) or and selecting, based on thepresence of an RMT-mediated disorder a gene mutation in the RMT gene atherapy that includes the administration of a provided compound. Incertain embodiments, the disease is cancer.

In certain embodiments, a method of treatment is provided for a subjectin need thereof comprising the steps of determining the presence of anRMT-mediated disorder or a gene mutation in the RMT gene and treatingthe subject in need thereof, based on the presence of a RMT-mediateddisorder or gene mutation in the RMT gene with a therapy that includesthe administration of a provided compound. In certain embodiments, thesubject is a cancer patient.

In some embodiments, a compound provided herein is useful in treating aproliferative disorder, such as cancer. For example, while not beingbound to any particular mechanism, protein arginine methylation by PRMTsis a modification that has been implicated in signal transduction, genetranscription, DNA repair and mRNA splicing, among others; andoverexpression of PRMTs within these pathways is often associated withvarious cancers. Thus, compounds which inhibit the action of PRMTs, asprovided herein, are effective in the treatment of cancer.

In some embodiments, compounds provided herein are effective in treatingcancer through the inhibition of PRMT1. For example, PRMT1overexpression has been observed in various human cancers, including,but not limited to, breast cancer, prostate cancer, lung cancer, coloncancer, bladder cancer, and leukemia. In one example, PRMT1 specificallydeposits an asymmetric dimethylarginine (aDMA) mark on histone H4 atarginine 3 (H4R3me2a), and this mark is associated with transcriptionactivation. In prostate cancer, the methylation status of H4R3positively correlates with increasing tumor grade and can be used topredict the risk of prostate cancer recurrence (Seligson et al., Nature2005 435, 1262-1266). Thus, in some embodiments, inhibitors of PRMT1, asdescribed herein, are useful in treating cancers associated with themethylation status of H4R3, e.g., prostate cancer. Additionally, themethylarginine effector molecule TDRD3 interacts with the H4R3me2a mark,and overexpression of TDRD3 is linked to poor prognosis for the survivalof patients with breast cancer (Nagahata et al., Cancer Sci. 2004 95,218-225). Thus, in some embodiments, inhibitors of PRMT1, as describedherein, are useful in treating cancers associated with overexpression ofTDRD3, e.g., breast cancer, as inhibition of PRMT1 leads to a decreasein methylation of H4R3, thereby preventing the association ofoverexpressed TDRD3 with H4R3me2a. In other examples, PRMT1 is known tohave non-histone substrates. For example, PRMT1, when localized to thecytoplasm, methylates proteins that are involved in signal transductionpathways, e.g., the estrogen receptor (ER). The expression status of ERin breast cancer is critical for prognosis of the disease, and bothgenomic and non-genomic ER pathways have been implicated in thepathogenesis of breast cancer. For example, it has been shown that PRMT1methylates ERa, and that ERa methylation is required for the assembly ofERa with SRC (a proto-oncogene tyrosine-protein kinase) and focaladhesion kinase (FAK). Further, the silencing of endogenous PRMT1resulted in the inability of estrogen to activate AKT. These resultssuggested that PRMT1-mediated ERa methylation is required for theactivation of the SRCPI3KFAK cascade and AKT, coordinating cellproliferation and survival. Thus, hypermethylation of ERa in breastcancer is thought to cause hyperactivation of this signaling pathway,providing a selective survival advantage to tumor cells (Le Romancer etal., Mol. Cell 2008 31, 212-221; Le Romancer et al., Steroids 2010 75,560-564). Accordingly, in some embodiments, inhibitors of PRMT1, asdescribed herein, are useful in treating cancers associated with ERamethylation, e.g., breast cancer. In yet another example, PRMT1 has beenshown to be involved in the regulation of leukemia development. Forexample, SRC-associated in mitosis 68 kDa protein (SAM68; also known asKHDRBS1) is a well-characterized PRMT1 substrate, and when either SAM68or PRMT1 is fused directly to the myeloid/lymphoid leukemia (MLL) gene,these fusion proteins can activate MLL oncogenic properties, implyingthat the methylation of SAM68 by PRMT1 is a critical signal for thedevelopment of leukemia (Cheung et al., Nature Cell Biol. 2007 9,1208-1215). Accordingly, in some embodiments, inhibitors of PRMT1, asdescribed herein, are useful in treating cancers associated with SAM68methylation, e.g., leukemia. In still another example, PRMT1 isimplicated in leukemia development through its interaction with AE9a, asplice isoform of AML1-ETO (Shia et al., Blood 2012 119:4953-62).Knockdown of PRMT1 affects expression of certain AE9a-activated genesand suppresses AE9a′s self-renewal capability. It has also been shownthat AE9a recruits PRMT1 to AE9a activated gene promoters, which leadsto increased H4 Arg3 methylation, H3 Lys9/14 acetylation, andtranscription activated. Accordingly, in some embodiments, inhibitors ofPRMT1, as described herein, are useful in treating cancers associatedwith AML1-ETO, e.g., leukemia. Thus, without being bound by anyparticular mechanism, the inhibition of PRMT1, e.g., by compoundsdescribed herein, is beneficial in the treatment of cancer.

In some embodiments, compounds provided herein are effective in treatingcancer through the inhibition of PRMT3. In one example, the DAL1 tumorsuppressor protein has been shown to interact with PRMT3 and inhibitsits methyltransferase activity (Singh et al., Oncogene 2004 23,7761-7771). Epigenetic downregulation of DAL1 has been reported inseveral cancers (e.g., meningiomas and breast cancer), thus PRMT3 isexpected to display increased activity, and cancers that display DAL1silencing may, in some aspects, be good targets for PRMT3 inhibitors,e.g., those described herein. Thus, without being bound by anyparticular mechanism, the inhibition of PRMT3, e.g., by compoundsdescribed herein, is beneficial in the treatment of cancer.

In some embodiments, compounds provided herein are effective in treatingcancer through the inhibition of PRMT4, also known as CARM1. Forexample, PRMT4 levels have been shown to be elevated incastration-resistant prostate cancer (CRPC), as well as in aggressivebreast tumors (Hong et al., Cancer 2004 101, 83-89; Majumder et al.,Prostate 2006 66, 1292-1301). Thus, in some embodiments, inhibitors ofPRMT4, as described herein, are useful in treating cancers associatedwith PRMT4 overexpression. PRMT4 has also been shown to affectERa-dependent breast cancer cell differentiation and proliferation(Al⁻Dhaheri et al., Cancer Res. 2011 71, 2118-2128), thus in someaspects PRMT4 inhibitors, as described herein, are useful in treatingERa-dependent breast cancer by inhibiting cell differentiation andproliferation . In another example, PRMT4 has been shown to be recruitedto the promoter of E2F1 (which encodes a cell cycle regulator) as atranscriptional co-activator (Frietze et al., Cancer Res. 2008 68,301-306). Thus, PRMT4-mediated upregulation of E2F1 expression maycontribute to cancer progression and chemoresistance as increasedabundance of E2F1 triggers invasion and metastasis by activating growthreceptor signaling pathways, which in turn promote an antiapoptotictumor environment (Engelmann and Piitzer, Cancer Res 2012 72; 571).Accordingly, in some embodiments, the inhibition of PRMT4, e.g., bycompounds provided herein, is useful in treating cancers associated withE2F1 upregulation. Thus, without being bound by any particularmechanism, the inhibition of PRMT4, e.g., by compounds described herein,is beneficial in the treatment of cancer.

In some embodiments, compounds provided herein are effective in treatingcancer through the inhibition of PRMT6. For example, PRMT6 has beenreported to be overexpressed in a number of cancers, e.g., bladder andlung cancer (Yoshimatsu et al., Int. J. Cancer 2011 128, 562-573). Thus,in some embodiments, the inhibition of PRMT6, by compounds providedherein, is useful in treating cancers associated with PRMT6overexpression. In some aspects, PRMT6 is primarily thought to functionas a transcriptional repressor, although it has also been reported thatPRMT6 functions as a co-activator of nuclear receptors. For example, asa transcriptional repressor, PRMT6 suppresses the expression ofthrombospondin 1 (TSP1; also known as THBS 1; a potent natural inhibitorof angiogenesis and endothelial cell migration) and p21 (a naturalinhibitor of cyclin dependent kinase), thereby contributing to cancerdevelopment and progression (Michaud-Levesque and Richard, J. Biol.Chem. 2009 284, 21338-21346; Kleinschmidt et al., PLoS ONE 2012 7,e41446). Accordingly, in some embodiments, the inhibition of PRMT6, bycompounds provided herein, is useful in treating cancer by preventingthe repression of THBs1 and/or p21. Thus, without being bound by anyparticular mechanism, the inhibition of PRMT6, e.g., by compoundsdescribed herein, is beneficial in the treatment of cancer.

In some embodiments, compounds provided herein are effective in treatingcancer through the inhibition of PRMT8. For example, deep-sequencingefforts of cancer genomes (e.g., COSMIC) have revealed that of all thePRMTs, PRMT8 is reported to be the most mutated. Of 106 sequencedgenomes, 15 carry mutations in the PRMT8 coding region, and nine ofthese result in an amino acid change (Forbes et al., Nucleic Acids Res.2011 39, D945D950). Because of its high rate of mutation in cancer,PRMT8 is thought to contribute to the initiation or progression ofcancer. Thus, without being bound by any particular mechanism, theinhibition of PRMT8, e.g., by compounds described herein, is beneficialin the treatment of cancer.

In some embodiments, compounds described herein are useful for treatinga cancer including, but not limited to, acoustic neuroma,adenocarcinoma, adrenal gland cancer, anal cancer, angiosarcoma (e.g.,lymphangiosarcoma, lymphangioendotheliosarcoma, hemangiosarcoma),appendix cancer, benign monoclonal gammopathy, biliary cancer (e.g.,cholangiocarcinoma), bladder cancer, breast cancer (e.g., adenocarcinomaof the breast, papillary carcinoma of the breast, mammary cancer,medullary carcinoma of the breast), brain cancer (e.g., meningioma;glioma, e.g., astrocytoma, oligodendroglioma; medulloblastoma), bronchuscancer, carcinoid tumor, cervical cancer (e.g., cervicaladenocarcinoma), choriocarcinoma, chordoma, craniopharyngioma,colorectal cancer (e.g., colon cancer, rectal cancer, colorectaladenocarcinoma), epithelial carcinoma, ependymoma, endotheliosarcoma(e.g., Kaposi's sarcoma, multiple idiopathic hemorrhagic sarcoma),endometrial cancer (e.g., uterine cancer, uterine sarcoma), esophagealcancer (e.g., adenocarcinoma of the esophagus, Barrett's adenocarinoma),Ewing sarcoma, eye cancer (e.g., intraocular melanoma, retinoblastoma),familiar hypereosinophilia, gall bladder cancer, gastric cancer (e.g.,stomach adenocarcinoma), gastrointestinal stromal tumor (GIST), head andneck cancer (e.g., head and neck squamous cell carcinoma, oral cancer(e.g., oral squamous cell carcinoma (OSCC), throat cancer (e.g.,laryngeal cancer, pharyngeal cancer, nasopharyngeal cancer,oropharyngeal cancer)), hematopoietic cancers (e.g., leukemia such asacute lymphocytic leukemia (ALL) (e.g., B-cell ALL, T-cell ALL), acutemyelocytic leukemia (AML) (e.g., B-cell AML, T-cell AML), chronicmyelocytic leukemia (CML) (e.g., B-cell CML, T-cell CML), and chroniclymphocytic leukemia (CLL) (e.g., B-cell CLL, T-cell CLL); lymphoma suchas Hodgkin lymphoma (HL) (e.g., B-cell HL, T-cell HL) and nonHodgkinlymphoma (NHL) (e.g., B-cell NHL such as diffuse large cell lymphoma(DLCL) (e.g., diffuse large Bcell lymphoma (DLBCL)), follicularlymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma(CLL/SLL), mantle cell lymphoma (MCL), marginal zone B-cell lymphomas(e.g., mucosa-associated lymphoid tissue (MALT) lymphomas, nodalmarginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma),primary mediastinal B-cell lymphoma, Burkitt lymphoma, lymphoplasmacyticlymphoma (e.g., “Waldenström's macroglobulinemia”), hairy cell leukemia(HCL), immunoblastic large cell lymphoma, precursor B-lymphoblasticlymphoma and primary central nervous system (CNS) lymphoma; and T-cellNHL such as precursor T-lymphoblastic lymphoma/leukemia, peripheralT-cell lymphoma (PTCL) (e.g., cutaneous T-cell lymphoma (CTCL) (e.g.,mycosis fungiodes, Sezary syndrome), angioimmunoblastic T-cell lymphoma,extranodal natural killer T-cell lymphoma, enteropathy type T-celllymphoma, subcutaneous panniculitis-like T-cell lymphoma, anaplasticlarge cell lymphoma); a mixture of one or more leukemia/lymphoma asdescribed above; and multiple myeloma (MM)), heavy chain disease (e.g.,alpha chain disease, gamma chain disease, mu chain disease),hemangioblastoma, inflammatory myofibroblastic tumors, immunocyticamyloidosis, kidney cancer (e.g., nephroblastoma a.k.a. Wilms’ tumor,renal cell carcinoma), liver cancer (e.g., hepatocellular cancer (HCC),malignant hepatoma), lung cancer (e.g., bronchogenic carcinoma, smallcell lung cancer (SCLC), nonsmall cell lung cancer (NSCLC),adenocarcinoma of the lung), leiomyosarcoma (LMS), mastocytosis (e.g.,systemic mastocytosis), myelodysplastic syndrome (MDS), mesothelioma,myeloproliferative disorder (MPD) (e.g., polycythemia Vera (PV),essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a.myelofibrosis (MF), chronic idiopathic myelofibrosis, chronic myelocyticleukemia (CML), chronic neutrophilic leukemia (CNL), hypereosinophilicsyndrome (HES)), neuroblastoma, neurofibroma (e.g., neurofibromatosis(NF) type 1 or type 2, schwannomatosis), neuroendocrine cancer (e.g.,gastroenteropancreatic neuroendoctrine tumor (GEP-NET), carcinoidtumor), osteosarcoma, ovarian cancer (e.g., cystadenocarcinoma, ovarianembryonal carcinoma, ovarian adenocarcinoma), papillary adenocarcinoma,pancreatic cancer (e.g., pancreatic andenocarcinoma, intraductalpapillary mucinous neoplasm (IPMN), Islet cell tumors), penile cancer(e.g., Paget's disease of the penis and scrotum), pinealoma, primitiveneuroectodermal tumor (PNT), prostate cancer (e.g., prostateadenocarcinoma), rectal cancer, rhabdomyosarcoma, salivary gland cancer,skin cancer (e.g., squamous cell carcinoma (SCC), keratoacanthoma (KA),melanoma, basal cell carcinoma (BCC)), small bowel cancer (e.g.,appendix cancer), soft tissue sarcoma (e.g., malignant fibroushistiocytoma (MFH), liposarcoma, malignant peripheral nerve sheath tumor(MPNST), chondrosarcoma, fibrosarcoma, myxosarcoma), sebaceous glandcarcinoma, sweat gland carcinoma, synovioma, testicular cancer (e.g.,seminoma, testicular embryonal carcinoma), thyroid cancer (e.g.,papillary carcinoma of the thyroid, papillary thyroid carcinoma (PTC),medullary thyroid cancer), urethral cancer, vaginal cancer and vulvarcancer (e.g., Paget's disease of the vulva).

In some embodiments, a compound provided herein is useful in treatingdiseases associated with increased levels of circulating asymmetricdimethylarginine (aDMA), e.g., cardiovascular disease, diabetes, kidneyfailure, renal disease, pulmonary disease, etc. Circulating aDMA isproduced by the proteolysis of asymmetrically dimethylated proteins.PRMTs which mediate aDMA methylation include, e.g., PRMT1, PRMT3, PRMT4,PRMT6, and PRMT8. aDMA levels are directly involved in various diseasesas aDMA is an endogenous competitive inhibitor of nitric oxide synthase(NOS), thereby reducing the production of nitric oxide (NO) (Vallance etal., J. Cardiovasc. Pharmacol. 1992 20(Suppl. 12):S60-2). NO functionsas a potent vasodilator in endothelial vessels, and as such inhibitingits production has major consequences on the cardiovascular system. Forexample, since PRMT1 is a major enzyme that generates aDMA, thedysregulation of its activity is likely to regulate cardiovasculardiseases(Boger et al., Ann. Med. 2006 38:126-36), and otherpathophysiological conditions such as diabetes mellitus (Sydow et al.,Vasc. Med. 2005 10(Suppl. 1):S35-43), kidney failure (Vallance et al.,Lancet 1992 339:572-5), and chronic pulmonary diseases (Zakrzewicz etal., BMC Pulm. Med. 2009 9:5). Additionally, it has been demonstratedthat the expression of PRMT1 and PRMT3 are increased in coronary heartdisease (Chen et al., Basic Res. Cardiol. 2006 101:346-53). In anotherexample, aDMA elevation is seen in patients with renal failure, due toimpaired clearance of this metabolite from the circulation (Jacobi etal., Am. J. Nephrol. 2008 28:224-37). Thus, circulating aDMA levels isobserved in many pathophysiological situations. Accordingly, withoutbeing bound by any particular mechanism, the inhibition of PRMTs, e.g.,by compounds described herein, results in the decrease of circulatingaDMA, which is beneficial in the treatment of diseases associated withincreased levels of circulating aDMA, e.g., cardiovascular disease,diabetes, kidney failure, renal disease, pulmonary disease, etc. Incertain embodiments, a compound described herein is useful for treatingor preventing vascular diseases.

In some embodiments, a compound provided herein is useful in treatingmetabolic disorders. For example, PRMT1 has been shown to enhance mRNAlevels of FoxO1 target genes in gluconeogenesis, which results inincreased hepatic glucose production, and knockdown of PRMT promotesinhibition of Fox01 activity and thus inhibition of hepaticgluconeogenesis (Choi et al., Hepatology 2012 56:1546-56). Additionally,genetic haploinsufficiency of Prmt1 has been shown to reduce bloodglucose levels in mouse models. Thus, without being bound by anyparticular mechanism, the inhibition of PRMT1, e.g., by compoundsdescribed herein, is beneficial in the treating of metabolic disorders,such as diabetes. In some embodiments, a provided compound is useful intreating type I diabetes. In some embodiments, a provided compound isuseful in treating type II diabetes.

In some embodiments, a compound provided herein is useful in treatingmuscular dystrophies. For example, PRMT1, as well as PRMT3 and PRMT6,methylate the nuclear poly(A)-binding protein (PABPN1) in a regionlocated near its C-terminus (Perreault et al., J. Biol. Chem. 2007282:7552-62). This domain is involved in the aggregation of the PABPN1protein, and abnormal aggregation of this protein is involved in thedisease oculopharyngeal muscular dystrophy (Davies et al., Int. J.Biochem. Cell. Biol. 2006 38:1457-62). Thus, without being bound by anyparticular mechanism, the inhibition of PRMTs, e.g., by compoundsdescribed herein, is beneficial in the treatment of musculardystrophies, e.g., oculopharyngeal muscular dystrophy, by decreasing theamount of methylation of PABPN1, thereby decreasing the amount of PABPN1aggregation.

CARM1 is also the most abundant PRMT expressed in skeletal muscle cells,and has been found to selectively control the pathways modulatingglycogen metabolism, and associated AMPK (AMP-activated protein kinase)and p38 MAPK (mitogen-activated protein kinase) expression. See, e.g.,Wang et al., Biochem (2012) 444:323-331. Thus, in some embodiments,inhibitors of CARM1, as described herein, are useful in treatingmetabolic disorders, e.g., for example skeletal muscle metabolicdisorders, e.g., glycogen and glucose metabolic disorders. Exemplaryskeletal muscle metabolic disorders include, but are not limited to,Acid Maltase Deficiency (Glycogenosis type 2; Pompe disease), Debrancherdeficiency (Glycogenosis type 3), Phosphorylase deficiency (McArdle's;GSD 5), X-linked syndrome (GSD9D), Autosomal recessive syndrome (GSD9B),Tarui's disease (Glycogen storage disease VII; GSD 7), PhosphoglycerateMutase deficiency (Glycogen storage disease X; GSDX; GSD 10), Lactatedehydrogenase A deficiency (GSD 11), Branching enzyme deficiency (GSD4), Aldolase A (muscle) deficiency, β-Enolase deficiency,Triosephosphate isomerase (TIM) deficiency, Lafora's disease(Progressive myoclonic epilepsy 2), Glycogen storage disease (Muscle,Type 0, Phosphoglucomutase 1 Deficiency (GSD 14)), and GlycogeninDeficiency (GSD 15).

In some embodiments, a compound provided herein is useful in treatingautoimmune disease. For example, several lines of evidence stronglysuggest that PRMT inhibitors may be valuable for the treatment ofautoimmune diseases, e.g., rheumatoid arthritis. PRMTs are known tomodify and regulate several critical immunomodulatory proteins. Forexample, post-translational modifications (e.g., arginine methylation),within T cell receptor signaling cascades allow T lymphocytes toinitiate a rapid and appropriate immune response to pathogens.Co-engagement of the CD28 costimulatory receptor with the T cellreceptor elevates PRMT activity and cellular protein argininemethylation, including methylation of the guanine nucleotide exchangefactor Vavl (Blanchet et al., J. Exp. Med. 2005 202:371-377). PRMTinhibitors are thus expected to diminish methylation of the guanineexchange factor Vavl, resulting in diminished IL-2 production. Inagreement, siRNA directed against PRMT5 was shown to both inhibitNFAT-driven promoter activity and IL-2 secretion (Richard et al.,Biochem J. 2005 388:379-386). In another example, PRMT1 is known tocooperate with PRMT4 to enhance NFkB p65-driven transcription andfacilitate the transcription of p65 target genes like TNFα (Covic etal., Embo. J. 2005 24:85-96). Thus, in some embodiments, PRMT1 and/orPRMT4 inhibitors, e.g., those described herein, are useful in treatingautoimmune disease by decreasing the transcription of p65 target geneslike TNFα. These examples demonstrate an important role for argininemethylation in inflammation. Thus, without being bound by any particularmechanism, the inhibition of PRMTs, e.g., by compounds described herein,is beneficial in the treatment of autoimmune diseases.

In some embodiments, a compound provided herein is useful in treatingneurological disorders, such as amyotrophic lateral sclerosis (ALS). Forexample, a gene involved in ALS, TLS/FUS, often contains mutatedarginines in certain familial forms of this disease (Kwiatkowski et al.,Science 2009 323:1205-8). These mutants are retained in the cytoplasm,which is similar to reports documenting the role arginine methylationplays in nuclear-cytoplasmic shuffling (Shen et al., Genes Dev. 199812:679-91). This implicates PRMT, e.g., PRMT1, function in this disease,as it was demonstrated that TLS/FUS is methylated on at least 20arginine residues (Rappsilber et al., Anal. Chem. 2003 75:3107-14).Thus, in some embodiments, the inhibition of PRMTs, e.g., by compoundsprovided herein, are useful in treating ALS by decreasing the amount ofTLS/FUS arginine methylation.

Scheme 1 shows a general synthesis route to pyrazole compounds offormula I, wherein Q′ is either the same as Q as or is precursor of Qwhich after functional group modification or substitution yields Qwherein Q, R³, R^(x), X, Y and Z are as defined above. In the first stepiodopyrazole carboxaldehydes of general formula XI are allowed to reactwith mono-Boc protected ethylenediamines XII under reductive aminationconditions (e.g. sodium cyanoborohydride and catalytic acid such asacetic acid) in an appropriate solvent such as methanol to giveintermediates of general formula XIII Suzuki reaction of the latter withboronic acids or boronic esters of general formula XIV in the presenceof a palladium catalyst (e.g. PdCl₂(dppf)) and a base (e.g. potassiumcarbonate) in an organic solvent (e.g. toluene) at elevated temperatureyields intermediates of general formula XV. In a subsequent optionalstep or steps, functional groups on Q′ may be modified to yield certainembodiments of final compounds of formula I. For example compoundswherein Q is substituted with an alkoxy group can be synthesized byalkylating intermediates of formula XV where Q′ has a corresponding OHgroup by alkylation reaction with a suitable alkylbromide or iodideusing an appropriate base (e.g. potassium carbonate) in a suitableorganic solvent (e.g. tetrahydrofuran). In a final deprotection step theN-Boc protecting can be removed by treating XV with an acid (e.g. HCl)in a suitable organic solvent (e.g. ethanol) to give compounds offormula I.

In certain embodiments, iodopyrazole carboxaldehydes of general formulaXI may be prepared from suitable known pyrazole compound intermediatesby established synthetic chemistry methods. Standard methods includedirect iodination of a pyrazole 3-carboxylate and Sandmeyer reaction ofa 3-amino pyrazole 4-carboxylate. In certain embodiments, iodopyrazolecarboxaldehydes are derived from iodopyrazole carboxylates by reductionto a hydroxymethyl group followed by oxidation to carboxaldehyde. Themono-Boc protected ethylenediamines XII can be synthesized by standardmethods known in the literature for derivatizing or preparingethylenediamines. For example intermediates of formula XII may beprepared by treatment of the corresponding unprotected diamineprecursorswith Boc₂O and purifying the mixture of mono and dibocylatedproducts. Heteroaromatic boronic acids or esters of general formula XIVare either commercially available or can be prepared by standard methodfor example by boronylation of the corresponding commercially availableheteroaryl bromides.

In certain embodiments, pyrazole compounds of general formula II areprepared from iodopyrazole carboxaldehydes of general formula XXI asdepicted in Scheme 2. In cases where R⁴ is hydrogen compounds of generalformula II are equivalent to compounds of general formula III which aretautomers. In certain embodiments R^(4′) is a protecting group such astetrahydropyranyl (THP) which maybe cleaved to hydrogen under acidicconditions in the final Boc-deprotection step. In certain embodiments,iodopyrazole carboxaldehydes of general formula XXI can be prepared asdepicted in Scheme 3.

In certain embodiments, iodopyrazole carboxaldehydes of general formulaXXI are prepared as depicted in Scheme 4 which also providesiodopyrazole carboxyaldehydes of general formula XXXI. Thus, alkylationof intermediates of general formula XXX gives a mixture of pyrazolenitrogen alkylated isomers which are separated by chromatography to givepure isomers XXI and XXXI. In certain embodiments, pyrazole compounds ofgeneral formula III can be prepared from iodopyrazole carboxaldehydes ofgeneral formula XXXI as depicted in Scheme 5.

In certain embodiments, pyrazole compounds of general formula IV areprepared from iodopyrazole carboxaldehydes of general formula XLI asdepicted in Scheme 6. In certain embodiments where R⁴ is hydrogencompounds of general formula IV are equivalent to compounds of generalformula V which are tautomers. In certain embodiments where R⁴ incompounds of formula IV is hydrogen, R^(4′) in intermediate XLI may be aselected protecting group such as tetrahydropyranyl (THP) which can becleaved to hydrogen under acidic conditions in the finalBoc-deprotection step.

In certain embodiments, iodopyrazole carboxaldehydes of general formulaXLI and LI can be prepared as depicted in Scheme 7. In certainembodiments, an R⁴ group of iodopyrazole carboxaldehydes is introducedby alkylation of intermediates of formula XLVII. This reaction can givea mixture of intermediate compounds of formulas XLI and LI which may beseparated by chromatography. The THP protected intermediates of formulaXLVI can be used to prepare compounds of formula IV where R⁴═H as alsodepicted in Scheme 7.

In certain embodiments, pyrazole compounds of general formula V areprepared from iodopyrazole carboxaldehydes of general formula LI asdepicted in Scheme 8.

In certain embodiments, phenyl boronic acids or esters of generalformula XIV are commercially available. In certain embodiments phenylboronic acids or esters of general formula XIV can be prepared fromcommercially available or known corresponding heteroaryl bromideprecursors of general formula LX by standard methods. One such method toprepare pinacol boranes of general formula XIVa is depicted in Scheme 9.

EXAMPLES

In order that the invention described herein may be more fullyunderstood, the following examples are set forth. It should beunderstood that these examples are for illustrative purposes only andare not to be construed as limiting this invention in any manner.

Synthetic Methods

General methods and experimental procedures for preparing andcharacterizing compounds of the present invention are set forth below.Wherever needed, reactions were heated using conventional hotplateapparatus or heating mantle or microwave irradiation equipment.Reactions were conducted with or without stirring, under atmospheric orelevated pressure in either open or closed vessels. Reaction progresswas monitored using conventional techniques such as TLC, HPLC, UPLC, orLCMS using instrumentation and methods described below. Reactions werequenched and crude compounds isolated using conventional methods asdescribed in the specific examples provided. Solvent removal was carriedout with or without heating, under atmospheric or reduced pressure,using either a rotary or centrifugal evaporator. Compound purificationwas carried out as needed using a variety of traditional methodsincluding, but not limited to, preparative chromatography under acidic,neutral, or basic conditions using either normal phase or reverse phaseHPLC or flash columns or Prep-TLC plates. Compound purity and massconfirmations were conducted using standard HPLC and/or UPLC and/or MSspectrometers and/or LCMS and/or GC equipment (e.g., including, but notlimited to the following instrumentation: Waters Alliance 2695 with 2996PDA detector connected with ZQ detector and ESI source; ShimadzuLDMS-2020; Waters Acquity H Class with PDA detector connected with SQdetector and ESI source; Agilent 1100 Series with PDA detector; WatersAlliance 2695 with 2998 PDA detector; AB SCIEX API 2000 with ESI source;Agilent 7890 GC). Exemplified compounds were dissolved in either MeOH orMeCN to a concentration of approximately 1 mg/mL and analyzed byinjection of 0.5-10 μL into an appropriate LCMS system using the methodsprovided in the following table :

MS MS Heat Detector Mobile Phase Mobile Phase Flow Rate Block VoltageMethod Column A B (mL/min) Gradient Profile Temp (° C.) (kV) A Shim-packWater/0.05% ACN/0.05% 1 5% to 100% B in 2.0 250 1.5 XR-ODS TFA TFAminutes, 100% B for 1.1 2.21 μm minutes, 100% to 5% B in 3.0 × 50 mm 0.2minutes, then stop B Gemini-NX Water/0.04% ACN 1 5% to 100% B in 2.0 2000.75 3 μm C18 Ammonia minutes, 100% B for 1.1 110A minutes, 100% to 5% Bin 0.1 minutes, then stop C Shim-pack Water/0.05% ACN/0.05% 1 5% to 100%B in 2.0 250 0.85 XR-ODS FA FA minutes, 100% B for 1.1 1.6 μm minutes,100% to 5% B in 2.0 × 50 mm 0.1 minutes, then stop D Shim-packWater/0.05% ACN/0.05% 1 5% to 100% B in 2.0 250 0.95 XR-ODS TFA TFAminutes, 100% B for 1.1 2.2 μm minutes, 100% to 5% B in 3.0 × 50 mm 0.1minutes, then stop E Waters Water/0.05% ACN/0.05% 0.9 5% to 100% B in2.0 250 1.5 Xselect C18 FA FA minutes, 100% B for 1.2 3.5 μm minutes,100% to 5% B in 3.0 × 50 mm 0.1 minutes, then stop F Shim-packWater/0.05% ACN/0.05% 1 5% to 80% B in 3.25 200 0.95 XR-ODS TFA TFAminutes, 80% B for 1.35 2.2 μm minutes, 80% to 5% B in 0.3 3.0 × 50 mmminutes, then stop G Shim-pack Water/0.05% ACN/0.05% 1 5% to 70% B in2.50 200 0.95 XR-ODS TFA TFA minutes, 70% B for 0.70 2.2 μm minutes, 70%to 5% B in 0.1 3.0 × 50 mm minutes, then stop H Shim-pack Water/0.05%ACN/0.05% 1 5% to 100% B in 2.20 250 0.95 XR-ODS TFA TFA minutes, 100% Bfor 1.00 2.2 μm minutes, 100% to 5% B in 3.0 × 50 mm 0.1 minutes, thenstop I Shim-pack Water/0.05% ACN/0.05% 1 5% to 100% B in 1.20 250 0.95XR-ODS minutes, 100% B for 1.00 2.2 μm TFA TFA minutes, 100% to 5% B in3.0 × 50 mm 0.1 minutes, then stop J Shim-pack Water/0.05% ACN/0.05% 15% to 70% B in 3.20 250 0.95 XR-ODS TFA TFA minutes, 70% B for 0.75 2.2μm minutes, 70% to 5% B in 3.0 × 50 mm 0.35 minutes, then stop KShim-pack Water/0.05% ACN/0.05% 1 5% to 80% B in 3.00 250 1.5 XR-ODS TFATFA minutes, 80% B for 0.8 2.2 μm minutes, 80% to 5% B in 0.1 3.0 × 50mm minutes, then stop L Shim-pack Water/0.05% ACN/0.05% 1 5% to 100% Bin 3.00 250 1.5 XR-ODS TFA TFA minutes, 100% B for 0.8 2.2 μm minutes,100% to 5% B in 3.0 × 50 mm 0.1 minutes, then stop M Shim-packWater/0.05% ACN/0.05% 1 5% to 100% B in 2.20 250 1.5 XR-ODS TFA TFAminutes, 100% B for 1.00 2.2 μm minutes, 100% to 5% B in 3.0 × 50 mm 0.1minutes, then stop N Shim-pack Water/0.05% ACN/0.05% 1 5% to 80% B in2.20 250 1.5 XR-ODS TFA TFA minutes, 80% B for 1.0 2.2 μm minutes, 80%to 5% B in 0.1 3.0 × 50 mm minutes, then stop O Zorbax Water/0.05%ACN/0.05% 1 5% to 70% B in 8.00 250 1.5 Eclipse Plus TFA TFA minutes,70% B for 2.0 C18 minutes, then stop 4.6 × 100 mm P Shim-packWater/0.05% ACN/0.05% 1 5% to 65% B in 3.00 250 1.5 XR-ODS TFA TFAminutes, 65% B for 0.80 2.2 μm minutes, 100% to 5% B in 3.0 × 50 mm 0.1minutes, then stop Q Shim-pack Water/0.05% ACN/0.05% 1 5% to 60% B in2.50 250 0.95 XR-ODS TFA TFA minutes, 60% B for 0.7 2.2 μm minutes, 60%to 5% B in 0.1 3.0 × 50 mm minutes, then stop R Shim-pack Water/0.05%ACN/0.05% 1 5% to 50% B in 2.50 250 0.95 XR-ODS TFA TFA minutes, 50% Bfor 0.7 2.2 μm minutes, 50% to 5% B in 0.1 3.0 × 50 mm minutes, thenstop S XBridge Water/0.05% ACN/0.05% 1 5% to 95% B in 2.20 250 0.9 C183.5 μm TFA TFA minutes, 95% B for 1.00 3.0 × 50 mm minutes, 95% to 5% Bin 0.1 minutes, then stop T Shim-pack Water/0.05% ACN/0.05% 0.7 5% to100% B in 2.0 250 0.85 XR-ODS FA FA minutes, 100% B for 1.1 1.6 μmminutes, 100% to 5% B in 2.0 × 50 mm 0.1 minutes, then stop U Shim-packWater/0.05% ACN/0.05% 1 5% to 40% B in 2.50 250 0.95 XR-ODS TFA TFAminutes, 40% B for 0.7 2.2 μm minutes, 40% to 5% B in 0.1 3.0 × 50 mmminutes, then stop V Shim-pack Water/0.05% ACN/0.05% 1 5% to 60% B in4.20 200 1.05 XR-ODS TFA TFA minutes, 60% B for 1.0 2.2 μm minutes, 60%to 5% B in 0.1 3.0 × 50 mm minutes, then stop W Shim-pack Water/0.05%ACN/0.05% 1 5% to 100% B in 2.20 200 0.95 XR-ODS TFA TFA minutes, 100% Bfor 1.00 2.2 μm minutes, 100% to 5% B in 3.0 × 50 mm 0.1 minutes, thenstop X Shim-pack Water/0.05% ACN/0.05% 0.7 5% to 100% B in 2.0 200 0.85XR-ODS FA FA minutes, 100% B for 1.1 1.6 μm minutes, 100% to 5% B in 2.0× 50 mm 0.1 minutes, then stop Y Ecliplis Plus Water/0.05% ACN 1 5% to100% B in 2.0 250 1 C18 3.5 μm TFA minutes, 100% B for 1.0 4.6 × 50 mmminutes, 100% to 5% B in 0.1 minutes, then stop Z Ecliplis Plus Water/10ACN/5% 1 5% to 100% B in 2.0 250 1.1 C18 3.5 μm mM water minutes, 100% Bfor 1.0 4.6 × 50 mm ammonium minutes, 100% to 5% B in carbonate 0.1minutes, then stop A1 Shim-pack Water/0.05% ACN 1 5% to 100% B in 2.0250 1 XR-ODS TFA minutes, 100% B for 1.0 2.2 μm minutes, 100% to 5% B in3.0 × 50 mm 0.1 minutes, then stop A2 Ecliplis Plus Water/ ACN 1 5% to100% B in 2.0 250 0.95 C18 3.5 μm 10 mM minutes, 100% B for 1.4 4.6 × 50mm ammonium minutes, 100% to 5% B in acetate 0.1 minutes, then stop A3Acquity Water/ ACN/0.1% 0.55 5% B at 0.01 min up to 0.4 BEH C18 5 mM FAmin, 35% B at 0.8 min, 55% 1.7 μm ammonium B at 1.2 min, 100% B in 1.32.1 × 50 mm acetate/ minutes, at 2.5 min up to 0.1% FA 3.30 min, 5% B at3.31 min up to 4.0 min, then stop

Compound structure confirmations were carried out using standard 300 or400 MHz NMR spectrometers with NOe's conducted whenever necessary.

The following abbreviations are used herein:

Abbreviation Meaning ACN acetonitrile atm. atmosphere DCMdichloromethane DHP dihydropyran DIBAL diisobutyl aluminum hydride DIEAdiisopropyl ethylamine DMF dimethyl formamide DMF-DMA dimethyl formamidedimethyl acetal DMSO dimethyl sulfoxide dppf1,1′-bis(diphenylphosphino)ferrocene EA ethyl acetate ESI electrosprayionization EtOH ethanol FA formic acid GC gas chromatography h hour Hexhexanes HMDS hexamethyl disilazide HPLC high performance liquidchromatography IPA isopropanol LCMS liquid chromatography/massspectrometry MeOH methanol min minutes NBS N-bromo succinimide NCSN-chloro succinimide NIS N-iodo succinimide NMR nuclear magneticresonance NOe nuclear Overhauser effect Prep. preparative PTSApara-toluene sulfonic acid Rf retardation factor rt room temperature RTretention time sat. saturated SGC silica gel chromatography TBAFtetrabutyl ammonium fluoride TEA triethylamine TFA trifluoroacetic acidTHF tetrahydrofuran TLC thin layer chromatography UPLC ultra performanceliquid chromatography

Intermediate Synthesis Synthesis of intermediatetert-butyl(2-(((3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)methyl)(methyl)amino)ethyl)carbamate

Step 1:tert-butyl(2-(((3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)methyl)(methyl)amino)ethyl)carbamate

A mixture of 3-iodo-1-(oxan-2-yl)-1H-pyrazole-4-carbaldehyde (3.2 g,10.45 mmol, 1.00 equiv), tert-butyl N-[2-(methylamino)ethyl]carbamate(2.2 g, 12.63 mmol, 1.21 equiv) and NaBH(OAc)₃ (6.65 g, 31.38 mmol, 3.00equiv) in dichloroethane (30 mL) was stirred for 2 h at roomtemperature. The reaction was quenched with 50 mL of saturated aqueoussodium bicarbonate solution. The resulting mixture was extracted with3×200 mL of dichloromethane. The combined organic layers was dried overanhydrous sodium sulfate and concentrated under vacuum. The residue waspurified on a silica gel column eluted with 30-100% ethyl acetate inpetroleum ether to give 4.05 g (83%) oftert-butyl(2-(((3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)methyl)(methyl)amino)ethyl)carbamateas a light yellow oil. ¹H NMR (300 MHz, CDCl₃): δ 7.48 (s, 1H),5.35-5.30 (m, 1H), 4.13-4.03 (m, 1H), 3.71-3.63 (m, 1H), 3.36 (s, 2H),3.26-3.25 (m, 2H), 2.52-2.49 (m, 2H), 2.21 (s, 3H), 2.09-2.01 (m, 3H),1.68-1.58 (m, 3H), 1.44 (s, 9H) ppm. LCMS (method C, ESI): RT=0.58 min,m/z=465.0 [M+H]⁺.

Synthesis of intermediatetert-butyl(2-(((3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)methyl)(methyl)amino)ethyl)(methyl)carbamate

Step 1: Ethyl 3-iodo-1H-pyrazole-4-carboxylate

To a stirred solution of ethyl 3-amino-1H-pyrazole-4-carboxylate (10 g,64.45 mmol, 1.00 equiv) in 50% sulfuric acid (90 mL) at 5° C. was addeddropwise a solution of NaNO₂ (7.4 g, 107.25 mmol, 1.66 equiv) in water(15 mL). The reaction was stirred at 5° C. for another 30 min. Asolution of KI (32.1 g, 193.37 mmol, 3.00 equiv) in water (15 mL) wasadded dropwise at 5° C. The reaction was allowed to stir at 5° C. for 1h and then quenched by the addition of 50 mL of water. The precipitatewas collected by filtration and then dissolved in 150 mL of ethylacetate. The resulting solution was washed sequentially with lx100 mL ofsaturated Na₂SO₃ solution, lx100 mL of saturated sodium bicarbonatesolution and lx100 mL of brine. The organic layer was dried overanhydrous sodium sulfate and concentrated under vacuum to give 10.8 g(63%) of ethyl 3-iodo-1H-pyrazole-4-carboxylate as a yellow solid. ¹HNMR (300 MHz, CDCl₃): δ8.18 (s, 1H), 4.38-4.29 (m, 2H), 1.41-1.33 (m,3H) ppm. LCMS (method B, ESI): RT=1.36 min, m/z=267.0 [M+H]⁺.

Step 2: Ethyl3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-carboxylate

A solution of ethyl 3-iodo-1H-pyrazole-4-carboxylate (10.8 g, 40.60mmol, 1.00 equiv), 3,4-dihydro-2H-pyran (10 g, 118.88 mmol, 2.93 equiv)and TsOH (780 mg, 4.53 mmol, 0.11 equiv) in THF (100 mL) was stirred for2 h at 60° C. The reaction mixture was cooled to room temperature andquenched by the addition of 100 mL of saturated sodium bicarbonatesolution. The resulting solution was extracted with 2×80 mL ofdichloromethane. The combined organic layers was dried over anhydroussodium sulfate and concentrated under vacuum. The residue was purifiedon a silica gel column eluted with ethyl acetate/petroleum ether (1:20)to give 13 g (91%) of ethyl3-iodo-1-(oxan-2-yl)-1H-pyrazole-4-carboxylate as a yellow oil. ¹H NMR(400 MHz, CDCl₃): δ 8.04 (s, 1H), 5.40-5.38 (m, 1H), 4.34-4.29 (m, 2H),4.08-4.05 (m, 1H), 3.73-3.70 (m, 1H), 2.07-1.98 (m, 3H), 1.69-1.62 (m,3H), 1.39-1.32 (m, 3H) ppm. LCMS (method C, ESI): RT=1.53 min, m/z=351.0[M+H]⁺.

Step 3: 3-Iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-carboxylicacid

To a solution of ethyl 3-iodo-1-(oxan-2-yl)-1H-pyrazole-4-carboxylate(85 g, 242.75 mmol, 1.00 equiv) in THF (300 mL) and methanol (300 mL)was added a solution of LiOH (17.5 g, 730.69 mmol, 3.01 equiv) in water(400 mL). The resulting solution was stirred at room temperatureovernight and then concentrated under vacuum to remove the organicsolvent. The resulting solution was diluted with 400 mL of H₂O and thenacidified to pH 6.0 with 1M hydrochloric acid. The mixture was extractedwith 3×800 mL of dichloromethane. The combined organic layers was washedwith 3×1000 mL of brine, dried over anhydrous sodium sulfate andconcentrated under vacuum to give 75 g (96%) of3-iodo-1-(oxan-2-yl)-1H-pyrazole-4-carboxylic acid as an off-whitesolid. LCMS (method D, ESI): RT=1.23 min, m/z=323.0 [M+H]⁺.

Step 4: (3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)methanol

To a solution of 3-iodo-1-(oxan-2-yl)-1H-pyrazole-4-carboxylic acid (28g, 86.93 mmol, 1.00 equiv) in anhydrous THF (300 mL) maintained undernitrogen at 5° C. was added a 1M solution of BH₃ in THF (300 mL)dropwise with stirring. The reaction was stirred overnight at roomtemperature and then quenched by the addition of 300 mL of saturatedNH₄Cl solution. The resulting mixture was extracted with 3×1000 mL ofdichloromethane. The combined organic layers was dried over anhydroussodium sulfate and concentrated under vacuum. The residue was purifiedon a silica gel column eluted with ethyl acetate/petroleum ether (1:1)to give 12.67 g (47%) of (3-iodo-1-(oxan-2-yl)-1H-pyrazol-4-yl)methanolas a white solid. ¹H NMR (400 MHz, DMSO-d6): δ 7.73 (s, 1H), 5.37-5.34(m, 1H), 4.92 (s, 1H), 4.20 (d, J=3.6 Hz, 2H), 3.89-3.88 (m, 1H),3.65-3.57 (m, 1H), 2.09-2.00 (m, 1H), 1.99-1.90 (m, 2H), 1.69-1.61 (m,1H), 1.49-1.46 (m, 2H) ppm. LCMS (method A, ESI): RT=1.16 min, m/z=309.0[M+H]⁺.

Step 5: 3-Iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-4-carbaldehyde

Into a 250-mL 3-necked round-bottom flask purged and. To a stirredsolution of oxalyl chloride (18.576 g, 146.35 mmol, 3.01 equiv) inanhydrous dichloromethane (300 mL) maintained under nitrogen at -78° C.was added DMSO (15.138 g, 193.75 mmol, 3.98 equiv) dropwise. Thereaction mixture was stirred at -65° C. for 30 min. A solution of(3-iodo-1-(oxan-2-yl)-1H-pyrazol-4-yl)methanol (15.0 g, 48.68 mmol, 1.00equiv) in dichloromethane (100 mL) was then added dropwise at −65° C.and the reaction was stirred for another 60 min at −65° C. Triethylamine(40.6 mL) was added dropwise at −65° Cand the reaction was stirred for30 min at −65° C. The reaction was warmed to 0° C. then quenched by theaddition of 100 mL of saturated NH₄Cl solution. The resulting mixturewas extracted with 3×400 mL of dichloromethane. The combined organiclayers was dried over anhydrous sodium sulfate and concentrated undervacuum. The residue was purified on a silica gel column eluted withethyl acetate/petroleum ether (1:20) to give 13.48 g (90%) of3-iodo-1-(oxan-2-yl)-1H-pyrazole-4-carbaldehyde as a golden oil. ¹H NMR(300 MHz, DMSO-d6): δ 9.69 (s, 1H), 8.57 (s, 1H), 5.49 (dd, J=2.7 Hz,9.9 Hz, 1H), 3.95-3.91 (m, 1H), 3.68-3.62 (m, 1H), 2.11-2.01 (m, 3H),1.69-1.62 (m, 3H) ppm. LCMS (method A, ESI): RT=1.35 min, m/z=307.0[M+H]⁺.

Step 6: tert-Butyl(2-(((3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)methyl)(methyl)amino)ethyl)(methyl)carbamate

A mixture of 3-iodo-1-(oxan-2-yl)-1H-pyrazole-4-carbaldehyde (21.5 g,70.24 mmol, 1.00 equiv), tert-butylN-methyl-N-(2-(methylamino)ethyl)carbamate (20 g, 106.23 mmol, 1.51equiv) and NaBH(OAc)₃ (29.8 g, 137.98 mmol, 1.96 equiv) indichloroethane (300 mL) was stirred for 1 h at room temperature. Thereaction was diluted with 300 mL of dichloromethane and then washed with3×300 mL of brine. The organic layer was dried over anhydrous sodiumsulfate and concentrated under vacuum. The residue was purified on asilica gel column eluted with 0-7% methanol in dichloromethane to give31 g (92%) of tert-butyl(2-(((3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)methyl)(methyl)amino)ethyl)(methyl)carbamateas a yellow oil. ¹H NMR (300 MHz, CDCl₃): δ 7.62 (s, 1H), 5.34-5.30 (m,1H), 4.06-4.02 (m, 1H), 3.68-3.62 (m, 1H), 3.42-3.38 (m, 4H), 2.85 (s,4H), 2.62-2.53 (m, 2H), 2.47-2.46 (m, 2H), 2.13-1.97 (m, 3H), 1.74-1.69(m, 3H), 1.46 (s, 9H) ppm. LCMS (method A, ESI): RT=1.17 min, m/z=479.0[M+H]⁺.

Compound 19N¹-methyl-N¹-((3-(1-methyl-1H-indazol-6-yl)-1H-pyrazol-4-yl)methyDethane-1,2-diamine

Step 1: (R/S) tert-butyl2-(methyl((3-(1-methyl-1H-indazol-6-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)methyDamino)ethyDcarbamate

A mixture of tert-butylN-[2-([[3-iodo-1-(oxan-2-yl)-1H-pyrazol-4-yl]methyll(methyl)amino)eth-ylicarbamate(200 mg, 0.43 mmol, 1.00 equiv), K₃PO₄ (273 mg, 1.29 mmol, 3.00 equiv),(1-methyl-1H-indazol-6-yl)boronic acid (113 mg, 0.64 mmol, 1.50 equiv)and Pd(dppf)Cl₂.CH₂Cl₂ (70 mg, 0.10 mmol, 0.20 equiv) in ethylene glycoldimethyl ether (20 mL) was stirred under nitrogen at 95° C. overnight.The resulting mixture was cooled to room temperature then concentratedunder vacuum. The crude product was purified by Pre-HPLC with thefollowing conditions (1#-Pre-HPLC-005 (Waters)): Column, XBridge ShieldRP18 OBD Column, 5 μm, 19×150mm; mobile phase, water with 10 mmolNH₄HCO₃ and CH₃CN (18% CH₃CN up to 58% in 10 min, up to 95% in 1 min,down to 18% in 2 min); Detector, UV 254/220 nm to yield 50 mg (25%) oftert-butyl2-(methyl43-(1-methyl-1H-indazol-6-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)methyl)amino)ethylcarbamateas a colorless oil. LCMS (method A, ESI): RT=1.16 min, m/z=469.0 [M+H]⁺.

Step 2:N¹-methyl-N¹-((3-(1-methyl-1H-indazol-6-yl)-1H-pyrazol-4-yl)methypethane-1,2-diamine(Compound 19)

A solution of tert-butylN-[2-[methyl([[3-(1-methyl-1H-indazol-6-yl)-1-(oxan-2-yl)-1H-pyrazol-4-yl]methyl])amino]ethyll]carbamate(50 mg, 0.11 mmol, 1.00 equiv) in tetrahydrofuran (3 mL) and 12Nhydrochloric acid (2 mL) was stirred at room temperature overnight. ThepH of the solution was adjusted to 7 with triethylamine. The resultingmixture was concentrated and the residue purified by Pre-HPLC with thefollowing conditions (1#-Pre-HPLC-005 (Waters)): Column, XBridge ShieldRP18 OBD Column, 5 μm, 19×150mm; mobile phase, water with 10 mmolNH₄HCO₃ and CH₃CN (18% CH₃CN up to 58% in 10 min, up to 95% in 1 min,down to 18% in 2 min); Detector, UV 254/220 nm to give 5 mg (16%) ofN¹-methyl-N¹-((3-(1-methyl-1H-indazol-6-yl)-1H-pyrazol-4-yl)methyl)ethane-1,2-diamineas a light yellow oil. ¹H-NMR (300MHz, CDCl₃): δ 8.05 (s, 1H), 7.89-7.84(m, 2H), 7.73 (s, 1H), 7.54-7.50 (m, 1H), 4.12 (s, 3H), 3.67 (s, 2H),2.84 (d, J=6.3 Hz, 2H), 2.55 (d, J=6.3 Hz, 2H), 2.27 (s, 3H) ppm. LCMS(method Al, ESI): RT=0.90 min, m/z=285.0 [M+H]⁺.

Compound 21

N¹-((3-(imidazo[1,2-a]pyridin-6-yl)-1H-pyrazol-4-yl)methyl)-N¹-methylethane-1,2-diamine

Step 1: tert-butyl2-(((3-(imidazo[1,2-a]pyridin-6-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)methyl)(methyDamino)ethyl)carbamate

A mixture of (R/S) tert-butylN-[2-([[3-iodo-1-(oxan-2-yl)-1H-pyrazol-4-yl]methyl](methyl)amino)ethylicarbamate(200 mg, 0.43 mmol, 1.00 equiv), 1H,8aH-imidazo[1,2-a]pyridin-6-ylboronic acid (105 mg, 0.64 mmol, 1.50equiv), Pd(dppf)Cl₂.CH₂Cl₂ (70 mg, 0.10 mmol, 0.20 equiv) and K₃PO₄ (273mg, 1.29 mmol, 3.00 equiv) in ethylene glycol dimethyl ether (20 mL) wasstirred under nitrogen at 95° C. overnight. The resulting mixture wascooled to room temperature and concentrated under vacuum. The residuewas diluted with 10 mL of methanol and then purified by Prep-HPLC withthe following conditions (1#-Pre-HPLC-005 (Waters)): Column, XBridgeShield RP18 OBD Column, 5 μm, 19×150 mm; mobile phase, water with 10mmol NH₄HCO₃ and CH₃CN (18% CH₃CN up to 58% in 10 min, up to 95% in 1min, down to 18% in 2 min); Detector, UV 254/220 nm to afford 40 mg(20%) of tert-butyl2-(((3-(imidazo[1,2-a]pyridin-6-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)methyl)(methyl)amino)ethyl)carbamateas a colorless oil. LCMS (method A, ESI): RT=1.04 min, m/z=455.0 [M+H]⁺.

Step 2: Compound 21N¹-((3-(imidazo[1,2-a]pyridin-6-yl)-1H-pyrazol-4-yl)methyl)-N¹-methylethane-1,2-diamine

A solution of tert-butyl2-(((3-(imidazo[1,2-a]pyridin-6-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)methyl)(methyl)amino)ethyl)carbamate(40 mL, 1.00 equiv) in tetrahydrofuran (3 mL) and 12N hydrochloric acid(2 mL) was stirred at room temperature overnight. The pH of the mixturewas adjusted to 7 by addition of triethylamine. The resulting mixturewas concentrated under vacuum and the residue purified by Prep-HPLCunder the following conditions (1#-Pre-HPLC-005 (Waters)): Column,XBridge Shield RP18 OBD Column, 5 μm, 19×150 mm; mobile phase, waterwith 10 mmol NH₄HCO₃ and CH₃CN (18% CH₃CN up to 58% in 10 min, up to 95%in 1 min, down to 18% in 2 min); Detector, UV 254/220 nm to give 5 mg(21%) ofN¹-((3-(imidazo[1,2-a]pyridin-6-yl)-1H-pyrazol-4-yl)methyl)-N¹-methylethane-1,2-diamineas a colorless oil. ¹H-NMR (300 MHz, CD₃OD): δ 8.94 (s, 1H), 7.93 (s,1H), 7.74-7.72 (m, 2H), 7.65-7.62 (m, 2H), 3.59 (s, 2H), 2.87-2.82 (m,2H), 2.58-2.54 (m, 2H), 2.27 (s, 3H) ppm. LCMS (method A2, ESI): RT=1.32min, m/z=271.0 [M+H]⁺.

Compound 23N¹-((2′-isobutyl-3,4′-bi(1H-pyrazol)-4-yl)methyl)-N¹-methylethane-1,2-diamine

Step 1:1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

A mixture of 4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1 g,5.15 mmol, 1.00 equiv), 1-bromo-2-methylpropane (1.05 g, 7.66 mmol, 1.49equiv) and Cs₂CO₃ (3.36 g, 10.31 mmol, 2.00 equiv) in acetonitrile (60mL) was stirred at 80° C. for 4 h. The reaction was cooled to roomtemperature and the solid material was removed by filtration. Thefiltrate was diluted with ethyl acetate (30 mL) and then washed withbrine (40 mL). The organic layer was dried over anhydrous sodium sulfateand concentrated under vacuum to give 1.14 g (88%) of1-iso-butyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazoleas a colorless oil. ¹H-NMR (300 MHz, CDCl₃): δ 7.78 (s, 1H), 7.65 (s,1H), 3.91 (d, J=7.2Hz, 2H), 2.24-2.19 (m, 1H), 1.32 (s, 12H), 0.90 (d,J=7.2Hz, 6H) ppm. LCMS (method D, ESI): RT=1.51 min, m/z=251.0 [M+H]⁺.

Step 2: (R/S) tert-butyl2-(((2′-iso-butyl-1-(tetrahydro-2H-pyran-2-yl)-3,4′-bi(1H-pyrazol)-4-yl)methyl)(methyDamino)ethyl)carbamate

A mixture of tert-butylN-[2-([[3-iodo-1-(oxan-2-yl)-1H-pyrazol-4-yl]methyl](methyl)amino)ethylicarbamate(800 mg, 1.72 mmol, 1.00 equiv),1-iso-butyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(860 mg, 3.44 mmol, 2.00 equiv), Pd(dppf)Cl₂ (251 mg, 0.34 mmol, 0.20equiv) and potassium carbonate (712 mg, 5.15 mmol, 2.99 equiv) in1,4-dioxane (50 mL) and water (10 mL) was stirred at 90° C. for 12 h.The reaction was cooled to room temperature and diluted with H₂O (20 mL)and the resulting mixture was extracted with 2×50 mL of ethyl acetate.The combined organic layers was washed with 2×100 mL of brine, driedover anhydrous sodium sulfate and concentrated under vacuum. The residuewas purified on a silica gel column eluted with 0-30% of ethyl acetatein petroleum ether to give 400 mg (50%) of tert-butyl2-(((2′-iso-butyl-1-(tetrahydro-2H-pyran-2-yl)-3,4′-bi(1H-pyrazol)-4-yl)methyl)(methyl)amino)ethyl)carbamateas a brown oil. LCMS (method D, ESI): RT=1.17 min, m/z=461.0 [M+H]⁺.

Step 3: Compound 23N¹-((2′-iso-butyl-3,4′-bi(1H-pyrazol)-4-yl)methyl)-N¹-methylethane-1,2-diamine

A solution of tert-butyl2-(((2′-iso-butyl-1-(tetrahydro-2H-pyran-2-yl)-3,4′-bi(1H-pyrazol)-4-yl)methyl)(methyDamino)ethyl)carbamate(400 mg, 0.90 mmol, 1.00 equiv) in 4 N hydrochloric acid (30 mL) wasstirred for 2 h at 60° C. The resulting mixture was concentrated undervacuum and the pH value of the residue was adjusted to 7 with saturatedsodium bicarbonate solution. The aqueous layer was concentrated undervacuum and the crude product was purified by Prep-HPLC with thefollowing conditions (Prep-HPLC-019): Column, XBridge Shield RP18 OBDColumn, 5 μm, 19×150 mm; mobile phase, water with 0.05% TFA and MeCN(2.0% MeCN up to 15.0% in 10 min, up to 95.0% in 1 min, hold 95.0% in 1min, down to 2.0% in 2 min); Detector, UV 220/254nm to yield 221.8 mg(50%) ofN¹-((2′-iso-butyl-3,4′-bi(1H-pyrazol)-4-yl)methyl)-N¹-methylethane-1,2-diaminetrifluoroacetate as a colorless oil. ¹H-NMR (300 MHz, D₂O): δ 7.93 (s,1H), 7.87 (s, 1H), 7.76 (s, 1H), 4.38 (s, 2H), 3.93 (d, J=7.2 Hz, 2H),3.39-3.18 (m, 4H), 2.62 (s, 3H), 2.12-1.98 (m, 1H), 0.76 (d, J=7.2 Hz,6H) ppm. LCMS (method M, ESI): RT=0.97 min, m/z=277.1 [M+H]⁺.

Compound 24N¹-((1′-benzyl-3,4′-bi(1H-pyrazol)-4-yl)methyl)-N¹-methylethane-1,2-diamine

Step 1: (R/S) tert-butyl2-(((2′-benzyl-1-(tetrahydro-2H-pyran-2-yl)-3,4′-bi(1H-pyrazol)-4-yl)methyl)(methyl)amino)ethyl)carbamate

A mixture of (R/S) tert-butylN-[2-([[3-iodo-1-(oxan-2-yl)-1H-pyrazol-4-yl]methyll(methyl)amino)ethylicarbamate(200 mg, 0.43 mmol, 1.00 equiv), Pd(dppf)Cl₂.CH₂Cl₂ (107 mg, 0.30equiv), (1-benzyl-1H-pyrazol-4-yl)boronic acid (159 mg, 0.79 mmol, 1.30equiv) and K₃PO₄ (279 mg, 1.31 mmol, 3.00 equiv) in ethylene glycoldimethyl ether (20 mL) and water (1 mL) was stirred under nitrogen at100° C. overnight. The resulting mixture was cooled to room temperatureand concentrated under vacuum. The residue was dissolved in 10 mL ofmethanol then purified by Prep-HPLC with the following conditions(1#-Pre-HPLC-005 (Waters)): Column, XBridge Shield RP18 OBD Column, 5μm, 19×150 mm; mobile phase, water with 10 mmol NH₄HCO₃ and CH₃CN (18%CH₃CN up to 58% in 10 min, up to 95% in 1 min, down to 18% in 2 min);Detector, UV 254/220 nm to give 100 mg (47%) of tert-butyl2-(((2′-benzyl-1-(tetrahydro-2H-pyran-2-yl)-3,4′-bi(1H-pyrazol)-4-yl)methyl)(methyl)amino)ethyl)carbamateas a yellow oil. LCMS (method C, ESI): RT=1.24 min, m/z=495.1 [M+H]⁺.

Step 2:N¹-((1′-benzyl-3,4′-bi(1H-pyrazol)-4-yl)methyl)-N¹-methylethane-1,2-diamine(Compound 24)

A solution of tert-butyl2-(((2′-benzyl-1-(tetrahydro-2H-pyran-2-yl)-3,4′-bi(1H-pyrazol)-4-yl)methyl)(methyl)amino)ethyl)carbamate(100 mg, 0.20 mmol, 1.00 equiv) in tetrahydrofuran (8 mL) and 12Nhydrochloric acid (1 mL) was stirred overnight at room temperature. Theresulting mixture was concentrated under vacuum. The residue wasdissolved in 5 mL of methanol and the pH value of the solution wasadjusted to 8 with saturated aqueous sodium carbonate solution. Theprecipitate was removed by filtration. The filtrate which contained thecrude product was purified by Pre-HPLC with the following conditions(1#-Pre-HPLC-005(Waters)): Column, XBridge Shield RP18 OBD Column, 5 μm,19×150mm; mobile phase, water with 10 mmol NH₄HCO₃ and CH₃CN (18% CH₃CNup to 58% in 10 min, up to 95% in 1 min, down to 18% in 2 min);Detector, UV 254/220 nm to give 23 mg (37%) ofN¹-((1′-benzyl-3,4′-bi(1H-pyrazol)-4-yl)methyl)-N¹-methylethane-1,2-diamineas a white solid. ¹H-NMR (300MHz, CD₃OD): 8 8.04 (s, 1H), 7.88 (s, 1H),7.60 (s, 1H), 7.41-7.29 (m, 5H), 5.41 (s, 2H), 3.52 (s, 2H), 2.77-2.73(m, 2H), 2.51-2.47 (m, 2H), 2.22 (s, 3H) ppm. LCMS (method A1, ESI):RT=1.04 min, m/z=311.0 [M+H]⁺.

Compound 27N¹-((3-(1H-indazol-5-yl)-1H-pyrazol-4-yl)methyl)-N¹-methylethane-1,2-diamine

Step 1: 1-(tert-butoxycarbonyl)-1H-indazol-5-ylboronic acid

A solution of (1H-indazol-5-yl)boronic acid (300 mg, 1.85 mmol, 1.00equiv), triethylamine (280 mg), Boc₂O (804 mg, 3.68 mmol, 1.99 equiv)and 4-dimethylaminopyridine (23 mg, 0.19 mmol, 0.10 equiv) inacetonitrile (15 mL) was stirred at 25° C. overnight. Water (20 mL) wasthen added and the resulting mixture was extracted with 3×60 mL of ethylacetate. The combined organic extracts was washed with 2×3 mL of waterand 3×3 mL of brine. The organic layer was dried over anhydrous sodiumsulfate and concentrated under vacuum. The residue was purified on asilica gel column eluted with 0-5% of methanol in dichloromethane togive 320 mg (68%) of 1-(tert-butoxycarbonyl)-1H-indazol-5-ylboronic acidas a white solid. LCMS (method A, ESI): RT=1.34 min, m/z=263.0 [M+H]⁺.

Step 2: (R/S) tert-butyl5-(4-(((2-(tert-butoxycarbonylamino)ethyl)(methypaminonnethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-indazole-1-carboxylate

A mixture of (R/S) tert-butylN-[2-([[3-iodo-1-(oxan-2-yl)-1H-pyrazol-4-yl]methyll(methyl)amino)ethylicarbamate(200 mg, 0.43 mmol, 1.00 equiv), K₃PO₄.3H₂O (439 mg, 1.65 mmol, 3.83equiv), 1-(tert-butoxycarbonyl)-1H-indazol-5-ylboronic acid (300 mg,1.14 mmol, 2.66 equiv) and Pd(dppf)Cl₂.CH₂Cl₂ (135 mg) in ethyleneglycol dimethyl ether (20 mL) and water (1 mL) was stirred undernitrogen at 85° C. for 3 h. The resulting mixture was cooled to roomtemperature and concentrated under vacuum. The residue was dissolved in5 mL of methanol and 5 mL of DMSO and then purified by Prep-HPLC withthe following conditions (1#-Pre-HPLC-005 (Waters)): Column, XBridgeShield RP18 OBD Column, 5_([)1m, 19×150mm; mobile phase, water with 10mmol NH₄HCO₃ and CH₃CN (18% CH₃CN up to 58% in 10 min, up to 95% in 1min, down to 18% in 2 min); Detector, UV 254/220 nm to give 50 mg (21%)of (R/S) tert-butyl5-(4-(((2-(tert-butoxycarbonylamino)ethyl)(methyl)amino)methyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-indazole-1-carboxylateas a colorless oil. LCMS (method A, ESI): RT=1.34 min, m/z=555.1 [M+H]⁺.

Step 3:N¹-((3-(1H-indazol-5-yl)-1H-pyrazol-4-yl)-methyl)-N¹-methylethane-1,2-diamine(Compound 27)

A solution of (R/S) tert-butyl5-(4-(((2-(tert-butoxycarbonylamino)ethyl)(methyl)amino)methyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)-1H-indazole-1-carboxylate(50 mg, 0.09 mmol, 1.00 equiv) in tetrahydrofuran (10 mL) and 12Nhydrochloric acid (2 mL) was stirred overnight at 25° C. The resultingmixture was concentrated under vacuum to remove most of the THF. The pHvalue of the solution was adjusted to 9 with 10% sodium carbonatesolution. The resulting mixture was concentrated under vacuum. Theresidue was dissolved in 5 mL of methanol and then purified by Pre-HPLCwith the following conditions (1#-Pre-HPLC-005 (Waters)): Column,XBridge Shield RP18 OBD Column, 5_([)1m, 19×150mm; mobile phase, waterwith 10 mmol NH₄HCO₃ and CH₃CN (18% CH₃CN up to 58% in 10 min, up to 95%in 1 min, down to 18% in 2 min); Detector, UV 254/220 nm to give 7 mg(29%) of(2-aminoethyl)([[3-(1H-indazol-5-yl)-1H-pyrazol-4-yl]methyThmethylamineas a white solid. ¹H-NMR (300MHz, CD₃OD): δ 8.14 (s, 1H), 8.10 (s, 1H),7.72-7.64 (m, 3H), 3.63 (s, 2H), 3.10-3.09 (m, 2H), 2.86-2.77 (m, 2H),2.24 (s, 3H) ppm. LCMS (method Al, ESI): RT=0.78 min, m/z=271.0 [M+H]⁺.

Biological Methods

PRMT1 Biochemical Assay General Materials. S-adenosylmethionine (SAM),S-adenosylhomocysteine (SAH), bicine, Tween20, dimethylsulfoxide (DMSO),bovine skin gelatin (BSG), and Tris(2-carboxyethyl)phosphinehydrochloride solution (TCEP) were purchased from Sigma-Aldrich at thehighest level of purity possible. ³H-SAM was purchase from AmericanRadiolabeled Chemicals with a specific activity of 80 Ci/mmol. 384-wellstreptavidin Flashplates were purchased from PerkinElmer.

Substrates. Peptide representative of human histone H4 residues 36-50was synthesized with an N-terminal linker-affinity tag motif and aC-terminal amide cap by 21^(st) Century Biochemicals. The peptide waspurified by high-performance liquid chromatography (HPLC) to greaterthan 95% purity and confirmed by liquid chromatography mass spectrometry(LC-MS). The sequence was Biot-Ahx-RLARRGGVKRISGLI-amide (SEQ ID NO.:1).

Molecular Biology: Full-length human PRMT1 isoform 1 (NM_001536.5)transcript clone was amplified from an HEK 293 cDNA library,incorporating flanking 5′ sequence encoding a FLAG tag (DYKDDDDK) (SEQID NO.:2) fused directly to Met 1 of PRMT1. The amplified gene wassubcloned into pFastBacl (Life Technologies) modified to encode anN-terminal GST tag and a TEV cleavage sequence(MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDENLYFQGGNS)(SEQ ID NO.:3)fused to Asp of the Flag tag of PRMT1.

Protein Expression. Recombinant baculovirus were generated according toBac-to-Bac kit instructions (Life Technologies). Protein over-expressionwas accomplished by infecting exponentially growing High Five insectcell culture at 1.5×10⁶cell/ml with 1:100 ratio of virus. Infectionswere carried out at 27° C. for 48 hours, harvested by centrifugation,and stored at −80° C. for purification.

Protein Purification. Expressed full-length human GST-tagged PRMT1protein was purified from cell paste by glutathione sepharose affinitychromatography after equilibration of the resin with 50 mM phosphatebuffer, 200 mM NaCl, 5% glycerol, 5 mM (3-mercaptoethanol, pH7.8 (BufferA). GST-tagged PRMT1 was eluted with 50 mM Tris, 2 mM glutathione, pH7.8, dialysed in buffer A and concentrated to 1 mg/mL. The purity ofrecovered protein was 73%. Reference: Wasilko, D. J. and S. E. Lee:“TIPS: titerless infected-cells preservation and scale-up” BioprocessJ., 5 (2006), pp. 29-32.

Predicted Translations:

GST-tagged PRMT1  (SEQ ID NO.: 4)MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDENLYFQGGNSDYKDDDDKMAAAEAANCIMENFVATLANGMSLQPPLEEVSCGQAESSEKPNAEDMTSKDYYFDSYAHFGIHEEMLKDEVRTLTYRNSMFHNRHLFKDKVVLDVGSGTGILCMFAAKAGARKVIGIECSSISDYAVKIVKANKLDHVVTIIKGKVEEVELPVEKVDIIISEWMGYCLFYESMLNTVLYARDKWLAPDGLIFPDRATLYVTAIEDRQYKDYKIHWWENVYGFDMSCIKDVAIKEPLVDVVDPKQLVTNACLIKEVDIYTVKVEDLTFTSPFCLQVKRNDYVHALVAYFNIEFTRCHKRTGFSTSPESPYTHWKQTVFYMEDYLTVKTGEEIFGTIGMRPNAKNNRDLDFTIDLDFKGQLCEL SCSTDYRMR

General Procedure for PRMT1 Enzyme Assays on Peptide Substrates. Theassays were all performed in a buffer consisting of 20 mM Bicine(pH=7.6), 1 mM TCEP, 0.005% BSG, and 0.002% Tween 20, prepared on theday of use. Compounds in 100% DMSO (1 ul) were spotted into apolypropylene 384-well V-bottom plates (Greiner) using a Platemate Plusoutfitted with a 384-channel head (Thermo Scientific). DMSO (1 ul) wasadded to Columns 11, 12, 23, 24, rows A-H for the maximum signal controland lul of SAH, a known product and inhibitor of PRMT1, was added tocolumns 11, 12, 23, 24, rows I-P for the minimum signal control. Acocktail (40 ul) containing the PRMT1 enzyme was added by MultidropCombi (Thermo-Fisher). The compounds were allowed to incubate with PRMT1for 30 min at room temperature, then a cocktail (10 ul) containing SAMand peptide was added to initiate the reaction (final volume =51 ul).The final concentrations of the components were as follows: PRMT1 was0.5 nM, ³H-SAM was 200 nM, non-radiolabeled SAM was 1.5 uM, peptide was20 nM, SAH in the minimum signal control wells was 1 mM, and the DMSOconcentration was 2%. The assays were stopped by the addition ofnon-radiolabeled SAM (10 ul) to a final concentration of 300 uM, whichdilutes the ³H-SAM to a level where its incorporation into the peptidesubstrate is no longer detectable. 50 ul of the reaction in the 384-wellpolypropylene plate was then transferred to a 384-well Flashplate andthe biotinylated peptides were allowed to bind to the streptavidinsurface for at least 1 hour before being washed once with 0.1%Tween20 ina Biotek ELx405 plate washer. The plates were then read in a PerkinElmerTopCount plate reader to measure the quantity of ³H-labeled peptidebound to the Flashplate surface, measured as disintegrations per minute(dpm) or alternatively, referred to as counts per minute (cpm).inhibition calculation

${\% \mspace{14mu} {inch}} = {100 - {\left( \frac{{dpm}_{cmpd} - {dpm}_{\min}}{{dpm}_{\max} - {dpm}_{\min}} \right) \times 100}}$

Where dpm=disintegrations per minute, cmpd=signal in assay well, and minand max are the respective minimum and maximum signal controls.

Four-Parameter IC₅₀ Fit

$Y = {{Bottom} + \frac{\left( {{Top} - {Bottom}} \right)}{\left( {1 + \left( \frac{X}{{IC}_{50}} \right)^{{Hill}\mspace{14mu} {Coefficient}}} \right.}}$

Where top and bottom are the normally allowed to float, but may be fixedat 100 or 0 respectively in a 3-parameter fit. The Hill Coefficientnormally allowed to float but may also be fixed at 1 in a 3-parameterfit. Y is the % inhibition and X is the compound concentration.

PRMT6 Biochemical Assay

General Materials. S-adenosylmethionine (SAM), S-adenosylhomocysteine(SAH), bicine, Tween20, dimethylsulfoxide (DMSO), bovine skin gelatin(BSG), sodium butyrate and Tris(2-carboxyethyl)phosphine hydrochloridesolution (TCEP) were purchased from Sigma-Aldrich at the highest levelof purity possible. ³H-SAM was purchase from American RadiolabeledChemicals with a specific activity of 80 Ci/mmol. 384-well streptavidinFlashplates were purchased from PerkinElmer.

Substrates. Peptide representative of human histone H4 residues 36-50was synthesized with an N-terminal linker-affinity tag motif and aC-terminal amide cap by 21^(st) Century Biochemicals. The peptide waspurified by high-performance liquid chromatography (HPLC) to greaterthan 95% purity and confirmed by liquid chromatography mass spectrometry(LC-MS). The sequence was Biot-Ahx-RLARRGGVKRISGLI-amide and contained amonomethylated lysine at position 44 (SEQ ID NO.:5).

Molecular Biology: Full-length human PRMT6 (NM_018137.2) transcriptclone was amplified from an HEK 293 cDNA library, incorporating aflanking 5′ sequence encoding a FLAG tag (MDYKDDDDK) (SEQ ID NO.:6)fused directly to Ser 2 of PRMT6 and a 3′ sequence encoding a hexa Hissequence (HHHHHH) fused directly to Asp 375. The amplified gene wassubcloned into pFastBacMam (Viva Biotech).

Protein Expression. Recombinant baculovirus were generated according toBac-to-Bac kit instructions (Life Technologies). Protein over-expressionwas accomplished by infecting exponentially growing HEK 293F cellculture at 1.3×10⁶cell/ml with virus (MOI=10) in the presence of 8 mMsodium butyrate. Infections were carried out at 37° C. for 48 hours,harvested by centrifugation, and stored at -80° C. for purification.

Protein Purification. Expressed full-length human Flag- and His-taggedPRMT6 protein was purified from cell paste by NiNTA agarose affinitychromatography after equilibration of the resin with buffer containing50 mM Tris, 300 mM NaCl, 10% glycerol, pH 7.8 (Buffer Ni-A). Column waswashed with 20 mM imidazole in the same buffer and Flag-PRMT6-His waseluted with 150 mM imidazole. Pooled fractions were dialysed againstbuffer Ni-A and further purified by anti-flag M2 affinitychromatography. Flag-PRMT6-His was eluted with 200 ug/ml FLAG peptide inthe same buffer. Pooled fractions were dialysed in 20 mM Tris, 150 mMNaCl, 10% glycerol and 5 mM 13-mercaptoethanol, pH 7.8. The purity ofrecovered protein was 95%.

Predicted Translations:

Flag-PRMT6-His  (SEQ ID NO.: 7)MDYKDDDDKSQPKKRKLESGGGGEGGEGTEEEDGAEREAALERPRRTKRERDQLYYECYSDVSVHEEMIADRVRTDAYRLGILRNWAALRGKTVLDVGAGTGILSIFCAQAGARRVYAVEASAIWQQAREVVRFNGLEDRVHVLPGPVETVELPEQVDAIVSEWMGYGLLHESMLSSVLHARTKWLKEGGLLLPASAELFIAPISDQMLEWRLGFWSQVKQHYGVDMSCLEGFATRCLMGHSEIVVQGLSGEDVLARPQRFAQLELSRAGLEQELEAGVGGRFRCSCYGSAPMHGFAIWFQVTFPGGESEKPLVLSTSPFHPATHWKQALLYLNEPVQVEQDTDVSGEITLLPSRDNPRRLRVLLRYKVGDQEEKTKDFAMEDHHHHHH

General Procedure for PRMT6 Enzyme Assays on Peptide Substrates. Theassays were all performed in a buffer consisting of 20 mM Bicine(pH=7.6), 1 mM TCEP, 0.005% BSG, and 0.002% Tween 20, prepared on theday of use. Compounds in 100% DMSO (1 ul) were spotted into apolypropylene 384-well V-bottom plates (Greiner) using a Platemate Plusoutfitted with a 384-channel head (Thermo Scientific). DMSO (1 ul) wasadded to Columns 11, 12, 23, 24, rows A-H for the maximum signal controland lul of SAH, a known product and inhibitor of PRMT6, was added tocolumns 11, 12, 23, 24, rows I-P for the minimum signal control. Acocktail (40 ul) containing the PRMT6 enzyme was added by MultidropCombi (Thermo-Fisher). The compounds were allowed to incubate with PRMT6for 30 min at room temperature, then a cocktail (10 ul) containing SAMand peptide was added to initiate the reaction (final volume=51 ul). Thefinal concentrations of the components were as follows: PRMT6 was 1 nM,³H-SAM was 200 nM, non-radiolabeled SAM was 250 nM, peptide was 75 nM,SAH in the minimum signal control wells was 1 mM, and the DMSOconcentration was 2%. The assays were stopped by the addition ofnon-radiolabeled SAM (10 ul) to a final concentration of 400 uM, whichdilutes the ³H-SAM to a level where its incorporation into the peptidesubstrate is no longer detectable. 50 ul of the reaction in the 384-wellpolypropylene plate was then transferred to a 384-well Flashplate andthe biotinylated peptides were allowed to bind to the streptavidinsurface for at least 1 hour before being washed once with 0.1%Tween20 ina Biotek ELx405 plate washer. The plates were then read in a PerkinElmerTopCount plate reader to measure the quantity of ³H-labeled peptidebound to the Flashplate surface, measured as disintegrations per minute(dpm) or alternatively, referred to as counts per minute (cpm).

% Inhibition Calculation

${\% \mspace{14mu} {inch}} = {100 - {\left( \frac{{dpm}_{cmpd} - {dpm}_{\min}}{{dpm}_{\max} - {dpm}_{\min}} \right) \times 100}}$

Where dpm=disintegrations per minute, cmpd=signal in assay well, and minand max are the respective minimum and maximum signal controls.

Four-Parameter IC₅₀ Fit

$Y = {{Bottom} + \frac{\left( {{Top} - {Bottom}} \right)}{\left( {1 + \left( \frac{X}{{IC}_{50}} \right)^{{Hill}\mspace{14mu} {Coefficient}}} \right.}}$

Where top and bottom are the normally allowed to float, but may be fixedat 100 or 0 respectively in a 3-parameter fit. The Hill Coefficientnormally allowed to float but may also be fixed at 1 in a 3-parameterfit. Y is the % inhibition and X is the compound concentration.

PRMT8 Biochemical Assay

General Materials. S-adenosylmethionine (SAM), S-adenosylhomocysteine(SAH), bicine, Tween20, dimethylsulfoxide (DMSO), bovine skin gelatin(BSG), isopropyl-13-D-thiogalactopyranoside (IPTG), andTris(2-carboxyethyl)phosphine hydrochloride solution (TCEP) werepurchased from Sigma-Aldrich at the highest level of purity possible.³H-SAM was purchase from American Radiolabeled Chemicals with a specificactivity of 80 Ci/mmol. 384-well streptavidin Flashplates were purchasedfrom PerkinElmer.

Substrates. Peptide representative of human histone H4 residues 31-45was synthesized with an N-terminal linker-affinity tag motif and aC-terminal amide cap by 21^(st) Century Biochemicals. The peptide waspurified by high-performance liquid chromatography (HPLC) to greaterthan 95% purity and confirmed by liquid chromatography mass spectrometry(LC-MS). The sequence was Biot-Ahx-KPAIRRLARRGGVKR-amide (SEQ ID NO.:8).

-   Molecular Biology: Full-length human PRMT8 (NM_019854.4) isoform 1    transcript clone was amplified from an HEK 293 cDNA library and    subcloned into pGEX-4T-1 (GE Life Sciences). The resulting construct    encodes an N-terminal GST tag and a thrombin cleavage sequence    (MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYI    DGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLK    VDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKL    VCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSPEF) (SEQ ID    NO.:9) fused directly to Met 1 of PRMT8.-   Protein Expression. E. coli (BL21(DE3) Gold, Stratagene) made    competent by the CaCl₂ method were transformed with the PRMT8    construct and ampicillin selection. Protein over-expression was    accomplished by growing the PRMT8 expressing E. coli clone and    inducing expression with 0.3 mM IPTG at 16° C. The culture was grown    for 12 hours, harvested by centrifugation, and stored at -80° C. for    purification.-   Protein Purification. Expressed full-length human GST-tagged PRMT8    protein was purified from cell paste by glutathione sepharose    affinity chromatography after the resin was equilibrated with 50 mM    phosphate buffer, 200 mM NaCl, 5% glycerol, 5 mM (3-mercaptoethanol,    pH7.8 (Buffer A). GST-tagged PRMT8 was eluted with 50 mM Tris, 2 mM    glutathione, pH 7.8. Pooled fractions were cleaved by thrombin (10U)    and dialysed in buffer A. GST was removed by reloading the cleaved    protein sample onto glutathione sepharose column and PRMT8 was    collected in the flow-through fractions. PRMT8 was purified further    by ceramic hydroxyapatite chromatography. The column was washed with    50 mM phosphate buffer, 100 mM NaCl, 5% glycerol, 5 mM    (3-mercaptoethanol, pH 7.8 and PRMT8 was eluted by 100 mM phosphate    in the same buffer. Protein was concentrated and buffer was    exchanged to 50 mM Tris, 300 mM NaCl, 10% glycerol, 5 mM    (3-mercaptoethanol, pH 7.8 by ultrafiltration. The purity of    recovered protein was 89%.

Predicted Translations:

GST-tagged PRMT8  (SEQ ID NO.: 10)MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSPEFMGMKHSSRCLLLRRKMAENAAESTEVNSPPSQPPQPVVPAKPVQCVHHVSTQPSCPGRGKMSKLLNPEEMTSRDYYFDSYAHFGIHEEMLKDEVRTLTYRNSMYHNKHVFKDKVVLDVGSGTGILSMFAAKAGAKKVFGIECSSISDYSEKIIKANHLDNIITIFKGKVEEVELPVEKVDIIISEWMGYCLFYESMLNTVIFARDKWLKPGGLMFPDRAALYVVAIEDRQYKDFKIHWWENVYGFDMTCIRDVAMKEPLVDIVDPKQVVTNACLIKEVDIYTVKTEELSFTSAFCLQIQRNDYVHALVTYFNIEFTKCHKKMGFSTAPDAPYTHWKQTVFYLEDYLTVRRGEEIYGTISMKPNAKNVRDLDFTVDLDFKGQLCETSVSNDYKMR

General Procedure for PRMT8 Enzyme Assays on Peptide Substrates. Theassays were all performed in a buffer consisting of 20 mM Bicine(pH=7.6), 1 mM TCEP, 0.005% BSG, and 0.002% Tween 20, prepared on theday of use. Compounds in 100% DMSO (1 ul) were spotted into apolypropylene 384-well V-bottom plates (Greiner) using a Platemate Plusoutfitted with a 384-channel head (Thermo Scientific). DMSO (1 ul) wasadded to Columns 11, 12, 23, 24, rows A-H for the maximum signal controland lul of SAH, a known product and inhibitor of PRMT8, was added tocolumns 11, 12, 23, 24, rows I-P for the minimum signal control. Acocktail (40 ul) containing the PRMT8 enzyme was added by MultidropCombi (Thermo-Fisher). The compounds were allowed to incubate with PRMT8for 30 min at room temperature, then a cocktail (10 ul) containing³H-SAM and peptide was added to initiate the reaction (final volume =51ul). The final concentrations of the components were as follows: PRMT8was 1.5 nM, ³H-SAM was 50 nM, non-radiolabeled SAM was 550 nM, peptidewas 150 nM, SAH in the minimum signal control wells was 1 mM, and theDMSO concentration was 2%. The assays were stopped by the addition ofnon-radiolabeled SAM (10 ul) to a final concentration of 400 uM, whichdilutes the ³H-SAM to a level where its incorporation into the peptidesubstrate is no longer detectable. 50 ul of the reaction in the 384-wellpolypropylene plate was then transferred to a 384-well Flashplate andthe biotinylated peptides were allowed to bind to the streptavidinsurface for at least 1 hour before being washed once with 0.1%Tween20 ina Biotek ELx405 plate washer. The plates were then read in a PerkinElmerTopCount plate reader to measure the quantity of ³H-labeled peptidebound to the Flashplate surface, measured as disintegrations per minute(dpm) or alternatively, referred to as counts per minute (cpm).

% Inhibition Calculation

${\% \mspace{14mu} {inch}} = {100 - {\left( \frac{{dpm}_{cmpd} - {dpm}_{\min}}{{dpm}_{\max} - {dpm}_{\min}} \right) \times 100}}$

Where dpm=disintegrations per minute, cmpd=signal in assay well, and minand max are the respective minimum and maximum signal controls.

Four-Parameter IC₅₀ Fit

$Y = {{Bottom} + \frac{\left( {{Top} - {Bottom}} \right)}{\left( {1 + \left( \frac{X}{{IC}_{50}} \right)^{{Hill}\mspace{14mu} {Coefficient}}} \right.}}$

Where top and bottom are the normally allowed to float, but may be fixedat 100 or 0 respectively in a 3-parameter fit. The Hill Coefficientnormally allowed to float but may also be fixed at 1 in a 3-parameterfit. Y is the % inhibition and X is the compound concentration.

PRMT3 Biochemical Assay

General Materials. S-adenosylmethionine (SAM), S-adenosylhomocysteine(SAH), bicine, Tween20, dimethylsulfoxide (DMSO), bovine skin gelatin(BSG),), isopropyl-13-D-thiogalactopyranoside (IPTG), andTris(2-carboxyethyl)phosphine hydrochloride solution (TCEP) werepurchased from Sigma-Aldrich at the highest level of purity possible.³H-SAM was purchase from American Radiolabeled Chemicals with a specificactivity of 80 Ci/mmol. 384-well streptavidin Flashplates were purchasedfrom PerkinElmer.

Substrates. Peptide containing the classic RMT substrate motif wassynthesized with an N-terminal linker-affinity tag motif and aC-terminal amide cap by 21^(st) Century Biochemicals. The peptide waspurified by high-performance liquid chromatography (HPLC) to greaterthan 95% purity and confirmed by liquid chromatography mass spectrometry(LC-MS). The sequence was Biot-Ahx-GGRGGFGGRGGFGGRGGFG-amide (SEQ IDNO.:11).

Molecular Biology: : Full-length human PRMT3 (NM_005788.3) isoform 1transcript clone was amplified from an HEK 293 cDNA library andsubcloned into pGEX-KG (GE Life Sciences). The resulting constructencodes an N-terminal GST tag and a thrombin cleavage sequence(MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGS) (SEQ ID NO.:12)fused directly to Cys 2 of PRMT3.

Protein Expression. E. coli (BL21(DE3) Gold, Stratagene) made competentby the CaCl₂ method were transformed with the PRMT3 construct andampicillin selection. Protein over-expression was accomplished bygrowing the PRMT3 expressing E. coli clone and inducing expression with0.3 mM IPTG at 16° C. The culture was grown for 12 hours, harvested bycentrifugation, and stored at -80° C. for purification.

Protein Purification. Expressed full-length human GST-tagged PRMT3protein was purified from cell paste by glutathione sepharose affinitychromatography after equilibration of the resin with 50 mM phosphatebuffer, 200 mM NaCl, 5% glycerol, 1 mM EDTA, 5 mM (3-mercaptoethanol,pH6.5 (Buffer A). GST-tagged PRMT3 was eluted with 50 mM Tris, 2 mMglutathione, pH 7.1 and 50 mM Tris, 20 mM glutathione, pH 7.1. Pooledfractions were dialysed in 20 mM Tris, 50 mM NaCl, 5% glycerol, 1 mMEDTA, 1 mM DTT, pH7.5 (Buffer B) and applied to a Q Sepharose Fast Flowcolumn. GST-tagged PRMT3 was eluted by 500 mM NaCl in buffer B. Pooledfractions were dialyzed in 25 mM phosphate buffer, 100 mM NaCl, 5%glycerol, 2 mM DTT, pH 6.8 (Buffer C) and loaded on to a ceramichydroxyapatite column. GST-tagged PRMT3 eluted with 25-400 mM phosphatein buffer C. Protein was concentrated and buffer was exchanged to 20 mMTris, 150 mM NaCl, 5% glycerol, 5 mM f3-mercaptoethanol, pH7.8 byultrafiltration. The purity of recovered protein was 70%.

Predicted Translations:

GST-tagged PRMT3  (SEQ ID NO.: 13)MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLVPRGSCSLASGATGGRGAVENEEDLPELSDSGDEAAWEDEDDADLPHGKQQTPCLFCNRLFTSAEETFSHCKSEHQFNIDSMVHKHGLEFYGYIKLINFIRLKNPTVEYMNSIYNPVPWEKEEYLKPVLEDDLLLQFDVEDLYEPVSVPFSYPNGLSENTSVVEKLKHMEARALSAEAALARAREDLQKMKQFAQDFVMHTDVRTCSSSTSVIADLQEDEDGVYFSSYGHYGIHEEMLKDKIRTESYRDFIYQNPHIFKDKVVLDVGCGTGILSMFAAKAGAKKVLGVDQSEILYQAMDIIRLNKLEDTITLIKGKIEEVHLPVEKVDVIISEWMGYFLLFESMLDSVLYAKNKYLAKGGSVYPDICTISLVAVSDVNKHADRIAFWDDVYGFKMSCMKKAVIPEAVVEVLDPKTLISEPCGIKHIDCHTTSISDLEFSSDFTLKITRTSMCTAIAGYFDIYFEKNCHNRVVFSTGPQSTKTHWKQTVFLLEKPFSVKAGEALKGKVTVHKNKKDPRSLTVTLTLNNST QTYGLQ

General Procedure for PRMT3 Enzyme Assays on Peptide Substrates. Theassays were all performed in a buffer consisting of 20 mM Bicine(pH=7.6), 1 mM TCEP, 0.005% BSG, and 0.002% Tween 20, prepared on theday of use. Compounds in 100% DMSO (1 ul) were spotted into apolypropylene 384-well V-bottom plates (Greiner) using a Platemate Plusoutfitted with a 384-channel head (Thermo Scientific). DMSO (1 ul) wasadded to Columns 11, 12, 23, 24, rows A-H for the maximum signal controland lul of SAH, a known product and inhibitor of PRMT3, was added tocolumns 11, 12, 23, 24, rows I-P for the minimum signal control. Acocktail (40 ul) containing the PRMT3 enzyme was added by MultidropCombi (Thermo-Fisher). The compounds were allowed to incubate with PRMT3for 30 min at room temperature, then a cocktail (10 ul) containing SAMand peptide was added to initiate the reaction (final volume =51 ul).The final concentrations of the components were as follows: PRMT3 was0.5 nM, ³H-SAM was 100 nM, non-radiolabeled SAM was 1.8 uM, peptide was330 nM, SAH in the minimum signal control wells was 1 mM, and the DMSOconcentration was 2%. The assays were stopped by the addition ofpotassium chloride (10 ul) to a final concentration of 100 mM. 50 ul ofthe reaction in the 384-well polypropylene plate was then transferred toa 384-well Flashplate and the biotinylated peptides were allowed to bindto the streptavidin surface for at least 1 hour before being washed oncewith 0.1%Tween20 in a Biotek ELx405 plate washer. The plates were thenread in a PerkinElmer TopCount plate reader to measure the quantity of³H-labeled peptide bound to the Flashplate surface, measured asdisintegrations per minute (dpm) or alternatively, referred to as countsper minute (cpm).

% Inhibition Calculation

${\% \mspace{14mu} {inch}} = {100 - {\left( \frac{{dpm}_{cmpd} - {dpm}_{\min}}{{dpm}_{\max} - {dpm}_{\min}} \right) \times 100}}$

Where dpm=disintegrations per minute, cmpd=signal in assay well, and minand max are the respective minimum and maximum signal controls.

Four-Parameter IC₅₀ Fit

$Y = {{Bottom} + \frac{\left( {{Top} - {Bottom}} \right)}{\left( {1 + \left( \frac{X}{{IC}_{50}} \right)^{{Hill}\mspace{14mu} {Coefficient}}} \right.}}$

Where top and bottom are the normally allowed to float, but may be fixedat 100 or 0 respectively in a 3-parameter fit. The Hill Coefficientnormally allowed to float but may also be fixed at 1 in a 3-parameterfit. Y is the % inhibition and X is the compound concentration. CARM1Biochemical Assay

General Materials. S-adenosylmethionine (SAM), S-adenosylhomocysteine(SAH), bicine, Tween20, dimethylsulfoxide (DMSO), bovine skin gelatin(BSG), sodium butyrate and Tris(2-carboxyethyl)phosphine hydrochloridesolution (TCEP) were purchased from Sigma-Aldrich at the highest levelof purity possible. ³H-SAM was purchase from American RadiolabeledChemicals with a specific activity of 80 Ci/mmol. 384-well streptavidinFlashplates were purchased from PerkinElmer.

Substrates. Peptide representative of human histone H3 residues 16-30was synthesized with an N-terminal linker-affinity tag motif and aC-terminal amide cap by 21^(st) Century Biochemicals. The peptide waspurified by high-performance liquid chromatography (HPLC) to greaterthan 95% purity and confirmed by liquid chromatography mass spectrometry(LC-MS). The sequence was Biot-Ahx-PRKQLATKAARKSAP-amide and contained amonomethylated arginine at position 26 (SEQ ID NO.:14).

Molecular Biology: Human CARM1 (PRMT4) (NM_199141.1) transcript clonewas amplified from an HEK 293 cDNA library, incorporating a flanking 5′sequence encoding a FLAG tag (MDYKDDDDK) (SEQ ID NO.:6) fused directlyto Ala 2 of CARM1 and 3′ sequence encoding a hexa His sequence(EGHHHHHH) (SEQ ID NO.:15) fused directly to Ser 608. The gene sequenceencoding isoforml containing a deletion of amino acids 539-561 wasamplified subsequently and subcloned into pFastBacMam (Viva Biotech).

Protein Expression. Recombinant baculovirus were generated according toBac-to-Bac kit instructions (Life Technologies). Protein over-expressionwas accomplished by infecting exponentially growing HEK 293F cellculture at 1.3×10⁶cell/ml with virus (MOI=10) in the presence of 8 mMsodium butyrate. Infections were carried out at 37° C. for 48 hours,harvested by centrifugation, and stored at −80° C. for purification.

Protein Purification. Expressed full-length human Flag- and His-taggedCARM1 protein was purified from cell paste by anti-flag M2 affinitychromatography with resin equilibrated with buffer containing 20 mMTris, 150 mM NaCl, 5% glycerol, pH 7.8. Column was washed with 500 mMNaCl in buffer A and Flag-CARM1-His was eluted with 200 ug/ml FLAGpeptide in buffer A. Pooled fractions were dialyzed in 20 mM Tris, 150mM NaCl, 5% glycerol and 1 mM DTT, pH 7.8. The purity of recoveredprotein was 94.

Predicted Translations:

Flag-CARM1-His  (SEQ ID NO.: 16)MDYKDDDDKAAAAAAVGPGAGGAGSAVPGGAGPCATVSVFPGARLLTIGDANGEIQRHAEQQALRLEVRAGPDSAGIALYSHEDVCVFKCSVSRETECSRVGKQSFIITLGCNSVLIQFATPNDFCSFYNILKTCRGHTLERSVFSERTEESSAVQYFQFYGYLSQQQNMMQDYVRTGTYQRAILQNHTDFKDKIVLDVGCGSGILSFFAAQAGARKIYAVEASTMAQHAEVLVKSNNLTDRIVVIPGKVEEVSLPEQVDIIISEPMGYMLFNERMLESYLHAKKYLKPSGNMFPTIGDVHLAPFTDEQLYMEQFTKANFWYQPSFHGVDLSALRGAAVDEYFRQPVVDTFDIRILMAKSVKYTVNFLEAKEGDLHRIEIPFKFHMLHSGLVHGLAFWFDVAFIGSIMTVWLSTAPTEPLTHWYQVRCLFQSPLFAKAGDTLSGTCLLIANKRQSYDISIVAQVDQTGSKSSNLLDLKNPFFRYTGTTPSPPPGSHYTSPSENMWNTGSTYNLSSGMAVAGMPTAYDLSSVIASGSSVGHNNLIPLGSSGAQGSGGGSTSAHYAVNSQFTMGGPAISMASPMSIPTNTMHYGSEGHHHHH H

General Procedure for CARM1 Enzyme Assays on Peptide Substrates. Theassays were all performed in a buffer consisting of 20 mM Bicine(pH=7.6), 1 mM TCEP, 0.005% BSG, and 0.002% Tween 20, prepared on theday of use. Compounds in 100% DMSO (1 ul) were spotted into apolypropylene 384-well V-bottom plates (Greiner) using a Platemate Plusoutfitted with a 384-channel head (Thermo Scientific). DMSO (1 ul) wasadded to Columns 11, 12, 23, 24, rows A-H for the maximum signal controland lul of SAH, a known product and inhibitor of CARM1, was added tocolumns 11, 12, 23, 24, rows I-P for the minimum signal control. Acocktail (40 ul) containing the CARM1 enzyme was added by MultidropCombi (Thermo-Fisher). The compounds were allowed to incubate with CARM1for 30 min at room temperature, then a cocktail (10 ul) containing³H-SAM and peptide was added to initiate the reaction (final volume=51u1). The final concentrations of the components were as follows:CARM1 was 0.25 nM, ³H-SAM was 30 nM, peptide was 250 nM, SAH in theminimum signal control wells was 1 mM, and the DMSO concentration was2%. The assays were stopped by the addition of non-radiolabeled SAM(10u1) to a final concentration of 300 uM, which dilutes the ³H-SAM to alevel where its incorporation into the peptide substrate is no longerdetectable. 50u1 of the reaction in the 384-well polypropylene plate wasthen transferred to a 384-well Flashplate and the biotinylated peptideswere allowed to bind to the streptavidin surface for at least 1 hourbefore being washed once with 0.1%Tween20 in a Biotek ELx405 platewasher. The plates were then read in a PerkinElmer TopCount plate readerto measure the quantity of ³H-labeled peptide bound to the Flashplatesurface, measured as disintegrations per minute (dpm) or alternatively,referred to as counts per minute (cpm).

% Inhibition Calculation

${\% \mspace{14mu} {inch}} = {100 - {\left( \frac{{dpm}_{cmpd} - {dpm}_{\min}}{{dpm}_{\max} - {dpm}_{\min}} \right) \times 100}}$

Where dpm=disintegrations per minute, cmpd=signal in assay well, and minand max are the respective minimum and maximum signal controls.

Four-Parameter IC₅₀ Fit

$Y = {{Bottom} + \frac{\left( {{Top} - {Bottom}} \right)}{\left( {1 + \left( \frac{X}{{IC}_{50}} \right)^{{Hill}\mspace{14mu} {Coefficient}}} \right.}}$

Where top and bottom are the normally allowed to float, but may be fixedat 100 or 0 respectively in a 3-parameter fit. The Hill Coefficientnormally allowed to float but may also be fixed at 1 in a 3-parameterfit. Y is the % inhibition and X is the compound concentration.

TABLE 2 Biochemical IC₅₀ Cmpd No. PRMT1 PRMT6 PRMT8 PRMT3 CARM1 1 A A BC B 2 B C D D E 3 B A C D D 4 B B C E E 5 B B D E E 6 B B D D D 7 B B CE D 8 B A D E D 9 A A B D C 10 E E E E E 11 B B C E E 12 B B C E E 13 AA B C B 14 C C E E E 15 C C D E — 16 A A B D — 17 A A B D — 18 B A C E —19 A A B D — 20 A A C D — 21 A A B D — 22 A A B D — 23 A A B D — 24 A AB D — 25 E E — — — 26 — E — — — 27 A A B — — 28 B B C — — 29 C C D — —30 B A D — — “—” indicates no data provided. For Table 2, “A” indicatesan IC₅₀ ≦ 0.100 μM, “B” indicates an IC₅₀ of 0.101-1.00 μM, “C”indicates an IC₅₀ of 1.01-3.00 μM, “D” indicates an IC₅₀ of 3.01-10 μM,and IC₅₀ ≧ 10.01 μM.RKO methylation Assay

RKO adherent cells were purchased from ATCC (American Type CultureCollection), Manassas, Va., USA. DMEM/Glutamax medium,penicillin-streptomycin, heat inactivated fetal bovine serum, 0.05%trypsin and D-PBS were purchased from Life Technologies, Grand Island,N.Y., USA. Odyssey blocking buffer, 800CW goat anti-rabbit IgG (H+L)antibody, and Licor Odyssey infrared scanner were purchased from LicorBiosciences, Lincoln, Nebr., USA. Mono-methyl arginine antibody waspurchased from Cell Signaling Technology, Danvers, Mass., USA. Methanolwas purchased from VWR, Franklin, Mass., USA. 10% Tween 20 was purchasedfrom KPL, Inc., Gaithersburg, Md., USA. DRAQ5 was purchased fromBiostatus Limited, Leicestershire, UK.

RKO adherent cells were maintained in growth medium (DMEM/Glutamaxmedium supplemented with 10% v/v heat inactivated fetal bovine serum and100 units/mL penicillin-streptomycin) and cultured at 37° C. under 5%CO₂

Cell treatment, In Cell Western (ICW) for detection of mono-methylarginine and DNA content. RKO cells were seeded in assay medium at aconcentration of 20,000 cells per mL to a poly-D-lysine coated 384 wellculture plate (BD Biosciences 356697) with 50 _([)t.L per well. Compound(100 nL) from a 96-well source plate was added directly to 384 well cellplate. Plates were incubated at 37° C., 5% CO₂ for 72 hours. After threedays of incubation, plates were brought to room temperature outside ofthe incubator for ten minutes and blotted on paper towels to remove cellmedia. 50 _([)t.L of ice cold 100% methanol was added directly to eachwell and incubated for 30 min at room temperature. After 30 min, plateswere transferred to a Biotek EL406 plate washer and washed 2 times with100 _([)t.L per well of wash buffer (1×PBS). Next 60 μL per well ofOdyssey blocking buffer (Odyssey Buffer with 0.1% Tween 20 (v/v)) wereadded to each plate and incubated 1 hour at room temperature. Blockingbuffer was removed and 20 _([)t.L per well of primary antibody was added(mono-methyl arginine diluted 1:200 in Odyssey buffer with 0.1% Tween 20(v/v)) and plates were incubated overnight (16 hours) at 4° C. Plateswere washed 5 times with 100 _([)t.L per well of wash buffer. Next 20_([)t.L per well of secondary antibody was added (1:200 800CW goatanti-rabbit IgG (H+L) antibody, 1:1000 DRAQ5 (Biostatus limited) inOdyssey buffer with 0.1% Tween 20 (v/v)) and incubated for 1 hour atroom temperature. The plates were washed 5 times with 100 μL per wellwash buffer then 2 times with 100 μL per well of water. Plates wereallowed to dry at room temperature then imaged on the Licor Odysseymachine which measures integrated intensity at 700 nm and 800nmwavelengths. Both 700 and 800 channels were scanned.

Calculations: First, the ratio for each well was determined by:

$\left( \frac{{monomethyl}\mspace{14mu} {Arginine}\mspace{14mu} 800\mspace{14mu} {nm}\mspace{14mu} {value}}{{DRAQ}\; 5\mspace{14mu} 700\mspace{14mu} {nm}\mspace{14mu} {value}} \right)$

Each plate included fourteen control wells of DMSO only treatment(minimum activation) as well as fourteen control wells for maximumactivation treated with 20 μM of a reference compound. The average ofthe ratio values for each control type was calculated and used todetermine the percent activation for each test well in the plate.Reference compound was serially diluted three-fold in DMSO for a totalof nine test concentrations, beginning at 20 μM. Percent activation wasdetermined and EC₃₀ curves were generated using triplicate wells perconcentration of compound.

${{Percent}\mspace{14mu} {Activation}} = {100 - \left( {\left( \frac{\begin{matrix}{\left( {{Individual}\mspace{14mu} {Test}\mspace{14mu} {Sample}\mspace{14mu} {Ratio}} \right) -} \\\left( {{Minimum}\mspace{14mu} {Activation}\mspace{14mu} {Ratio}} \right)\end{matrix}}{\begin{matrix}{\left( {{Maximum}\mspace{14mu} {Activation}\mspace{14mu} {Ratio}} \right) -} \\\left( {{Minimum}\mspace{14mu} {Activation}\mspace{14mu} {Ratio}} \right)\end{matrix}} \right)*100} \right)}$

TABLE 3 In Cell Western Cmpd Cmpd No. EC₃₀ No. EC₃₀ 4 C 19 B 8 C 20 C 9B 21 B 12 C 22 B 13 B 23 A 14 C 24 A 15 C 25 C 16 C 26 C 17 A 27 A 18 C28 C For Table 3, “A” indicates an EC₃₀ ≦ 3.00 μM, “B” indicates an EC₃₀of 3.01-12.0 μM, and “C“ indicates an EC₃₀ ≧ 12.01 μM.

Other Embodiments

The foregoing has been a description of certain nonlimiting embodimentsof the invention. Those of ordinary skill in the art will appreciatethat various changes and modifications to this description may be madewithout departing from the spirit or scope of the present invention, asdefined in the following claims.

1-47. (canceled)
 48. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein: X is N, Z isNR⁴, and Y is CR⁵; or X is NR⁴. Z is N, and Y is CR5; or X is CR⁵, Z isNR⁴, and Y is N; or X is CR⁵, Z is N. and Y is NR⁴; R^(x): is optionallysubstituted C₁₋₄ alkyl or optionally substituted C₃₋₄ cycloalkyl; Q isan optionally substituted, monocyclic or bicyclic heteroaryl having 1-4heteroatoms independently selected from nitrogen, oxygen, and sulfur,wherein Q is not pyridine; R: hydrogen, C alkyl, or C₃₋₄ cycloalkyl; R⁴is hydrogen, C₁₋₄ alkyl, or C₃₋₄ cycloalkyl; and R⁵ is hydrogen, halo,—CN, optionally substituted C₁₋₄ alkyl, or optionally substituted C₃₋₄cycloalkyl.

or a pharmaceutically acceptable salt thereof.
 50. The compound of claim48, wherein the compound is of Formula (III):

or a pharmaceutically acceptable salt thereof.
 51. The compound of claim48, wherein the compound is of For V

or a pharmaceutically acceptable salt thereof.
 52. The compound of claim48, wherein the compound is of Formula (V):

or a phainiaceutically acceptable salt thereof
 53. The compound of claim48, wherein Q is an optionally substituted 8- to 10-membered heteroarylhaving 1-4 heteroatoms independently selected from nitrogen, oxygen, andsulfur.
 54. The compound of claim 53, wherein Q is an optionallysubstituted 9-membered heteroaryl having 1-3 heteroatoms independentlyselected from nitrogen, oxygen, and sulfur.
 55. The compound of claim48, wherein Q is an optionally substituted 5- to 6-membered. heteroarylhaving 1-3 heteroatoms independently selected from nitrogen, oxygen, andsulfur.
 56. The compound of claim 55, wherein Q is an optionallysubstituted 5-membered heteroaryl having 1-3 heteroatoms independentlyselected from nitrogen, oxygen, and sulfur.
 57. The compound of claim48, wherein Q is an unsubstituted, monocyclic or bicyclic heteroarylhaving 1-4 heteroatoms independently selected from nitrogen, oxygen, andsulfur.
 58. The compound of claim 48, wherein Q is substituted,monocyclic or bicyclic heteroaryl having 1-4 heteroatoms independentlyselected from nitrogen, oxygen, and sulfur.
 59. The compound of claim48, wherein Q is substituted or unsubstituted pyrrolyl, substituted orunsubstituted furanyl, substituted or unsubstituted thienyl, substitutedor unsubstituted imidazolyl, substituted or unsubstituted pyrazolyl,substituted or unsubstituted oxazolyl, substituted or unsubstitutedthiazolyl, substituted or unsubstituted isothiazolyl, substituted orunsubstituted triazolyi, substituted or unsubstituted thiadiazolyl,substituted or unsubstituted thiadiazolyl, substituted or unsubstitutedtetrazolyl, substituted or unsubstituted pyridyl, substituted orunsubstituted pyrimidyl, substituted or unsubstituted pyrazinyl,substituted or unsubstituted pyridazinyl, substituted or unsubstitutedtriazinyl, substituted or unsubstituted indolyl, substituted orunsubstituted isoindotyl, substituted or unsubstituted indazolyl,substituted or unsubstituted benzotriazolyl, substituted orunsubstituted benzothiophenyl, substituted or unsubstitutedisobenzothiophenyl, substituted or unsubstituted benzofuranyl,substituted or unsubstituted benzoisofuranyl; substituted orunsubstituted henzimidazolyl, substituted or unsubstituted benzoxazolyl,substituted or unsubstituted benzoxadia,zolyl, substituted orunsubstituted benzisoxazolyl, substituted or unsubstitutedbenzthiazolyl, substituted or unsubstituted benzisothiazolyl,substituted or unsubstituted benzthiadiazolyl, substituted orunsubstituted. indolizinyl, substituted or unsubstituted purinyl,substituted or unsubstituted pyrrolopyridinyl, substituted orunsubstituted triazolopyridinyl, substituted or unsubstitutednaphthyridinyl, substituted or unsubstituted pteridinyl, substituted orunsubstituted quinolinyl, substituted or unsubstituted isoquinolinyl,substituted or unsubstituted cinnolinyl, substituted or unsubstitutedquinoxalinyl, substituted or unsubstituted quinazolinyl, or substitutedor unsubstituted phthalazinyl.
 60. The compound of claim 48, wherein Qis selected from the group consisting of:

wherein: each R^(q) is independently selected from the group consistingof halo, —CN, —NO₂, optionally substituted alkyl, optionally substitutedalkenyl, optionally substituted alkynyl, optionally substitutedcarbocyclyl, optionally substituted aryl, optionally substitutedheterocyclyl, optionally substituted heteroaryl, —OR^(A), —N(R^(B))₂,—SRA, —C(═O)R^(A), —C(O)OR^(A), —C(O)SR^(A), —C(O)N(R^(B))₂,—C(O)N(R^(B))N(R^(B))₂, —OC(O)R^(A), —OC(O)N(R^(B))₂, —NR^(B)C(O)R^(A),—NR^(B)C(O)N(R^(B))₂, —NR^(B)C(O)N(R^(B))N(R^(B))₂, —NR^(B)C(O)OR^(A),—SC(O)R^(A), —C(═NR^(B))R^(A), —C(═NR^(B))R^(A), —C(═NOR^(A))R^(A),—C(═NR^(B))N(R^(B))₂, —NR^(B)C(═NR^(B))R^(B), —C(═S)R″, —C(═S)N(R^(B))₂,-NR^(B)C(═S)R^(A), —S(O)R^(A), —OS(O)₂R^(A), —SO₂RA, —NR^(B)SO₂R^(A),and —SO₂N(R^(B))₂; each R^(A) is independently selected from the groupconsisting of hydrogen, optionally substituted alkyl, optionallysubstituted alkenyl, optionally substituted alkynyl, optionallysubstituted carbocyclyl, optionally substituted heterocyclyl, optionallysubstituted aryl, optionally substituted heteroaryl, an oxygenprotecting group when attached to an oxygen atom, and a sulfurprotecting group when attached to a sulfur atom; and each R^(B) isindependently selected from the group consisting of hydrogen, optionallysubstituted alkyl, optionally substituted alkenyl, optionallysubstituted alkynyl, optionally substituted carbocyclyl, optionallysubstituted heterocyclyl, optionally substituted aryl, optionallysubstituted heteroaryl, and a nitrogen protecting group, or two R^(B)groups are taken together with their intervening atoms to form anoptionally substituted heterocyclic ring.
 61. The compound of claim 48,wherein R³ is hydrogen or methyl.
 62. The compound of claim 48, whereinR⁵ is hydrogen.
 63. The compound of claim 48, wherein Rx⁻ is methyl. 64.The compound of claim 48, wherein R^(x) is ethyl.
 65. The compound ofclaim 48, wherein Rx is hydroxyethyl or methoxyethyl.
 66. The compoundof claim 48, wherein R^(x) is cyclopropyl or isopropyl.
 67. The compoundof claim 48, wherein R⁴ is hydrogen.
 68. A pharmaceutical compositioncomprising a compound of claim 48 or a pharmaceutically acceptable saltthereof, and a pharmaceutically acceptable excipient.
 69. Apharmaceutical composition comprising a compound selected from the groupconsisting of:

and pharmaceutically acceptable salts thereof, and a pharmaceuticallyacceptable excipient.
 70. A kit or packaged pharmaceutical comprising acompound claim 48 or a pharmaceutically acceptable salt thereof, andinstructions for use thereof.
 71. A method of inhibiting an argininemethyl transferase (RMT) comprising contacting a cell with an effectiveamount of a compound of claim 48 or a pharmaceutically acceptable saltthereof.